PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34668334-2	2022	This study aimed to investigate an IVIVE for intestinal P-glycoprotein (Pgp, ABCB1)-mediated DDIs between three Pgp substrates, digoxin, dabigatran etexilate and quinidine, and two Pgp inhibitors, itraconazole and verapamil, via PBPK modeling.	Itraconazole	197-209	ATP binding cassette subfamily B member 1	Homo sapiens	56-70
34668334-2	2022	This study aimed to investigate an IVIVE for intestinal P-glycoprotein (Pgp, ABCB1)-mediated DDIs between three Pgp substrates, digoxin, dabigatran etexilate and quinidine, and two Pgp inhibitors, itraconazole and verapamil, via PBPK modeling.	Itraconazole	197-209	ATP binding cassette subfamily B member 1	Homo sapiens	72-75
34668334-2	2022	This study aimed to investigate an IVIVE for intestinal P-glycoprotein (Pgp, ABCB1)-mediated DDIs between three Pgp substrates, digoxin, dabigatran etexilate and quinidine, and two Pgp inhibitors, itraconazole and verapamil, via PBPK modeling.	Itraconazole	197-209	ATP binding cassette subfamily B member 1	Homo sapiens	77-82
34668334-2	2022	This study aimed to investigate an IVIVE for intestinal P-glycoprotein (Pgp, ABCB1)-mediated DDIs between three Pgp substrates, digoxin, dabigatran etexilate and quinidine, and two Pgp inhibitors, itraconazole and verapamil, via PBPK modeling.	Itraconazole	197-209	ATP binding cassette subfamily B member 1	Homo sapiens	181-184
34668334-4	2022	For Pgp inhibitors, PBPK models utilized the reported in vitro values of Pgp inhibition constants (Ki ), 1.0 muM for itraconazole and 2.0 muM for verapamil.	Itraconazole	117-129	ATP binding cassette subfamily B member 1	Homo sapiens	73-76
34620694-6	2022	Three sensitive substrates were identified: avapritinib (CYP3A), lonafarnib (CYP3A), and relugolix (P-gp), with AUCRs of 7.00, 5.07, and 6.25 when co-administered with itraconazole, ketoconazole, and erythromycin, respectively.	Itraconazole	168-180	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-62
34620694-6	2022	Three sensitive substrates were identified: avapritinib (CYP3A), lonafarnib (CYP3A), and relugolix (P-gp), with AUCRs of 7.00, 5.07, and 6.25 when co-administered with itraconazole, ketoconazole, and erythromycin, respectively.	Itraconazole	168-180	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-82
34620694-6	2022	Three sensitive substrates were identified: avapritinib (CYP3A), lonafarnib (CYP3A), and relugolix (P-gp), with AUCRs of 7.00, 5.07, and 6.25 when co-administered with itraconazole, ketoconazole, and erythromycin, respectively.	Itraconazole	168-180	phosphoglycolate phosphatase	Homo sapiens	100-104
34716565-2	2022	These studies aimed to assess the pharmacokinetics of BI 425809, a potent glycine-transporter-1 inhibitor, when co-administered with a strong cytochrome P450 3A4 (CYP3A4) inhibitor (itraconazole) and inducer (rifampicin).	Itraconazole	182-194	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-161
34716565-2	2022	These studies aimed to assess the pharmacokinetics of BI 425809, a potent glycine-transporter-1 inhibitor, when co-administered with a strong cytochrome P450 3A4 (CYP3A4) inhibitor (itraconazole) and inducer (rifampicin).	Itraconazole	182-194	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	163-169
34495458-5	2021	The initial model based on in vitro-in vivo extrapolation was refined using sensitivity analysis and non-linear mixed effects modeling to optimize parameter estimates and to improve model fit to data from a clinical drug-drug interaction study with the strong CYP3A4 inhibitor, itraconazole.	Itraconazole	278-290	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	260-266
34959655-8	2021	In the in vivo study that was carried out in rats, the AUC0-48h of the commercial formulation, Sporanox , was 1073.9 +- 314.7 ng h mL-1, and the bioavailability of the SD pellet (2969.7 +- 720.6 ng h mL-1) was three-fold higher than that of Sporanox  (*** p < 0.001).	Itraconazole	95-103	L1 cell adhesion molecule	Mus musculus	131-135
34664792-3	2021	Phenotyping studies indicated cytochrome P450 (CYP) 3A are the major CYP isoform responsible for zanubrutinib metabolism, which was confirmed by a clinical DDI study with itraconazole and rifampin.	Itraconazole	171-183	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-54
34426442-0	2021	Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan With Concomitant Ritonavir or Itraconazole in Patients With HER2-Expressing Advanced Solid Tumors.	Itraconazole	95-107	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-129
34426442-1	2021	PURPOSE: To evaluate drug-drug interactions between the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd; DS-8201a) and the OATP1B/CYP3A inhibitor ritonavir or the strong CYP3A inhibitor itraconazole.	Itraconazole	206-218	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-60
34426442-1	2021	PURPOSE: To evaluate drug-drug interactions between the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd; DS-8201a) and the OATP1B/CYP3A inhibitor ritonavir or the strong CYP3A inhibitor itraconazole.	Itraconazole	206-218	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	190-195
34160163-9	2021	Among oral antifungals, the mean MIC of itraconazole was within the range (0.84 (0.252) mug/ mL), whereas high mean MIC values were reported for terbinafine (0.05 (0.043) mug/mL).	Itraconazole	40-52	thrombopoietin	Mus musculus	93-95
34589147-0	2021	Itraconazole improves survival outcomes in patients with colon cancer by inducing autophagic cell death and inhibiting transketolase expression.	Itraconazole	0-12	transketolase	Homo sapiens	119-132
34589147-10	2021	Notably, itraconazole induced autophagy by enhancing LC3B and p62 expression.	Itraconazole	9-21	microtubule associated protein 1 light chain 3 beta	Homo sapiens	53-57
34589147-10	2021	Notably, itraconazole induced autophagy by enhancing LC3B and p62 expression.	Itraconazole	9-21	nucleoporin 62	Homo sapiens	62-65
34498807-2	2022	Three drug-drug interactions studies were conducted in healthy subjects to evaluate the effect of P-glycoprotein (P-gp) modulation (Study 1: P-gp inhibition by itraconazole; Study 2: P-gp induction by rifampin) on filgotinib pharmacokinetics and the potential of filgotinib to impact exposure of metformin, an organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) 1/2K substrate (Study 3).	Itraconazole	160-172	ATP binding cassette subfamily B member 1	Homo sapiens	141-145
34260894-11	2021	Model-based simulations of dose staggering predicted the maximum inhibition of P-gp when DABE microdose was concomitantly administered with itraconazole solution; simulations also highlighted dosing intervals required to minimise the DDI risk depending on the DABE dose administered (microdose vs. therapeutic).	Itraconazole	140-152	ATP binding cassette subfamily B member 1	Homo sapiens	79-83
34376577-0	2021	Itraconazole Exerts its Anti-Tumor Effect in Esophageal Cancer by Suppressing the HER2/AKT Signaling Pathway.	Itraconazole	0-12	erb-b2 receptor tyrosine kinase 2	Mus musculus	82-86
34376577-0	2021	Itraconazole Exerts its Anti-Tumor Effect in Esophageal Cancer by Suppressing the HER2/AKT Signaling Pathway.	Itraconazole	0-12	thymoma viral proto-oncogene 1	Mus musculus	87-90
34376577-4	2021	Using an unbiased kinase array, we found that itraconazole downregulated protein kinase AKT phosphorylation in OE33 esophageal adenocarcinoma cells.	Itraconazole	46-58	AKT serine/threonine kinase 1	Homo sapiens	88-91
34376577-5	2021	Itraconazole also decreased phosphorylation of downstream ribosomal protein S6, transcriptional expression of the upstream receptor tyrosine kinase HER2, and phosphorylation of upstream PI3K in esophageal cancer cells.	Itraconazole	0-12	ribosomal protein S6	Mus musculus	58-78
34376577-5	2021	Itraconazole also decreased phosphorylation of downstream ribosomal protein S6, transcriptional expression of the upstream receptor tyrosine kinase HER2, and phosphorylation of upstream PI3K in esophageal cancer cells.	Itraconazole	0-12	erb-b2 receptor tyrosine kinase 2	Homo sapiens	148-152
34376577-8	2021	HER2 total protein and phosphorylation of AKT and S6 proteins were decreased in xenografts from itraconazole-treated mice compared to xenografts from placebo-treated mice.	Itraconazole	96-108	erb-b2 receptor tyrosine kinase 2	Mus musculus	0-4
34376577-8	2021	HER2 total protein and phosphorylation of AKT and S6 proteins were decreased in xenografts from itraconazole-treated mice compared to xenografts from placebo-treated mice.	Itraconazole	96-108	thymoma viral proto-oncogene 1	Mus musculus	42-45
34376577-9	2021	In an early phase I clinical trial (NCT02749513) in esophageal cancer patients, itraconazole decreased HER2 total protein expression and phosphorylation of AKT and S6 proteins in tumors.	Itraconazole	80-92	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107
34376577-9	2021	In an early phase I clinical trial (NCT02749513) in esophageal cancer patients, itraconazole decreased HER2 total protein expression and phosphorylation of AKT and S6 proteins in tumors.	Itraconazole	80-92	AKT serine/threonine kinase 1	Homo sapiens	156-159
34376577-10	2021	These data demonstrate that itraconazole has potent anti-tumor properties in esophageal cancer, partially through blockade of HER2/AKT signaling.	Itraconazole	28-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-130
34376577-10	2021	These data demonstrate that itraconazole has potent anti-tumor properties in esophageal cancer, partially through blockade of HER2/AKT signaling.	Itraconazole	28-40	AKT serine/threonine kinase 1	Homo sapiens	131-134
34627431-8	2021	The protein levels of SMO and Glil were significantly down-regulated after treated by arsenic disulfide and itraconazole alone(P<0.01).	Itraconazole	108-120	smoothened, frizzled class receptor	Homo sapiens	22-25
34627431-11	2021	In addition, the combination of AS2S2 and itraconazole show a synergistic effects, which may be related with the down-regulated protein expression of SMO and Glil of Hedgehog signaling pathway.	Itraconazole	42-54	smoothened, frizzled class receptor	Homo sapiens	150-153
34480080-5	2021	Hh signalling appeared necessary to sustain cell growth, as SHH ligand depletion with Robotikinin or SMO inhibition, either with chemical inhibitors (Itraconazole or LDE-225) or SMO-specific siRNA, attenuated GLI1 activity and cell proliferation in both monolayer and organotypic raft culture.	Itraconazole	150-162	sonic hedgehog signaling molecule	Homo sapiens	60-63
34480080-5	2021	Hh signalling appeared necessary to sustain cell growth, as SHH ligand depletion with Robotikinin or SMO inhibition, either with chemical inhibitors (Itraconazole or LDE-225) or SMO-specific siRNA, attenuated GLI1 activity and cell proliferation in both monolayer and organotypic raft culture.	Itraconazole	150-162	GLI family zinc finger 1	Homo sapiens	209-213
31290765-11	2021	Esophageal SHH levels were lower in itraconazole vs control (P = 0.12).	Itraconazole	36-48	sonic hedgehog signaling molecule	Homo sapiens	11-14
34429859-4	2021	Here, we report that the antifungal compound itraconazole (ICZ), but not its main metabolite hydroxy-ICZ or ketoconazole, disrupts the binding of Rab7 to ORP3-VAP-A complexes, leading to inhibition of EV-mediated pro-metastatic morphological changes including cell migration behaviour of colon cancer cells.	Itraconazole	45-57	RAB7B, member RAS oncogene family	Homo sapiens	146-150
34429859-4	2021	Here, we report that the antifungal compound itraconazole (ICZ), but not its main metabolite hydroxy-ICZ or ketoconazole, disrupts the binding of Rab7 to ORP3-VAP-A complexes, leading to inhibition of EV-mediated pro-metastatic morphological changes including cell migration behaviour of colon cancer cells.	Itraconazole	45-57	oxysterol binding protein like 3	Homo sapiens	154-158
34429859-4	2021	Here, we report that the antifungal compound itraconazole (ICZ), but not its main metabolite hydroxy-ICZ or ketoconazole, disrupts the binding of Rab7 to ORP3-VAP-A complexes, leading to inhibition of EV-mediated pro-metastatic morphological changes including cell migration behaviour of colon cancer cells.	Itraconazole	45-57	VAMP associated protein A	Homo sapiens	159-164
34429859-4	2021	Here, we report that the antifungal compound itraconazole (ICZ), but not its main metabolite hydroxy-ICZ or ketoconazole, disrupts the binding of Rab7 to ORP3-VAP-A complexes, leading to inhibition of EV-mediated pro-metastatic morphological changes including cell migration behaviour of colon cancer cells.	Itraconazole	59-62	RAB7B, member RAS oncogene family	Homo sapiens	146-150
34429859-4	2021	Here, we report that the antifungal compound itraconazole (ICZ), but not its main metabolite hydroxy-ICZ or ketoconazole, disrupts the binding of Rab7 to ORP3-VAP-A complexes, leading to inhibition of EV-mediated pro-metastatic morphological changes including cell migration behaviour of colon cancer cells.	Itraconazole	59-62	oxysterol binding protein like 3	Homo sapiens	154-158
34429859-4	2021	Here, we report that the antifungal compound itraconazole (ICZ), but not its main metabolite hydroxy-ICZ or ketoconazole, disrupts the binding of Rab7 to ORP3-VAP-A complexes, leading to inhibition of EV-mediated pro-metastatic morphological changes including cell migration behaviour of colon cancer cells.	Itraconazole	59-62	VAMP associated protein A	Homo sapiens	159-164
34140765-2	2021	This study aimed to evaluate the impact of the strong CYP3A4 inhibitor itraconazole on the safety and pharmacokinetics of pyrotinib in Chinese healthy adults.	Itraconazole	71-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-60
34475046-6	2021	The 12/15-lipoxygenase inhibitor, which is involved in the conversion of 18-hydroxy-eicosapentaenoic acid to resolvin E3, attenuated the inhibitory effect of itraconazole.	Itraconazole	158-170	arachidonate 15-lipoxygenase	Homo sapiens	4-22
34145979-2	2021	A phase 1 open-label, 2-period, fixed-sequence, 2-part study (NCT03928327) characterized effects of a strong CYP3A4 inhibitor (itraconazole) and inducer (rifampin) on the pharmacokinetics (PK) of mobocertinib and its active metabolites, AP32960 and AP32914.	Itraconazole	127-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	109-115
34145979-6	2021	Based on these results, the strong CYP3A inhibitor itraconazole and inducer rifampin significantly influenced the PK of mobocertinib and its active metabolites.	Itraconazole	51-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-40
34267345-0	2022	Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-37
34267345-3	2022	In this study, we investigated the effects of CYP3A inhibitor itraconazole and CYP3A inducer rifampicin on the pharmacokinetics of almonertinib and HAS-719 in 64 healthy volunteers.	Itraconazole	62-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-51
31290765-13	2021	CONCLUSION: Itraconazole significantly decreases EAC development and SHH expression in a preclinical animal model of BM.	Itraconazole	12-24	sonic hedgehog signaling molecule	Homo sapiens	69-72
35218073-6	2022	Fosravuconazole is a novel broad-spectrum azole and a moderate inhibitor of Cyp3A4 that causes fewer drug interactions than itraconazole and voriconazole, indicating a promising drug for this disease.	Itraconazole	124-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82
35094205-0	2022	Itraconazole-Induced the Activation of Adenosine 5"-Monophosphate (Amp)-Activated Protein Kinase Inhibits Tumor Growth of Melanoma via Inhibiting ERK Signaling.	Itraconazole	0-12	mitogen-activated protein kinase 1	Homo sapiens	146-149
35094205-3	2022	This work investigated the function of itraconazole-induced 5"-monophosphate (AMP)-activated protein kinase alpha (AMPKalpha) in melanoma progression through ERK signaling.	Itraconazole	39-51	mitogen-activated protein kinase 1	Homo sapiens	158-161
35094205-11	2022	Itraconazole activated AMPK signaling and inhibited ERK signaling in melanoma cells.	Itraconazole	0-12	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	23-27
35094205-11	2022	Itraconazole activated AMPK signaling and inhibited ERK signaling in melanoma cells.	Itraconazole	0-12	mitogen-activated protein kinase 1	Homo sapiens	52-55
35094205-12	2022	Activation of ERK signaling reversed the effect of itraconazole on cellular process in melanoma.	Itraconazole	51-63	mitogen-activated protein kinase 1	Homo sapiens	14-17
35094205-13	2022	Moreover, itraconazole-induced AMPKalpha inhibited melanoma tumor growth in vivo by inhibiting ERK signaling.	Itraconazole	10-22	mitogen-activated protein kinase 1	Homo sapiens	95-98
35094205-14	2022	Itraconazole-induced AMPKalpha inhibits the progression of melanoma by inhibition of ERK signaling.	Itraconazole	0-12	mitogen-activated protein kinase 1	Homo sapiens	85-88
35616006-4	2022	Asciminib exposure (area under the curve (AUC)) unexpectedly decreased by ~40% when administered concomitantly with the strong CYP3A inhibitor itraconazole oral solution, whereas maximum plasma concentration (Cmax ) decreased by ~50%.	Itraconazole	143-155	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-132
35605912-3	2022	Then two clinical studies were performed to investigate the effects of itraconazole and rifampicin (potent CYP3A4/5 inhibitor and inducer, respectively) on the pharmacokinetics of youkenafil and its main metabolite, N-desethyl youkenafil (M1).	Itraconazole	71-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	107-115
35246464-3	2022	The use of 3 microM itraconazole was successfully validated for estimation of fm,CYP3A4 by demonstration of fm values within a 2-fold of in vivo estimates for 10 out of 13 CYP3A4 substrates in a reference set of marketed drugs.	Itraconazole	20-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87
35344780-8	2022	The interference of CYP3A modulators itraconazole and rifampicin with the analytes, and the mutual interference between the analytes were also investigated producing acceptable results.	Itraconazole	37-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-25
35517785-8	2022	Reduced cyclin D1 protein levels were consistent with G0/G1 phase arrest, especially when resulting from the combination of ITZ with rapamycin.	Itraconazole	124-127	cyclin D1	Homo sapiens	8-17
35389533-0	2022	Cytochrome P450 reaction phenotyping of itraconazole hydroxylation in the dog.	Itraconazole	40-52	Cytochrome P450 1A1	Canis lupus familiaris	0-15
35389533-6	2022	In rCYP experiments, CYP2D15 and CYP3A12 had highest activity for ITZ hydroxylation.	Itraconazole	66-69	cytochrome P450 2D15	Canis lupus familiaris	21-28
35389533-6	2022	In rCYP experiments, CYP2D15 and CYP3A12 had highest activity for ITZ hydroxylation.	Itraconazole	66-69	cytochrome P450 3A12	Canis lupus familiaris	33-40
35389533-7	2022	In inhibitor experiments, quinidine and erythromycin inhibited ITZ hydroxylation in CYP2D15 and CYP3A12, respectively, in an isoform-specific manner.	Itraconazole	63-66	cytochrome P450 2D15	Canis lupus familiaris	84-91
35389533-7	2022	In inhibitor experiments, quinidine and erythromycin inhibited ITZ hydroxylation in CYP2D15 and CYP3A12, respectively, in an isoform-specific manner.	Itraconazole	63-66	cytochrome P450 3A12	Canis lupus familiaris	96-103
35389533-10	2022	These findings support a role for CYP2D15 and CYP3A12 in ITZ biotransformation in canine liver.	Itraconazole	57-60	cytochrome P450 2D15	Canis lupus familiaris	34-41
35389533-10	2022	These findings support a role for CYP2D15 and CYP3A12 in ITZ biotransformation in canine liver.	Itraconazole	57-60	cytochrome P450 3A12	Canis lupus familiaris	46-53
35165925-1	2022	AIMS: Clinical drug interaction studies with itraconazole and rifampicin demonstrated acalabrutinib is a sensitive substrate of CYP3A.	Itraconazole	45-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	128-133
35247290-1	2022	This phase 1, open-label study evaluated the effect of food and administration of the cytochrome P450 3A4 and P-glycoprotein inhibitor itraconazole (ITZ) on the pharmacokinetics of AMG 986.	Itraconazole	135-147	ATP binding cassette subfamily B member 1	Homo sapiens	110-124
35247290-1	2022	This phase 1, open-label study evaluated the effect of food and administration of the cytochrome P450 3A4 and P-glycoprotein inhibitor itraconazole (ITZ) on the pharmacokinetics of AMG 986.	Itraconazole	149-152	ATP binding cassette subfamily B member 1	Homo sapiens	110-124
35242038-0	2022	Itraconazole Inhibits the Growth of Cutaneous Squamous Cell Carcinoma by Targeting HMGCS1/ACSL4 Axis.	Itraconazole	0-12	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1	Mus musculus	83-89
35242038-0	2022	Itraconazole Inhibits the Growth of Cutaneous Squamous Cell Carcinoma by Targeting HMGCS1/ACSL4 Axis.	Itraconazole	0-12	acyl-CoA synthetase long-chain family member 4	Mus musculus	90-95
35242038-12	2022	An integrated analysis of transcriptomic and proteomic analyses identified that 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and acyl-CoA synthetase long-chain family member 4 (ACSL4) were significantly upregulated in A431 cells treated with itraconazole.	Itraconazole	248-260	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1	Mus musculus	123-129
35242038-12	2022	An integrated analysis of transcriptomic and proteomic analyses identified that 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and acyl-CoA synthetase long-chain family member 4 (ACSL4) were significantly upregulated in A431 cells treated with itraconazole.	Itraconazole	248-260	acyl-CoA synthetase long-chain family member 4	Mus musculus	135-181
35242038-13	2022	HMGCS1 silencing reversed the antiproliferative activity of itraconazole in A431 cells.	Itraconazole	60-72	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1	Mus musculus	0-6
35242038-14	2022	Dual-luciferase assay showed that itraconazole could promote HMGCS1 transcription.	Itraconazole	34-46	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1	Mus musculus	61-67
35242038-18	2022	Conclusion: We proved itraconazole inhibits the growth of cSCC by regulating HMGCS1/ACSL4 axis.	Itraconazole	22-34	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1	Mus musculus	77-83
35242038-18	2022	Conclusion: We proved itraconazole inhibits the growth of cSCC by regulating HMGCS1/ACSL4 axis.	Itraconazole	22-34	acyl-CoA synthetase long-chain family member 4	Mus musculus	84-89
35350119-4	2022	The addition of insulin or glucose at physiologic levels in RPMI medium alone altered the MIC in either a positive or negative fashion, depending on the organisms and drug tested, with C. glabrata most significantly altered with a 40, >32- and 46-fold increase in MIC for amphotericin B, itraconazole and miconazole, respectively.	Itraconazole	288-300	insulin	Homo sapiens	16-23
34989180-3	2022	This phase 1, fixed-sequence, open-label, crossover trial (ClinicalTrials.gov identifier NCT03173170) investigated the effect of itraconazole, a potent CYP3A4 inhibitor, on felcisetrag pharmacokinetics in healthy adults.	Itraconazole	129-141	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	152-158
35370263-2	2022	An antifungal agent, itraconazole (ITCZ), that has antimicrobial activity against Aspergillus species, is used as a prophylactic agent against Aspergillus infection after LT. ITCZ and its metabolite, hydroxyitraconazole (OH-ITCZ), potently inhibit CYP3A and P-glycoprotein that metabolize or excrete calcineurin inhibitors (CNIs), which are the first-line immunosuppressants used after LT; thus, concomitant use of ITCZ and CNIs could induce an increase in the blood concentration of CNIs.	Itraconazole	21-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	248-253
35370263-2	2022	An antifungal agent, itraconazole (ITCZ), that has antimicrobial activity against Aspergillus species, is used as a prophylactic agent against Aspergillus infection after LT. ITCZ and its metabolite, hydroxyitraconazole (OH-ITCZ), potently inhibit CYP3A and P-glycoprotein that metabolize or excrete calcineurin inhibitors (CNIs), which are the first-line immunosuppressants used after LT; thus, concomitant use of ITCZ and CNIs could induce an increase in the blood concentration of CNIs.	Itraconazole	35-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	248-253
3030012-10	1987	The interaction with mammalian cytochrome P-450 decreases from miconazole greater than ketoconazole much greater than itraconazole and is much weaker than the interaction of the antimycotics with yeast cytochrome P-450.	Itraconazole	118-130	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
2560935-1	1989	The effect of novel azole derivatives (itraconazole and fluconazole) on 5-lipoxygenase activity was examined using human polymorphonuclear leukocytes (PMNL) as the enzyme source.	Itraconazole	39-51	arachidonate 5-lipoxygenase	Homo sapiens	72-86
2560935-2	1989	The novel imidazole derivative itraconazole proved to be a potent inhibitor (IC50 2 X 10(-6) M) of 5-lipoxygenase activity.	Itraconazole	31-43	arachidonate 5-lipoxygenase	Homo sapiens	99-113
2850750-7	1988	The choice of itraconazole--with its improved tissue affinity, its lower therapeutic dose requirements, and its increased selectivity for fungal cytochrome P-450--demonstrates very well that the use of animal and human pharmacology helps in the design of an antifungal drug with as much effect as possible on the fungus and as little effect as possible on the host.	Itraconazole	14-26	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-161
33201347-1	2021	PURPOSE: The antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4beta-hydroxycholesterol, which is a validated marker for hepatic cytochrome P450 (CYP) 3A4 activity.	Itraconazole	47-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	157-182
33826998-8	2021	In conclusion, itraconazole has unique characteristics that are distinct from those shared by the other azole anti-fungal drugs ketoconazole, voriconazole, and fluconazole with regard to the influence of genetic variations on the inhibition of CYP3A4.	Itraconazole	15-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	244-250
33387374-2	2021	Previous studies have reported that nadolol is a substrate of P-glycoprotein, and the coadministration with itraconazole, a typical P-glycoprotein inhibitor, results in elevated plasma concentrations and cumulative urinary excretion of nadolol.	Itraconazole	108-120	ATP binding cassette subfamily B member 1	Homo sapiens	62-76
33387374-2	2021	Previous studies have reported that nadolol is a substrate of P-glycoprotein, and the coadministration with itraconazole, a typical P-glycoprotein inhibitor, results in elevated plasma concentrations and cumulative urinary excretion of nadolol.	Itraconazole	108-120	ATP binding cassette subfamily B member 1	Homo sapiens	132-146
33387374-7	2021	In the drug interactions of nadolol with itraconazole, rifampicin, a well-known P-glycoprotein inducer, or grapefruit juice, there were significant correlations between the differences in AUC0-48 and those in Ae, 0-48 from the controls in individual subjects.	Itraconazole	41-53	ATP binding cassette subfamily B member 1	Homo sapiens	80-94
34049965-2	2021	Ipatasertib was metabolized by CYP3A4 to its major metabolite, M1 (G-037720), and was a P-gp substrate and OATP1B1/1B3 inhibitor in vitro A Phase I drug-drug interaction (DDI) study (n=15) was conducted in healthy subjects to evaluate the effect of itraconazole (200 mg solution QD, 4 days), a strong CYP3A4 and P-gp inhibitor, on pharmacokinetics of ipatasertib (100 mg single dose).	Itraconazole	249-261	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
33964991-4	2021	We thus conducted this study to investigate the effect of itraconazole (ICZ), a strong inhibitor of CYP3A and a moderate inhibitor of P-gp, on the pharmacokinetics (PK) of FDV.	Itraconazole	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-105
33964991-4	2021	We thus conducted this study to investigate the effect of itraconazole (ICZ), a strong inhibitor of CYP3A and a moderate inhibitor of P-gp, on the pharmacokinetics (PK) of FDV.	Itraconazole	58-70	phosphoglycolate phosphatase	Homo sapiens	134-138
33964991-4	2021	We thus conducted this study to investigate the effect of itraconazole (ICZ), a strong inhibitor of CYP3A and a moderate inhibitor of P-gp, on the pharmacokinetics (PK) of FDV.	Itraconazole	72-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-105
33964991-4	2021	We thus conducted this study to investigate the effect of itraconazole (ICZ), a strong inhibitor of CYP3A and a moderate inhibitor of P-gp, on the pharmacokinetics (PK) of FDV.	Itraconazole	72-75	phosphoglycolate phosphatase	Homo sapiens	134-138
33665257-4	2021	Also, we evaluated the inhibitory effect of itraconazole on P-gp using specific in vivo biodistribution through 99mTc-MIBI uptake.	Itraconazole	44-56	phosphoglycolate phosphatase	Mus musculus	60-64
33905526-4	2021	In the mouse Leydig cell line TM3, used as a proxy for ovarian theca cells, itraconazole exposure had a suppressing effect on genes downstream of HH signaling, such as Gli1.	Itraconazole	76-88	GLI-Kruppel family member GLI1	Mus musculus	168-172
33905526-5	2021	Exposing explanted rat ovaries (gestational day 22 or postnatal day 3) to 30 microM itraconazole for 72 h induced significant suppression of genes in the HH signaling pathway with altered Ihh, Gli1, Ptch1, and Smo expression similar to those previously observed in Ihh/Dhh knock-out mice.	Itraconazole	84-96	Indian hedgehog signaling molecule	Rattus norvegicus	188-191
33905526-5	2021	Exposing explanted rat ovaries (gestational day 22 or postnatal day 3) to 30 microM itraconazole for 72 h induced significant suppression of genes in the HH signaling pathway with altered Ihh, Gli1, Ptch1, and Smo expression similar to those previously observed in Ihh/Dhh knock-out mice.	Itraconazole	84-96	GLI family zinc finger 1	Rattus norvegicus	193-197
33905526-5	2021	Exposing explanted rat ovaries (gestational day 22 or postnatal day 3) to 30 microM itraconazole for 72 h induced significant suppression of genes in the HH signaling pathway with altered Ihh, Gli1, Ptch1, and Smo expression similar to those previously observed in Ihh/Dhh knock-out mice.	Itraconazole	84-96	patched 1	Rattus norvegicus	199-204
33905526-5	2021	Exposing explanted rat ovaries (gestational day 22 or postnatal day 3) to 30 microM itraconazole for 72 h induced significant suppression of genes in the HH signaling pathway with altered Ihh, Gli1, Ptch1, and Smo expression similar to those previously observed in Ihh/Dhh knock-out mice.	Itraconazole	84-96	smoothened, frizzled class receptor	Rattus norvegicus	210-213
33905526-5	2021	Exposing explanted rat ovaries (gestational day 22 or postnatal day 3) to 30 microM itraconazole for 72 h induced significant suppression of genes in the HH signaling pathway with altered Ihh, Gli1, Ptch1, and Smo expression similar to those previously observed in Ihh/Dhh knock-out mice.	Itraconazole	84-96	Indian hedgehog signaling molecule	Rattus norvegicus	265-268
33905526-5	2021	Exposing explanted rat ovaries (gestational day 22 or postnatal day 3) to 30 microM itraconazole for 72 h induced significant suppression of genes in the HH signaling pathway with altered Ihh, Gli1, Ptch1, and Smo expression similar to those previously observed in Ihh/Dhh knock-out mice.	Itraconazole	84-96	desert hedgehog signaling molecule	Rattus norvegicus	269-272
33497608-0	2021	Itraconazole synergistically increases therapeutic effect of paclitaxel and 99mTc-MIBI accumulation, as a probe of P-gp activity, in HT-29 tumor-bearing nude mice.	Itraconazole	0-12	phosphoglycolate phosphatase	Mus musculus	115-119
33497608-4	2021	Itraconazole successfully inhibited P-gp mediated 99mTc-MIBI efflux, increasing its in vitro accumulation in itraconazole-receiving dishes.	Itraconazole	0-12	phosphoglycolate phosphatase	Mus musculus	36-40
33497608-4	2021	Itraconazole successfully inhibited P-gp mediated 99mTc-MIBI efflux, increasing its in vitro accumulation in itraconazole-receiving dishes.	Itraconazole	109-121	phosphoglycolate phosphatase	Mus musculus	36-40
32928702-3	2021	This case highlights the dangerous and preventable combination of high glucose intake, glucocorticoids and itraconazole inhibition of CYP3A4 (with resultant glucocorticoid accumulation) that can result in a state of life- threatening HHS in an adolescent with previously stable CFRD.	Itraconazole	107-119	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	134-140
33786369-0	2021	Drug Repurposing of Itraconazole and Estradiol Benzoate against COVID-19 by Blocking SARS-CoV-2 Spike Protein-Mediated Membrane Fusion.	Itraconazole	20-32	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	96-101
28520375-4	2012	In CYP2D6 poor metabolizers who are taking concomitant strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin), a quarter of the usual dose should be used (Table 1) (2).	Itraconazole	87-99	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	3-9
33665257-6	2021	The data presented in this article are related to the research paper entitled "Itraconazole synergistically increases therapeutic effect of paclitaxel and 99mTc-MIBI accumulation, as a probe of P-gp activity, in HT-29 tumor-bearing nude mice".	Itraconazole	79-91	phosphoglycolate phosphatase	Mus musculus	194-198
33387577-3	2021	Recently, the azole antifungals itraconazole and posaconazole were identified to potently inhibit human 11beta-HSD2, and several case studies described patients with acquired AME.	Itraconazole	32-44	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	104-115
33387577-4	2021	To begin to understand why this adverse drug effect was missed during preclinical investigations, the inhibitory potential of itraconazole, its main metabolite hydroxyitraconazole (OHI) and posaconazole against 11beta-HSD2 from human and three commonly used experimental animals was assessed.	Itraconazole	126-138	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	211-222
32602215-1	2021	The effects of itraconazole, a strong CYP3A4 inhibitor, on the steady-state pharmacokinetics of vemurafenib were evaluated in a phase 1, multicenter, open-label, fixed-sequence study.	Itraconazole	15-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
33315900-5	2020	A photo-crosslinking study confirmed direct binding of itraconazole to a representative folding-defective mutant protein, NPC1-I1061T.	Itraconazole	55-67	NPC intracellular cholesterol transporter 1	Homo sapiens	122-126
33387577-7	2021	Exchange of the C-terminus and substitution of residues Leu170,Ile172 in mouse 11beta-HSD2 by the corresponding residues His170,Glu172 of the human enzyme resulted in a gain of sensitivity to itraconazole and posaconazole, resembling human 11beta-HSD2.	Itraconazole	192-204	hydroxysteroid 11-beta dehydrogenase 2	Mus musculus	79-90
33387577-7	2021	Exchange of the C-terminus and substitution of residues Leu170,Ile172 in mouse 11beta-HSD2 by the corresponding residues His170,Glu172 of the human enzyme resulted in a gain of sensitivity to itraconazole and posaconazole, resembling human 11beta-HSD2.	Itraconazole	192-204	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	240-251
33107218-3	2021	We report on how two acumapimod clinical DDI studies and a physiologically based pharmacokinetic (PBPK) model assessing how co-administration of a weak (azithromycin) and strong (itraconazole) CYP3A4 inhibitor affected acumapimod systemic exposure, informed decision-making and supported concomitant use of CYP3A4 and P-gp inhibitors.	Itraconazole	179-191	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	193-199
32847935-11	2020	Greater itraconazole levels were significantly and meaningfully associated with reduction in tumor volume (Spearman correlation -0.71; P=0.05) and tumor perfusion (Ktrans) (correlation -0.71; P=0.01), decreases in the pro-angiogenic cytokines interleukin 1b (correlation -0.73; P=0.01) and GM-CSF (correlation -1.00; P<0.001), and reduction in tumor microvessel density (correlation -0.69; P=0.03).	Itraconazole	8-20	colony stimulating factor 2	Homo sapiens	290-296
32535897-3	2020	This observation was made in a drug-drug interaction study with the BTK inhibitor fenebrutinib and itraconazole, in which, relative to the control group, the expected increase in fenebrutinib Cmax was not observed in the itraconazole group, and a delay in Tmax was observed in the itraconazole group.	Itraconazole	99-111	Bruton tyrosine kinase	Canis lupus familiaris	68-71
33312948-4	2020	This study aimed to investigate the effects of vismodegib and itraconazole on the expression of Hedgehog (HH) genes (PTCH1, SMO, and GLI1), cell cycle and cell death in OSCC cells.	Itraconazole	62-74	patched 1	Homo sapiens	117-122
33211216-1	2021	The inhibiting effects of itraconazole, an antifungal drug on vascular endothelial growth factor (VEGF) have recently been discovered.	Itraconazole	26-38	vascular endothelial growth factor A	Homo sapiens	62-96
33211216-1	2021	The inhibiting effects of itraconazole, an antifungal drug on vascular endothelial growth factor (VEGF) have recently been discovered.	Itraconazole	26-38	vascular endothelial growth factor A	Homo sapiens	98-102
33211216-2	2021	By inhibiting VEGF, itraconazole has shown potential in clinical trials as anti-cancer treatment.	Itraconazole	20-32	vascular endothelial growth factor A	Homo sapiens	14-18
32935287-6	2020	Itraconazole 200 mg/day elevated steady-state exposure to 5 mg/day balovaptan approximately 4.5-5.5-fold (Day 15 GMR [90% CI], 4.46 [4.06-4.90] for Cmax and 5.57 [5.00-6.21] for AUC) and extended the time to steady state from ~ 5 days to ~ 13-14 days.	Itraconazole	0-12	colony stimulating factor 2 receptor subunit alpha	Homo sapiens	113-116
32942154-0	2020	Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways.	Itraconazole	0-12	AKT serine/threonine kinase 1	Homo sapiens	70-73
32942154-0	2020	Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways.	Itraconazole	0-12	mechanistic target of rapamycin kinase	Homo sapiens	74-78
32942154-12	2020	Furthermore, itraconazole inhibited HCC cell growth and promoted apoptosis through the Hh, Wnt/catenin, AKT/mTOR/S6K, ROS and death receptor pathways.	Itraconazole	13-25	AKT serine/threonine kinase 1	Homo sapiens	104-107
32942154-12	2020	Furthermore, itraconazole inhibited HCC cell growth and promoted apoptosis through the Hh, Wnt/catenin, AKT/mTOR/S6K, ROS and death receptor pathways.	Itraconazole	13-25	mechanistic target of rapamycin kinase	Homo sapiens	108-112
33139055-1	2020	PURPOSE: This drug-drug interaction study determined whether the metabolism and distribution of the Polo-like kinase 1 inhibitor, volasertib, is affected by co-administration of the P-glycoprotein and cytochrome P-450 3A4 inhibitor, itraconazole.	Itraconazole	233-245	polo like kinase 1	Homo sapiens	100-118
33312948-4	2020	This study aimed to investigate the effects of vismodegib and itraconazole on the expression of Hedgehog (HH) genes (PTCH1, SMO, and GLI1), cell cycle and cell death in OSCC cells.	Itraconazole	62-74	smoothened, frizzled class receptor	Homo sapiens	124-127
33312948-4	2020	This study aimed to investigate the effects of vismodegib and itraconazole on the expression of Hedgehog (HH) genes (PTCH1, SMO, and GLI1), cell cycle and cell death in OSCC cells.	Itraconazole	62-74	GLI family zinc finger 1	Homo sapiens	133-137
33312948-10	2020	Gene expression of PTCH1, SMO, and GLI1 decreased in response to 24 h of treatment with vismodegib or itraconazole.	Itraconazole	102-114	patched 1	Homo sapiens	19-24
33312948-10	2020	Gene expression of PTCH1, SMO, and GLI1 decreased in response to 24 h of treatment with vismodegib or itraconazole.	Itraconazole	102-114	smoothened, frizzled class receptor	Homo sapiens	26-29
33312948-10	2020	Gene expression of PTCH1, SMO, and GLI1 decreased in response to 24 h of treatment with vismodegib or itraconazole.	Itraconazole	102-114	GLI family zinc finger 1	Homo sapiens	35-39
33312948-12	2020	An increase in the DNA fragmentation was observed after treatment and both inhibitors induced apoptosis after 72 h. In conclusion, SMO inhibitors vismodegib and itraconazole demonstrably reduced the expression of HH genes in CAL27 OSCC cell line.	Itraconazole	161-173	smoothened, frizzled class receptor	Homo sapiens	131-134
32515832-7	2020	Parsaclisib maximum plasma drug concentration (Cmax ) and area under the concentration-time curve extrapolated to infinity (AUC0-  ) were increased by 21% and 107% with concomitant itraconazole versus parsaclisib alone (GMR, 1.21; 90%CI, 1.14-1.29; and 2.07; 90%CI, 1.97-2.17, respectively).	Itraconazole	181-193	colony stimulating factor 2 receptor subunit alpha	Homo sapiens	220-223
33879433-0	2020	Hepato-protective role of itraconazole mediated cytochrome p450 pathway inhibition in liver fibrosis.	Itraconazole	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	48-63
33879433-6	2020	Based upon this fact, present study is aimed to evaluate the repurposing of Itraconazole in the prevention of hepatic fibrosis via inhibition of cytochrome P450 pathway.	Itraconazole	76-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	145-160
32649934-4	2020	By blocking VEGF/VEGFR-2 binding via pre-treatment with itraconazole we demonstrated that animals" condition was deteriorated soon at 1-2 h post-PNV exposure concurrently with decreased expression of VEGF, BBB-associated proteins, ZO-1, beta-catenin, laminin, P-gp (P-glycoprotein), Neu-N (neuron"s viability marker) and MAPKphosphorylated-p38, while phosphorylated-ERK and Src pathways were increased.	Itraconazole	56-68	vascular endothelial growth factor A	Rattus norvegicus	12-16
32649934-4	2020	By blocking VEGF/VEGFR-2 binding via pre-treatment with itraconazole we demonstrated that animals" condition was deteriorated soon at 1-2 h post-PNV exposure concurrently with decreased expression of VEGF, BBB-associated proteins, ZO-1, beta-catenin, laminin, P-gp (P-glycoprotein), Neu-N (neuron"s viability marker) and MAPKphosphorylated-p38, while phosphorylated-ERK and Src pathways were increased.	Itraconazole	56-68	kinase insert domain receptor	Rattus norvegicus	17-24
32649934-4	2020	By blocking VEGF/VEGFR-2 binding via pre-treatment with itraconazole we demonstrated that animals" condition was deteriorated soon at 1-2 h post-PNV exposure concurrently with decreased expression of VEGF, BBB-associated proteins, ZO-1, beta-catenin, laminin, P-gp (P-glycoprotein), Neu-N (neuron"s viability marker) and MAPKphosphorylated-p38, while phosphorylated-ERK and Src pathways were increased.	Itraconazole	56-68	vascular endothelial growth factor A	Rattus norvegicus	17-21
32968519-5	2020	As the detection limits were down to 0.013 and 0.1 microg ml-1 and quantitation limits were 0.04 and 0.032 microg ml-1 for terbinafine and itraconazole, respectively; the in vitro determination of terbinafine and itraconazole in spiked plasma samples was applicable.	Itraconazole	139-151	interleukin 17F	Homo sapiens	114-118
32459872-0	2020	Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).	Itraconazole	128-140	thyrotropin releasing hormone	Homo sapiens	57-60
32459872-0	2020	Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).	Itraconazole	128-140	ATP binding cassette subfamily B member 1	Homo sapiens	102-116
32459872-9	2020	Itraconazole has the potential to inhibit drug transport via intestinal P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP); therefore, substrate assessments of rovatirelin for the 2 transporters were evaluated using Caco-2 cell monolayers.	Itraconazole	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	72-86
32459872-9	2020	Itraconazole has the potential to inhibit drug transport via intestinal P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP); therefore, substrate assessments of rovatirelin for the 2 transporters were evaluated using Caco-2 cell monolayers.	Itraconazole	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	88-92
32459872-9	2020	Itraconazole has the potential to inhibit drug transport via intestinal P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP); therefore, substrate assessments of rovatirelin for the 2 transporters were evaluated using Caco-2 cell monolayers.	Itraconazole	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	98-130
32459872-9	2020	Itraconazole has the potential to inhibit drug transport via intestinal P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP); therefore, substrate assessments of rovatirelin for the 2 transporters were evaluated using Caco-2 cell monolayers.	Itraconazole	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	132-136
32459872-11	2020	The current study shows that itraconazole"s effect on rovatirelin pharmacokinetics is mediated through inhibition of CYP3A4/5 and intestinal P-gp.	Itraconazole	29-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	117-125
32459872-11	2020	The current study shows that itraconazole"s effect on rovatirelin pharmacokinetics is mediated through inhibition of CYP3A4/5 and intestinal P-gp.	Itraconazole	29-41	ATP binding cassette subfamily B member 1	Homo sapiens	141-145
33102531-6	2020	The long-tailed inhibitors (posaconazole and itraconazole) have stronger binding affinities than short-tailed inhibitors (fluconazole and voriconazole) because long-tailed inhibitors can form more hydrophobic interactions with CYP51.	Itraconazole	45-57	cytochrome P450 family 51 subfamily A member 1	Homo sapiens	227-232
32407849-8	2020	Itraconazole downregulated the protein expression of Hedgehog pathway to inhibit proliferation and migration of oral squamous cell carcinoma cells, which can be revised by recombinant human sonic hedgehog protein (rSHH).	Itraconazole	0-12	sonic hedgehog signaling molecule	Homo sapiens	190-212
32407849-8	2020	Itraconazole downregulated the protein expression of Hedgehog pathway to inhibit proliferation and migration of oral squamous cell carcinoma cells, which can be revised by recombinant human sonic hedgehog protein (rSHH).	Itraconazole	0-12	sonic hedgehog signaling molecule	Rattus norvegicus	214-218
32681018-10	2020	After using the Hedgehog agonist recombinant human Sonic Hedgehog (rhshh), itraconazole could counteract the activation of rhshh.	Itraconazole	75-87	sonic hedgehog signaling molecule	Homo sapiens	51-65
31578565-6	2020	Pb-infected mice treated with PTX/ITC presented a reduction in the pulmonary concentrations of OH-proline, associated with lower concentrations of interleukin (IL)-6, IL-17, and transforming growth factor (TGF)-beta1 and higher concentrations of IL-10 compared to the controls.	Itraconazole	34-37	interleukin 6	Mus musculus	147-165
32080863-10	2020	The PBPK model predicted 3.78- and 7.15-fold increases in the AUC of the potency-adjusted unbound active species with strong CYP3A4 inhibitors itraconazole and ketoconazole, respectively; and 1.62- and 2.37-fold increases with the concomitant use of moderate CYP3A4 inhibitors verapamil and diltiazem, respectively.	Itraconazole	143-155	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-131
32080863-10	2020	The PBPK model predicted 3.78- and 7.15-fold increases in the AUC of the potency-adjusted unbound active species with strong CYP3A4 inhibitors itraconazole and ketoconazole, respectively; and 1.62- and 2.37-fold increases with the concomitant use of moderate CYP3A4 inhibitors verapamil and diltiazem, respectively.	Itraconazole	143-155	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	259-265
32401271-14	2020	Ever itraconazole exposure was associated with increased SCC risk (AHR, 1.20; 95% CI, 1.00-1.45).	Itraconazole	5-17	serpin family B member 3	Homo sapiens	57-60
31578565-6	2020	Pb-infected mice treated with PTX/ITC presented a reduction in the pulmonary concentrations of OH-proline, associated with lower concentrations of interleukin (IL)-6, IL-17, and transforming growth factor (TGF)-beta1 and higher concentrations of IL-10 compared to the controls.	Itraconazole	34-37	interleukin 17A	Mus musculus	167-172
31578565-6	2020	Pb-infected mice treated with PTX/ITC presented a reduction in the pulmonary concentrations of OH-proline, associated with lower concentrations of interleukin (IL)-6, IL-17, and transforming growth factor (TGF)-beta1 and higher concentrations of IL-10 compared to the controls.	Itraconazole	34-37	transforming growth factor, beta 1	Mus musculus	178-216
31578565-6	2020	Pb-infected mice treated with PTX/ITC presented a reduction in the pulmonary concentrations of OH-proline, associated with lower concentrations of interleukin (IL)-6, IL-17, and transforming growth factor (TGF)-beta1 and higher concentrations of IL-10 compared to the controls.	Itraconazole	34-37	interleukin 10	Mus musculus	246-251
31287236-2	2020	A 3-arm, open-label, randomized, single-dose, fixed-sequence crossover study was conducted to characterize the effects of the strong inhibitors gemfibrozil (of CYP2C8) and itraconazole (of CYP3A) and the strong inducer rifampin (of CYP3A) on the single-dose pharmacokinetics of brigatinib.	Itraconazole	172-184	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	189-194
31578565-8	2020	The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-gamma and VEGF, and decreased concentrations of IL-6, IL-1beta, IL-17, and TGF-beta1.	Itraconazole	22-25	chemokine (C-C motif) ligand 3	Mus musculus	147-151
31578565-8	2020	The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-gamma and VEGF, and decreased concentrations of IL-6, IL-1beta, IL-17, and TGF-beta1.	Itraconazole	22-25	interferon gamma	Mus musculus	153-162
31578565-8	2020	The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-gamma and VEGF, and decreased concentrations of IL-6, IL-1beta, IL-17, and TGF-beta1.	Itraconazole	22-25	vascular endothelial growth factor A	Mus musculus	167-171
31578565-8	2020	The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-gamma and VEGF, and decreased concentrations of IL-6, IL-1beta, IL-17, and TGF-beta1.	Itraconazole	22-25	interleukin 6	Mus musculus	205-209
31578565-8	2020	The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-gamma and VEGF, and decreased concentrations of IL-6, IL-1beta, IL-17, and TGF-beta1.	Itraconazole	22-25	interleukin 1 beta	Mus musculus	211-219
31578565-8	2020	The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-gamma and VEGF, and decreased concentrations of IL-6, IL-1beta, IL-17, and TGF-beta1.	Itraconazole	22-25	interleukin 17A	Mus musculus	221-226
31578565-8	2020	The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-gamma and VEGF, and decreased concentrations of IL-6, IL-1beta, IL-17, and TGF-beta1.	Itraconazole	22-25	transforming growth factor, beta 1	Mus musculus	232-241
31893546-3	2020	In this study, a novel brain targeting drug delivery system based on bovine serum albumin (BSA) was constructed for enhancing ITZ distribution in brain.	Itraconazole	126-129	albumin	Mus musculus	76-89
32391164-1	2020	Background: Itraconazole (ITZ), a triazole antifungal agent, is metabolized to hydroxy-ITZ (OH-ITZ), keto-ITZ (KT-ITZ), and N-desalkyl ITZ (ND-ITZ) by cytochrome P450 3A4.	Itraconazole	12-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	151-170
32391164-1	2020	Background: Itraconazole (ITZ), a triazole antifungal agent, is metabolized to hydroxy-ITZ (OH-ITZ), keto-ITZ (KT-ITZ), and N-desalkyl ITZ (ND-ITZ) by cytochrome P450 3A4.	Itraconazole	26-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	151-170
31982514-4	2020	Compared to previous experiments revealing a threefold more potent inhibition of 11beta-HSD2 by itraconazole than with posaconazole, the current study found sevenfold stronger CYP11B1 inhibition by posaconazole over itraconazole.	Itraconazole	96-108	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	81-92
31982514-7	2020	Molecular modeling assessed the binding of posaconazole, itraconazole and OHI to 11beta-HSD2 and the relevant CYP enzymes, and predicted important interactions not formed by the other systemically used azole antifungals, thus providing an initial explanation for the observed inhibitory activities.	Itraconazole	57-69	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	81-92
31982514-8	2020	Together with available clinical observations, the presented data suggest that itraconazole primarily causes pseudohyperaldosteronism through cortisol-induced MR activation due to 11beta-HSD2 inhibition, and posaconazole by CYP11B1 inhibition and accumulation of the mineralocorticoids 11-deoxycorticosterone and 11-deoxycortisol because of feedback activation.	Itraconazole	79-91	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	180-191
32331453-4	2020	A recent cryo-EM structure has revealed an itraconazole binding site (IBS) in the SSD of human NPC1.	Itraconazole	43-55	NPC intracellular cholesterol transporter 1	Homo sapiens	95-99
31875923-3	2020	We evaluated the effect of steady-state rifampin (a strong CYP3A inducer) and steady-state itraconazole (a strong CYP3A inhibitor) on the pharmacokinetics (PK), safety, and tolerability of zanubrutinib in healthy Asian and non-Asian subjects.	Itraconazole	91-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-119
32077323-4	2020	Aim: In the present research, we evaluated the synergistic effects of ketamine with two azole derivatives, itraconazole and fluconazole, on strains of Candida spp.	Itraconazole	107-119	histocompatibility minor 13	Homo sapiens	159-162
31673875-12	2020	CONCLUSION: Coadministration of fluconazole or itraconazole or other moderate/strong CYP2C9 or CYP3A4 inhibitors may increase exposure to erdafitinib in healthy adults and thus may warrant erdafitinib dose reduction or use of alternative concomitant medications with no or minimal CYP2C9 or CYP3A4 inhibition potential.	Itraconazole	47-59	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	281-287
31673875-12	2020	CONCLUSION: Coadministration of fluconazole or itraconazole or other moderate/strong CYP2C9 or CYP3A4 inhibitors may increase exposure to erdafitinib in healthy adults and thus may warrant erdafitinib dose reduction or use of alternative concomitant medications with no or minimal CYP2C9 or CYP3A4 inhibition potential.	Itraconazole	47-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	291-297
32077323-7	2020	Results: Our achievements showed a synergistic effect between ketamine in addition to the two antifungal agents (fluconazole and itraconazole) against planktonic cells and biofilms of Candida spp.	Itraconazole	129-141	histocompatibility minor 13	Homo sapiens	192-195
31514064-3	2019	It is shown how the transversal action of the azoles - fluconazole, posaconazole and itraconazole - in both fungi and Leishmania is due to the occurrence of the same target, lanosterol 14-alpha-demethylase, in these two groups of species.	Itraconazole	85-97	cytochrome P450 family 51 subfamily A member 1	Homo sapiens	174-205
31728714-2	2020	CYP3A plays a major role in lorlatinib metabolism; therefore, a drug-drug interaction study was warranted to evaluate the impact of the strong CYP3A inhibitor, itraconazole, on lorlatinib plasma exposure.	Itraconazole	160-172	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-5
31728714-2	2020	CYP3A plays a major role in lorlatinib metabolism; therefore, a drug-drug interaction study was warranted to evaluate the impact of the strong CYP3A inhibitor, itraconazole, on lorlatinib plasma exposure.	Itraconazole	160-172	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-148
31960187-6	2020	RESULT: This review tries to highlight the effect of itraconazole on smoothened receptor (SMO) in the Hedgehog pathway, thereby reducing the glioma-associated oncogene homolog (GLI) release and finally exhibiting a range of anticancer effects, promoting apoptosis of cancer cells, and inhibiting proliferation by indirect inhibition of NF-kappaB pathway and inflammation, moreover, promoting the expression of cyclin-dependent kinase inhibitors, inhibiting the expression of target genes transcribed by GLI such as BCL-2 and Cyclin-D1.	Itraconazole	53-65	smoothened, frizzled class receptor	Homo sapiens	69-88
31960187-6	2020	RESULT: This review tries to highlight the effect of itraconazole on smoothened receptor (SMO) in the Hedgehog pathway, thereby reducing the glioma-associated oncogene homolog (GLI) release and finally exhibiting a range of anticancer effects, promoting apoptosis of cancer cells, and inhibiting proliferation by indirect inhibition of NF-kappaB pathway and inflammation, moreover, promoting the expression of cyclin-dependent kinase inhibitors, inhibiting the expression of target genes transcribed by GLI such as BCL-2 and Cyclin-D1.	Itraconazole	53-65	smoothened, frizzled class receptor	Homo sapiens	90-93
31960187-6	2020	RESULT: This review tries to highlight the effect of itraconazole on smoothened receptor (SMO) in the Hedgehog pathway, thereby reducing the glioma-associated oncogene homolog (GLI) release and finally exhibiting a range of anticancer effects, promoting apoptosis of cancer cells, and inhibiting proliferation by indirect inhibition of NF-kappaB pathway and inflammation, moreover, promoting the expression of cyclin-dependent kinase inhibitors, inhibiting the expression of target genes transcribed by GLI such as BCL-2 and Cyclin-D1.	Itraconazole	53-65	nuclear factor kappa B subunit 1	Homo sapiens	336-345
31960187-6	2020	RESULT: This review tries to highlight the effect of itraconazole on smoothened receptor (SMO) in the Hedgehog pathway, thereby reducing the glioma-associated oncogene homolog (GLI) release and finally exhibiting a range of anticancer effects, promoting apoptosis of cancer cells, and inhibiting proliferation by indirect inhibition of NF-kappaB pathway and inflammation, moreover, promoting the expression of cyclin-dependent kinase inhibitors, inhibiting the expression of target genes transcribed by GLI such as BCL-2 and Cyclin-D1.	Itraconazole	53-65	GLI family zinc finger 1	Homo sapiens	177-180
31960187-6	2020	RESULT: This review tries to highlight the effect of itraconazole on smoothened receptor (SMO) in the Hedgehog pathway, thereby reducing the glioma-associated oncogene homolog (GLI) release and finally exhibiting a range of anticancer effects, promoting apoptosis of cancer cells, and inhibiting proliferation by indirect inhibition of NF-kappaB pathway and inflammation, moreover, promoting the expression of cyclin-dependent kinase inhibitors, inhibiting the expression of target genes transcribed by GLI such as BCL-2 and Cyclin-D1.	Itraconazole	53-65	BCL2 apoptosis regulator	Homo sapiens	515-520
31960187-6	2020	RESULT: This review tries to highlight the effect of itraconazole on smoothened receptor (SMO) in the Hedgehog pathway, thereby reducing the glioma-associated oncogene homolog (GLI) release and finally exhibiting a range of anticancer effects, promoting apoptosis of cancer cells, and inhibiting proliferation by indirect inhibition of NF-kappaB pathway and inflammation, moreover, promoting the expression of cyclin-dependent kinase inhibitors, inhibiting the expression of target genes transcribed by GLI such as BCL-2 and Cyclin-D1.	Itraconazole	53-65	cyclin D1	Homo sapiens	525-534
31960187-7	2020	Besides, itraconazole increases the number of Bnip3, subsequently, inducing the dissociation of the Beclin-1/BCL-2 binding complex, as a result of ultimately promoting autophagy of cancer cells.	Itraconazole	9-21	BCL2 interacting protein 3	Homo sapiens	46-51
31960187-7	2020	Besides, itraconazole increases the number of Bnip3, subsequently, inducing the dissociation of the Beclin-1/BCL-2 binding complex, as a result of ultimately promoting autophagy of cancer cells.	Itraconazole	9-21	beclin 1	Homo sapiens	100-108
31960187-7	2020	Besides, itraconazole increases the number of Bnip3, subsequently, inducing the dissociation of the Beclin-1/BCL-2 binding complex, as a result of ultimately promoting autophagy of cancer cells.	Itraconazole	9-21	BCL2 apoptosis regulator	Homo sapiens	109-114
31965399-5	2020	The itraconazole encapsulated nanoparticles, conjugated with R5K peptide, were fabricated to allow multivalent binding interactions with VEGF.	Itraconazole	4-16	vascular endothelial growth factor A	Homo sapiens	137-141
31965399-6	2020	The R5K peptide blocked VEGF binding to its receptor, while itraconazole altered the signaling pathway of VEGF stimulation.	Itraconazole	60-72	vascular endothelial growth factor A	Homo sapiens	106-110
31888155-7	2019	At the molecular level, ITR NPs were more effective than ITR solution in inducing pro-apoptotic Bax and p53 while reducing anti-apoptotic Bcl2 protein expression.	Itraconazole	24-27	BCL2 associated X, apoptosis regulator	Homo sapiens	96-99
31888155-7	2019	At the molecular level, ITR NPs were more effective than ITR solution in inducing pro-apoptotic Bax and p53 while reducing anti-apoptotic Bcl2 protein expression.	Itraconazole	24-27	tumor protein p53	Homo sapiens	104-107
31888155-7	2019	At the molecular level, ITR NPs were more effective than ITR solution in inducing pro-apoptotic Bax and p53 while reducing anti-apoptotic Bcl2 protein expression.	Itraconazole	24-27	BCL2 apoptosis regulator	Homo sapiens	138-142
31888155-7	2019	At the molecular level, ITR NPs were more effective than ITR solution in inducing pro-apoptotic Bax and p53 while reducing anti-apoptotic Bcl2 protein expression.	Itraconazole	57-60	BCL2 associated X, apoptosis regulator	Homo sapiens	96-99
31888155-7	2019	At the molecular level, ITR NPs were more effective than ITR solution in inducing pro-apoptotic Bax and p53 while reducing anti-apoptotic Bcl2 protein expression.	Itraconazole	57-60	tumor protein p53	Homo sapiens	104-107
31888155-7	2019	At the molecular level, ITR NPs were more effective than ITR solution in inducing pro-apoptotic Bax and p53 while reducing anti-apoptotic Bcl2 protein expression.	Itraconazole	57-60	BCL2 apoptosis regulator	Homo sapiens	138-142
31833479-8	2019	RESULTS Itraconazole reduced the expression of stemness molecules CD133, ABCG2, and ALDH1 in A549 and NCI-H460 human lung cancer cells, and the numbers of sphere-forming cells were reduced.	Itraconazole	8-20	prominin 1	Homo sapiens	66-71
31833479-8	2019	RESULTS Itraconazole reduced the expression of stemness molecules CD133, ABCG2, and ALDH1 in A549 and NCI-H460 human lung cancer cells, and the numbers of sphere-forming cells were reduced.	Itraconazole	8-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	73-78
31833479-8	2019	RESULTS Itraconazole reduced the expression of stemness molecules CD133, ABCG2, and ALDH1 in A549 and NCI-H460 human lung cancer cells, and the numbers of sphere-forming cells were reduced.	Itraconazole	8-20	aldehyde dehydrogenase 1 family member A1	Homo sapiens	84-89
31129789-0	2019	Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.	Itraconazole	222-234	solute carrier organic anion transporter family member 1B1	Homo sapiens	82-89
31129789-0	2019	Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.	Itraconazole	222-234	solute carrier organic anion transporter family member 1B1	Homo sapiens	91-98
31728714-7	2020	Results During daily dosing with itraconazole (Period 2), the ratios of the adjusted geometric means for area under the plasma concentration-time profile extrapolated to infinity (AUCinf) and maximum plasma concentration (Cmax) of single-dose lorlatinib 100 mg were 141.79% (90% confidence interval, 128.71%, 156.21%) and 124.39% (110.20%, 140.41%), respectively, compared with Period 1 (lorlatinib alone).	Itraconazole	33-45	period circadian regulator 2	Homo sapiens	47-55
31919352-0	2020	Structural basis for itraconazole-mediated NPC1 inhibition.	Itraconazole	21-33	NPC intracellular cholesterol transporter 1	Homo sapiens	43-47
31919352-3	2020	Previous studies suggest that mutation of the NPC1-SSD or the addition of the anti-fungal drug itraconazole abolishes NPC1 activity in cells.	Itraconazole	95-107	NPC intracellular cholesterol transporter 1	Homo sapiens	118-122
31919352-5	2020	Here, we report a cryo-EM structure of human NPC1 bound to itraconazole, which reveals how this binding site in the center of NPC1 blocks a putative lumenal tunnel linked to the SSD.	Itraconazole	59-71	NPC intracellular cholesterol transporter 1	Homo sapiens	45-49
31919352-5	2020	Here, we report a cryo-EM structure of human NPC1 bound to itraconazole, which reveals how this binding site in the center of NPC1 blocks a putative lumenal tunnel linked to the SSD.	Itraconazole	59-71	NPC intracellular cholesterol transporter 1	Homo sapiens	126-130
31172535-6	2019	Avadomide exposures, when coadministered with the CYP3A inhibitor itraconazole, were 100.0% and 93.64% of that when administered alone, for AUC0-inf and Cmax , respectively.	Itraconazole	66-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-55
31392364-0	2019	Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.	Itraconazole	101-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90
31773379-8	2019	Other Shh inhibitors, including the antifungal itraconazole, have been investigated in small trials, but further research is needed before recommending their routine clinical use.	Itraconazole	47-59	sonic hedgehog signaling molecule	Homo sapiens	6-9
31668109-0	2022	Itraconazole Versus Propranolol: Therapeutic and Pharmacologic Effect On Serum Angiopoietin-2 In Patients With Infantile Hemangioma.	Itraconazole	0-12	angiopoietin 2	Homo sapiens	79-93
31668109-2	2022	Itraconazole is a world-wide tolerated antifungal but only a few studies have focused on its assessment in the treatment of IH.Objective: This study aim was to investigate the newly proposed antifungal drug ICZ and characterize different aspects of its usage as antiangiogenic drug.Methods: This is an interventional clinical trial to assess the efficacy of ICZ versus propranolol in the treatment of infantile hemangioma with studying the change in serum Ang2.	Itraconazole	0-12	angiopoietin 2	Homo sapiens	456-460
31668109-6	2022	We observed a decrease in serum ang2 level after usage of ICZ &amp; propranolol and the change in serum angiopoietin2 level before and after treatment in each group was statistically significant (p &lt; 0.001).Conclusion: Oral itraconazole can be an equivalent option for oral propranolol while safer and shorter treatment periods.	Itraconazole	227-239	angiopoietin 2	Homo sapiens	32-36
31668109-6	2022	We observed a decrease in serum ang2 level after usage of ICZ &amp; propranolol and the change in serum angiopoietin2 level before and after treatment in each group was statistically significant (p &lt; 0.001).Conclusion: Oral itraconazole can be an equivalent option for oral propranolol while safer and shorter treatment periods.	Itraconazole	227-239	angiopoietin 2	Homo sapiens	104-117
31692536-5	2019	The most important mechanism of ITZ in the treatment of cancer is inhibition of the Hh pathway through the inhibition of smoothened receptors (SMO), glioma-associated oncogene homologs (GLI), and their downstream targets.	Itraconazole	32-35	GLI family zinc finger 1	Homo sapiens	186-189
31479680-4	2019	RESULTS: The rates of synergy for the combination of MTX with fluconazole (FLC), itraconazole (ITC), and voriconazole (VRZ) were 91.3%, 65.2%, and 87% in checkerboard testing.	Itraconazole	95-98	metaxin 1	Homo sapiens	53-56
31215774-1	2019	Regulatory agencies currently recommend itraconazole (ITZ) as a strong cytochrome P450 3A (CYP3A) inhibitor for clinical drug-drug interaction (DDI) studies.	Itraconazole	40-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-89
31215774-1	2019	Regulatory agencies currently recommend itraconazole (ITZ) as a strong cytochrome P450 3A (CYP3A) inhibitor for clinical drug-drug interaction (DDI) studies.	Itraconazole	40-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-96
31215774-1	2019	Regulatory agencies currently recommend itraconazole (ITZ) as a strong cytochrome P450 3A (CYP3A) inhibitor for clinical drug-drug interaction (DDI) studies.	Itraconazole	54-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-89
31215774-1	2019	Regulatory agencies currently recommend itraconazole (ITZ) as a strong cytochrome P450 3A (CYP3A) inhibitor for clinical drug-drug interaction (DDI) studies.	Itraconazole	54-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-96
31271764-2	2019	The structurally-diverse small molecule compounds OSW-1, itraconazole (ITZ), T-00127-HEV2 (THEV) and TTP-8307 (TTP) inhibit viral replication through interaction with the OSBP protein.	Itraconazole	57-69	oxysterol binding protein	Homo sapiens	171-175
31271764-2	2019	The structurally-diverse small molecule compounds OSW-1, itraconazole (ITZ), T-00127-HEV2 (THEV) and TTP-8307 (TTP) inhibit viral replication through interaction with the OSBP protein.	Itraconazole	71-74	oxysterol binding protein	Homo sapiens	171-175
31044521-4	2019	The model reasonably predicted clinically observed acalabrutinib DDI with the CYP3A perpetrators itraconazole (4.80-fold vs. 5.21-fold observed) and rifampicin (0.21-fold vs. 0.23-fold observed).	Itraconazole	97-109	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	78-83
30845347-1	2019	AIMS: This phase I study evaluated the effects of the moderate cytochrome P450 (CYP) 3A inhibitor fluconazole and the strong CYP3A/P-glycoprotein (P-gp) inhibitor itraconazole on the pharmacokinetics of the investigational neural precursor cell expressed, developmentally downregulated 8 (NEDD8)-activating enzyme inhibitor pevonedistat in patients with advanced solid tumours.	Itraconazole	163-175	phosphoglycolate phosphatase	Homo sapiens	125-145
30845347-1	2019	AIMS: This phase I study evaluated the effects of the moderate cytochrome P450 (CYP) 3A inhibitor fluconazole and the strong CYP3A/P-glycoprotein (P-gp) inhibitor itraconazole on the pharmacokinetics of the investigational neural precursor cell expressed, developmentally downregulated 8 (NEDD8)-activating enzyme inhibitor pevonedistat in patients with advanced solid tumours.	Itraconazole	163-175	phosphoglycolate phosphatase	Homo sapiens	147-151
30845347-1	2019	AIMS: This phase I study evaluated the effects of the moderate cytochrome P450 (CYP) 3A inhibitor fluconazole and the strong CYP3A/P-glycoprotein (P-gp) inhibitor itraconazole on the pharmacokinetics of the investigational neural precursor cell expressed, developmentally downregulated 8 (NEDD8)-activating enzyme inhibitor pevonedistat in patients with advanced solid tumours.	Itraconazole	163-175	NEDD8 ubiquitin like modifier	Homo sapiens	223-287
30845347-1	2019	AIMS: This phase I study evaluated the effects of the moderate cytochrome P450 (CYP) 3A inhibitor fluconazole and the strong CYP3A/P-glycoprotein (P-gp) inhibitor itraconazole on the pharmacokinetics of the investigational neural precursor cell expressed, developmentally downregulated 8 (NEDD8)-activating enzyme inhibitor pevonedistat in patients with advanced solid tumours.	Itraconazole	163-175	NEDD8 ubiquitin like modifier	Homo sapiens	289-294
30813555-9	2019	Itraconazole (ITZ) is an antifungal agent that targets sterol-transport molecules such as OSBP and OSBP-related protein 4 (ORP4).	Itraconazole	0-12	oxysterol binding protein	Homo sapiens	90-94
30690033-0	2019	Itraconazole Induces Regression of Infantile Hemangioma via Downregulation of the Platelet-Derived Growth Factor-D/PI3K/Akt/mTOR Pathway.	Itraconazole	0-12	platelet-derived growth factor, D polypeptide	Mus musculus	82-114
30690033-0	2019	Itraconazole Induces Regression of Infantile Hemangioma via Downregulation of the Platelet-Derived Growth Factor-D/PI3K/Akt/mTOR Pathway.	Itraconazole	0-12	thymoma viral proto-oncogene 1	Mus musculus	120-123
30690033-0	2019	Itraconazole Induces Regression of Infantile Hemangioma via Downregulation of the Platelet-Derived Growth Factor-D/PI3K/Akt/mTOR Pathway.	Itraconazole	0-12	mechanistic target of rapamycin kinase	Mus musculus	124-128
30690033-6	2019	Importantly, itraconazole significantly reduced platelet-derived growth factor-D level, resulting in suppression of platelet-derived growth factor-beta activation and inhibition of its downstream effectors, such as PI3K, Akt, 4E-BP1, and p70S6K, which are important for cellular growth and survival of infantile hemangioma.	Itraconazole	13-25	platelet-derived growth factor, D polypeptide	Mus musculus	48-80
30690033-6	2019	Importantly, itraconazole significantly reduced platelet-derived growth factor-D level, resulting in suppression of platelet-derived growth factor-beta activation and inhibition of its downstream effectors, such as PI3K, Akt, 4E-BP1, and p70S6K, which are important for cellular growth and survival of infantile hemangioma.	Itraconazole	13-25	thymoma viral proto-oncogene 1	Mus musculus	221-224
30690033-6	2019	Importantly, itraconazole significantly reduced platelet-derived growth factor-D level, resulting in suppression of platelet-derived growth factor-beta activation and inhibition of its downstream effectors, such as PI3K, Akt, 4E-BP1, and p70S6K, which are important for cellular growth and survival of infantile hemangioma.	Itraconazole	13-25	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	226-232
30690033-6	2019	Importantly, itraconazole significantly reduced platelet-derived growth factor-D level, resulting in suppression of platelet-derived growth factor-beta activation and inhibition of its downstream effectors, such as PI3K, Akt, 4E-BP1, and p70S6K, which are important for cellular growth and survival of infantile hemangioma.	Itraconazole	13-25	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	238-244
30690033-7	2019	In conclusion, our results suggest that platelet-derived growth factor-D is a target of itraconazole in infantile hemangioma.	Itraconazole	88-100	platelet-derived growth factor, D polypeptide	Mus musculus	40-72
31235707-4	2019	At sub-MIC concentrations, fluconazole and miconazole stimulate catalase activity 2-3-fold but, unexpectedly, deletion of cytosolic catalase (ctt1) makes cells more resistant to these azoles and to clotrimazole, itraconazole and posaconazole.	Itraconazole	212-224	catalase T	Saccharomyces cerevisiae S288C	142-146
30260036-0	2019	Itraconazole inhibits proliferation of pancreatic cancer cells through activation of Bak-1.	Itraconazole	0-12	BCL2 antagonist/killer 1	Homo sapiens	85-90
30260036-6	2019	These data suggested that itraconazole exhibited antiproliferative effects in pancreatic cancer cells by inducing apoptosis through Bak-1 activation.	Itraconazole	26-38	BCL2 antagonist/killer 1	Homo sapiens	132-137
31140972-5	2019	CONCLUSION: Our study illustrated varying degrees of synergism between caspofungin or terbinafine and itraconazole, voriconazole, posaconazole or amphotericin B towards Chaetomium spp., which could be a reference for the clinical treatment of Chaetomium spp.	Itraconazole	102-114	histocompatibility minor 13	Homo sapiens	180-183
30985942-7	2019	The PBPK model predicted that the AUC for mirabegron with itraconazole (a CYP3A4 inhibitor) was 4.12-times that in healthy elderly subjects administered mirabegron alone, and predicted that the proportional change in AUC for desipramine (a CYP2D6 substrate) with mirabegron was greater than that in healthy subjects.	Itraconazole	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
30985942-7	2019	The PBPK model predicted that the AUC for mirabegron with itraconazole (a CYP3A4 inhibitor) was 4.12-times that in healthy elderly subjects administered mirabegron alone, and predicted that the proportional change in AUC for desipramine (a CYP2D6 substrate) with mirabegron was greater than that in healthy subjects.	Itraconazole	58-70	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	240-246
31024507-14	2019	Fusarium keratoplasticum showed high MIC values (8-&gt;32 mug mL-1) for itraconazole, voriconazole, posaconazole, and isavuconazole.	Itraconazole	72-84	2'-5' oligoadenylate synthetase 1B	Mus musculus	62-66
30813555-9	2019	Itraconazole (ITZ) is an antifungal agent that targets sterol-transport molecules such as OSBP and OSBP-related protein 4 (ORP4).	Itraconazole	0-12	oxysterol binding protein 2	Homo sapiens	99-121
30813555-9	2019	Itraconazole (ITZ) is an antifungal agent that targets sterol-transport molecules such as OSBP and OSBP-related protein 4 (ORP4).	Itraconazole	0-12	oxysterol binding protein 2	Homo sapiens	123-127
30813555-9	2019	Itraconazole (ITZ) is an antifungal agent that targets sterol-transport molecules such as OSBP and OSBP-related protein 4 (ORP4).	Itraconazole	14-17	oxysterol binding protein	Homo sapiens	90-94
30813555-9	2019	Itraconazole (ITZ) is an antifungal agent that targets sterol-transport molecules such as OSBP and OSBP-related protein 4 (ORP4).	Itraconazole	14-17	oxysterol binding protein 2	Homo sapiens	99-121
30813555-9	2019	Itraconazole (ITZ) is an antifungal agent that targets sterol-transport molecules such as OSBP and OSBP-related protein 4 (ORP4).	Itraconazole	14-17	oxysterol binding protein 2	Homo sapiens	123-127
31449848-6	2019	The flo8/flo8 mutation isolates exhibited increased resistance to fluconazole, voriconazole, and itraconazole compared with the wild-type and drug sensitivity was restored by FLO8 overexpression (flo8/flo8::FLO8).	Itraconazole	97-109	FLO8	Saccharomyces cerevisiae S288C	4-8
29989304-2	2019	We investigated whether an individual"s baseline in vivo CYP3A4 activity, assessed using the oral midazolam (MDZ) probe, could be used to predict the magnitude of drug-drug interaction between tacrolimus and the potent CYP3A4 inhibitor itraconazole.	Itraconazole	236-248	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-63
29989304-2	2019	We investigated whether an individual"s baseline in vivo CYP3A4 activity, assessed using the oral midazolam (MDZ) probe, could be used to predict the magnitude of drug-drug interaction between tacrolimus and the potent CYP3A4 inhibitor itraconazole.	Itraconazole	236-248	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	219-225
31449848-6	2019	The flo8/flo8 mutation isolates exhibited increased resistance to fluconazole, voriconazole, and itraconazole compared with the wild-type and drug sensitivity was restored by FLO8 overexpression (flo8/flo8::FLO8).	Itraconazole	97-109	FLO8	Saccharomyces cerevisiae S288C	9-13
31449848-6	2019	The flo8/flo8 mutation isolates exhibited increased resistance to fluconazole, voriconazole, and itraconazole compared with the wild-type and drug sensitivity was restored by FLO8 overexpression (flo8/flo8::FLO8).	Itraconazole	97-109	FLO8	Saccharomyces cerevisiae S288C	9-13
30327180-13	2019	CONCLUSION: Itraconazole modulates serum PSA levels without lowering serum testosterone.	Itraconazole	12-24	kallikrein related peptidase 3	Homo sapiens	41-44
30341799-7	2019	Reduced susceptibility to fluconazole (FLU), 5-flucytosine (5-FC) and itraconazole (ITR) was observed among C. neoformans isolates from Chinese paediatric patients, particularly among the ST5 isolates, which was similar to observations made on C. neoformans isolates from Chinese adult patients.	Itraconazole	70-82	DENN domain containing 2B	Homo sapiens	188-191
30341799-7	2019	Reduced susceptibility to fluconazole (FLU), 5-flucytosine (5-FC) and itraconazole (ITR) was observed among C. neoformans isolates from Chinese paediatric patients, particularly among the ST5 isolates, which was similar to observations made on C. neoformans isolates from Chinese adult patients.	Itraconazole	84-87	DENN domain containing 2B	Homo sapiens	188-191
30302786-2	2019	The objectives of this entry-into-human study were to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of risdiplam, and the effect of the strong CYP3A inhibitor itraconazole on the PK of risdiplam in healthy male volunteers.	Itraconazole	189-201	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	173-178
31449848-6	2019	The flo8/flo8 mutation isolates exhibited increased resistance to fluconazole, voriconazole, and itraconazole compared with the wild-type and drug sensitivity was restored by FLO8 overexpression (flo8/flo8::FLO8).	Itraconazole	97-109	FLO8	Saccharomyces cerevisiae S288C	9-13
30342850-2	2018	Our chemical suppressor screening in zebrafish embryos identified antifungal azoles including clotrimazole, miconazole, and itraconazole, as Wnt/beta-catenin signaling inhibitors.	Itraconazole	124-136	catenin (cadherin-associated protein), beta 1	Danio rerio	145-157
29320899-0	2019	In vitro analysis of itraconazole cis-diastereoisomers inhibition of nine cytochrome P450 enzymes: stereoselective inhibition of CYP3A.	Itraconazole	21-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-134
30481027-0	2018	Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibition.	Itraconazole	40-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-117
30481027-2	2018	The wider use of itraconazole in the treatment of cancer, however, has been limited by its potent inhibition of the drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4).	Itraconazole	17-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-160
30481027-2	2018	The wider use of itraconazole in the treatment of cancer, however, has been limited by its potent inhibition of the drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4).	Itraconazole	17-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	162-168
30166405-4	2018	Additional analyses in 16 healthy volunteers showed that dual pharmacological inhibition of CYP3A4 and P-glycoprotein using itraconazole resulted in increased tacrolimus metabolite/parent ratios (+65%, +112%, and 25% for 13-, 15-, and 31-DMT, respectively; P &lt; 0.01).	Itraconazole	124-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-98
30166405-4	2018	Additional analyses in 16 healthy volunteers showed that dual pharmacological inhibition of CYP3A4 and P-glycoprotein using itraconazole resulted in increased tacrolimus metabolite/parent ratios (+65%, +112%, and 25% for 13-, 15-, and 31-DMT, respectively; P &lt; 0.01).	Itraconazole	124-136	ATP binding cassette subfamily B member 1	Homo sapiens	103-117
30091221-0	2018	PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.	Itraconazole	82-94	phosphoglycolate phosphatase	Homo sapiens	27-31
30075232-3	2018	We investigated whether VEGF has a neuroprotective role by inhibiting its binding to receptor Flk-1 by itraconazole (ITZ).	Itraconazole	103-115	vascular endothelial growth factor A	Rattus norvegicus	24-28
30075232-3	2018	We investigated whether VEGF has a neuroprotective role by inhibiting its binding to receptor Flk-1 by itraconazole (ITZ).	Itraconazole	103-115	kinase insert domain receptor	Rattus norvegicus	94-99
30075232-3	2018	We investigated whether VEGF has a neuroprotective role by inhibiting its binding to receptor Flk-1 by itraconazole (ITZ).	Itraconazole	117-120	vascular endothelial growth factor A	Rattus norvegicus	24-28
30075232-3	2018	We investigated whether VEGF has a neuroprotective role by inhibiting its binding to receptor Flk-1 by itraconazole (ITZ).	Itraconazole	117-120	kinase insert domain receptor	Rattus norvegicus	94-99
29930379-9	2018	Using molecular docking simulations, we identify itraconazole as a C1GALT1 inhibitor that directly binds C1GALT1 and promotes its proteasomal degradation, leading to significant blockade of C1GALT1-mediated effects in HNSCC cells in vitro and in vivo.	Itraconazole	49-61	core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1	Homo sapiens	67-74
30068519-0	2018	Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.	Itraconazole	47-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	151-157
30068519-1	2018	Physiologically based pharmacokinetic (PBPK) modeling for itraconazole using a bottom-up approach is challenging, not only due to complex saturable pharmacokinetics (PK) and the presence of three metabolites exhibiting CYP3A4 inhibition, but also because of discrepancies in reported in vitro data.	Itraconazole	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	219-225
30068519-7	2018	In addition, itraconazole DDIs with midazolam and other CYP3A4 substrates were successfully predicted within a 2-fold error.	Itraconazole	13-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
29930379-9	2018	Using molecular docking simulations, we identify itraconazole as a C1GALT1 inhibitor that directly binds C1GALT1 and promotes its proteasomal degradation, leading to significant blockade of C1GALT1-mediated effects in HNSCC cells in vitro and in vivo.	Itraconazole	49-61	core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1	Homo sapiens	105-112
29930379-9	2018	Using molecular docking simulations, we identify itraconazole as a C1GALT1 inhibitor that directly binds C1GALT1 and promotes its proteasomal degradation, leading to significant blockade of C1GALT1-mediated effects in HNSCC cells in vitro and in vivo.	Itraconazole	49-61	core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1	Homo sapiens	105-112
30250932-0	2018	Itraconazole perturbs colorectal cancer dormancy through SUFU-mediated WNT inhibition.	Itraconazole	0-12	SUFU negative regulator of hedgehog signaling	Homo sapiens	57-61
30171694-1	2018	This study investigated the effect of itraconazole, a strong dual inhibitor of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), on the single dose pharmacokinetics of leniolisib.	Itraconazole	38-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-104
30171694-1	2018	This study investigated the effect of itraconazole, a strong dual inhibitor of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), on the single dose pharmacokinetics of leniolisib.	Itraconazole	38-50	ATP binding cassette subfamily B member 1	Homo sapiens	125-129
30171694-7	2018	These findings suggest that the interaction with itraconazole occurred mainly systemically through inhibition of CYP3A, and corroborate our in vitro findings that leniolisib is neither a sensitive CYP3A substrate nor a relevant in vivo substrate for intestinal or hepatic P-gp.	Itraconazole	49-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-118
30171694-8	2018	Assuming itraconazole levels achieved complete inhibition of CYP3A, the fractional contribution of CYP3A to the overall disposition of leniolisib is estimated to be about 50%.	Itraconazole	9-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-66
30028640-9	2018	CONCLUSIONS: The use of the reference-scaling approach with 3-period design (TRR, RTR, and RRT) was an efficient way to demonstrate that two commercially available oral itraconazole formulations met the predetermined bioequivalence criteria.	Itraconazole	169-181	nuclear receptor subfamily 6 group A member 1	Homo sapiens	82-85
30127974-9	2018	Itraconazole treatment inhibited the proliferation and altered cell cycle in SGC-7901 cells while promoting early apoptosis and DNA damage.	Itraconazole	0-12	sarcoglycan beta	Homo sapiens	77-80
30127974-11	2018	Combination itraconazole and 5-FU treatment showed a synergetic anticancer effect in SGC-7901 cells.	Itraconazole	12-24	sarcoglycan beta	Homo sapiens	85-88
29136186-8	2018	Only two heterozygous amino acid substitutions (A18P/A and R365G/R) in Erg3p were found in two isolates with cross-resistance to fluconazole, itraconazole, and voriconazole.	Itraconazole	142-154	ETS transcription factor ERG	Homo sapiens	71-76
29807040-0	2018	Structure-activity relationship study of itraconazole, a broad-range inhibitor of picornavirus replication that targets oxysterol-binding protein (OSBP).	Itraconazole	41-53	oxysterol binding protein	Homo sapiens	120-145
29807040-0	2018	Structure-activity relationship study of itraconazole, a broad-range inhibitor of picornavirus replication that targets oxysterol-binding protein (OSBP).	Itraconazole	41-53	oxysterol binding protein	Homo sapiens	147-151
29550418-6	2018	Short hairpin RNA (shRNA)-mediated knockdown of SOX9, as well as smoothened inhibition by itraconazole and vismodegib, reduces mTOR expression and the phosphorylation of known downstream mTOR targets.	Itraconazole	90-102	mechanistic target of rapamycin kinase	Homo sapiens	127-131
29550418-6	2018	Short hairpin RNA (shRNA)-mediated knockdown of SOX9, as well as smoothened inhibition by itraconazole and vismodegib, reduces mTOR expression and the phosphorylation of known downstream mTOR targets.	Itraconazole	90-102	mechanistic target of rapamycin kinase	Homo sapiens	187-191
29027194-2	2018	The aim of this study was to characterize the pediatric predictive performance of the PBPK approach for 10 drugs extensively metabolized by CYP1A2 (theophylline), CYP2C8 (desloratidine, montelukast), CYP2C9 (diclofenac), CYP2C19 (esomeprazole, lansoprazole), CYP2D6 (tramadol), and CYP3A4 (itraconazole, ondansetron, sufentanil).	Itraconazole	290-302	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	140-146
29684903-1	2018	In this work, we aimed at developing an improved topical SLN formulation combining itraconazole delivery with a coating layer of didodecyldimethylammonium bromide, thus repurposing the drug effectiveness by synergistic skin anticancer effectiveness.	Itraconazole	83-95	sarcolipin	Homo sapiens	57-60
29684903-8	2018	Ours results demonstrate the potentiality of repurposing itraconazole activity by using the combined nanoencapsulation strategy with the positively charged coating layer on SLN, which can be further investigated as a promising stable and safe approach to significantly reduce the viability of skin cancer cells.	Itraconazole	57-69	sarcolipin	Homo sapiens	173-176
29568906-0	2018	miR-124/MCP-1 signaling pathway modulates the protective effect of itraconazole on acute kidney injury in a mouse model of disseminated candidiasis.	Itraconazole	67-79	chemokine (C-C motif) ligand 2	Mus musculus	8-13
29469197-8	2018	Moderate DDI with itraconazole was predicted in subjects with wild-type CYP2C19 or UGT1A4.	Itraconazole	18-30	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	72-79
29469197-8	2018	Moderate DDI with itraconazole was predicted in subjects with wild-type CYP2C19 or UGT1A4.	Itraconazole	18-30	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	83-89
29172026-9	2018	A reduction of the enzymatic activity of the UGT2B7 was recorded in the presence of 9 of the 14 drugs under investigation (ketoconazole, miconazole, itraconazole, diclofenac, ibuprofen, clonazepam, lorazepam, lormetazepam, and triazolam), with a consequent significant reduction of the levels of the glucuronide metabolites.	Itraconazole	149-161	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	45-51
29469197-12	2018	DDI with itraconazole is likely to be dependent on the genotypes of CYP2C19 and UGT1A4.	Itraconazole	9-21	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	68-75
29469197-12	2018	DDI with itraconazole is likely to be dependent on the genotypes of CYP2C19 and UGT1A4.	Itraconazole	9-21	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	80-86
28436712-13	2018	Mechanistic static modeling that incorporated small non-CYP-mediated metabolic clearance and renal clearance components predicted an AUC ratio of 4.7 for the effect of itraconazole, a strong CYP3A4 inhibitor, on galunisertib.	Itraconazole	168-180	peptidylprolyl isomerase G	Homo sapiens	56-59
29592879-0	2018	Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation.	Itraconazole	0-12	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	80-84
29592879-3	2018	Itraconazole activated AMPK signaling, which was required for subsequent esophageal cancer cell death.	Itraconazole	0-12	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	23-27
29592879-4	2018	Pharmacologic AMPK inhibition, AMPKalpha1 shRNA, or dominant negative mutation (T172A) almost completely abolished itraconazole-induced cytotoxicity against esophageal cancer cells.	Itraconazole	115-127	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	14-18
29592879-5	2018	Significantly, itraconazole induced AMPK-dependent autophagic cell death (but not apoptosis) in esophageal cancer cells.	Itraconazole	15-27	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	36-40
29592879-6	2018	Furthermore, AMPK activation by itraconazole induced multiple receptor tyrosine kinases (RTKs: EGFR, PDGFRalpha, and PDGFRbeta), lysosomal translocation, and degradation to inhibit downstream Akt activation.	Itraconazole	32-44	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	13-17
29592879-6	2018	Furthermore, AMPK activation by itraconazole induced multiple receptor tyrosine kinases (RTKs: EGFR, PDGFRalpha, and PDGFRbeta), lysosomal translocation, and degradation to inhibit downstream Akt activation.	Itraconazole	32-44	epidermal growth factor receptor	Homo sapiens	95-99
29592879-6	2018	Furthermore, AMPK activation by itraconazole induced multiple receptor tyrosine kinases (RTKs: EGFR, PDGFRalpha, and PDGFRbeta), lysosomal translocation, and degradation to inhibit downstream Akt activation.	Itraconazole	32-44	platelet derived growth factor receptor alpha	Homo sapiens	101-111
29592879-6	2018	Furthermore, AMPK activation by itraconazole induced multiple receptor tyrosine kinases (RTKs: EGFR, PDGFRalpha, and PDGFRbeta), lysosomal translocation, and degradation to inhibit downstream Akt activation.	Itraconazole	32-44	platelet derived growth factor receptor beta	Homo sapiens	117-126
29592879-6	2018	Furthermore, AMPK activation by itraconazole induced multiple receptor tyrosine kinases (RTKs: EGFR, PDGFRalpha, and PDGFRbeta), lysosomal translocation, and degradation to inhibit downstream Akt activation.	Itraconazole	32-44	AKT serine/threonine kinase 1	Homo sapiens	192-195
29592879-10	2018	AMPK activation, RTK degradation, and Akt inhibition were observed in itraconazole-treated tumors.	Itraconazole	70-82	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	0-4
29592879-10	2018	AMPK activation, RTK degradation, and Akt inhibition were observed in itraconazole-treated tumors.	Itraconazole	70-82	AKT serine/threonine kinase 1	Homo sapiens	38-41
29592879-11	2018	Together, itraconazole inhibits esophageal cancer cell growth via activating AMPK signaling.	Itraconazole	10-22	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	77-81
29635947-7	2018	P-gp inducers, carbamazepine, and inhibitors such as itraconazole and verapamil show greater effects on the pharmacokinetics of (S)-fexofenadine.	Itraconazole	53-65	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
29385285-1	2018	We describe a case of apparent mineralocorticoid excess (hypertension, hypokalemia, metabolic alkalosis and low plasma renin activity) secondary to itraconazole therapy.	Itraconazole	148-160	renin	Homo sapiens	119-124
29634721-12	2018	However we have demonstrated itraconazole and voriconazole are modestly effective for CPA, especially if given for 12 months, but fewer than 50% of patients manage this duration.	Itraconazole	29-41	carboxypeptidase A1	Homo sapiens	86-89
29484419-0	2018	Itraconazole inhibits invasion and migration of pancreatic cancer cells by suppressing TGF-beta/SMAD2/3 signaling.	Itraconazole	0-12	transforming growth factor, beta 1	Mus musculus	87-95
29484419-0	2018	Itraconazole inhibits invasion and migration of pancreatic cancer cells by suppressing TGF-beta/SMAD2/3 signaling.	Itraconazole	0-12	SMAD family member 2	Mus musculus	96-103
28679023-0	2017	Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19.	Itraconazole	51-63	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	88-108
29434820-10	2018	Conversely, silencing of AMPK by small interfering RNA resulted in an increase of ITCZ-reduced gluconeogenesis and inhibition of ITCZ-induced glucose uptake with relative upregulation of PEPCK and G6Pase and downregulation of GLUT4 in the presence of 50 microg/ml ITCZ (P&lt;0.05).	Itraconazole	82-86	solute carrier family 2 member 4	Homo sapiens	226-231
28782144-7	2018	The ADIs can be explained by VDS accumulation owing to inherent loss of CYP3A5 (*3/*3) function, and inhibition of CYP3A4 activity by itraconazole.	Itraconazole	134-146	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-121
28782144-8	2018	WHAT IS NEW AND CONCLUSION: Syndrome of inappropriate antidiuretic hormone from co-administration of itraconazole and VDS has not previously been reported to our knowledge.	Itraconazole	101-113	arginine vasopressin	Homo sapiens	54-74
28940733-9	2018	Fluconazole, econazole, itraconazole and terbinafine inhibited fungal growth with MIC values ranging from 0.031 to &gt;64 mug mL-1 .	Itraconazole	24-36	L1 cell adhesion molecule	Mus musculus	126-130
30472702-0	2018	Itraconazole Attenuates Peritoneal Fibrosis Through Its Effect on the Sonic Hedgehog Signaling Pathway in Mice.	Itraconazole	0-12	sonic hedgehog	Mus musculus	70-84
30472702-5	2018	Itraconazole, an anti-fungal agent, was also recently recognized as an inhibitor of the SHH signaling pathway.	Itraconazole	0-12	sonic hedgehog	Mus musculus	88-91
30472702-12	2018	The expression of the following SHH signaling pathway components was upregulated in the CG group and suppressed by itraconazole treatment: SHH, patched, smoothened, and glioma-associated oncogene transcription factor 1.	Itraconazole	115-127	sonic hedgehog	Mus musculus	32-35
30472702-12	2018	The expression of the following SHH signaling pathway components was upregulated in the CG group and suppressed by itraconazole treatment: SHH, patched, smoothened, and glioma-associated oncogene transcription factor 1.	Itraconazole	115-127	sonic hedgehog	Mus musculus	139-142
30472702-16	2018	It also demonstrates that itraconazole treatment has protective effects on peritoneal fibrosis through the regulation of the SHH signaling pathway.	Itraconazole	26-38	sonic hedgehog	Mus musculus	125-128
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	0-12	vascular endothelial growth factor A	Homo sapiens	249-283
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	0-12	vascular endothelial growth factor A	Homo sapiens	285-289
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	0-12	fibroblast growth factor 2	Homo sapiens	292-322
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	0-12	fibroblast growth factor 2	Homo sapiens	324-328
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	0-12	kinase insert domain receptor	Homo sapiens	331-376
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	0-12	kinase insert domain receptor	Homo sapiens	378-384
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	0-12	mechanistic target of rapamycin kinase	Homo sapiens	405-434
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	0-12	mechanistic target of rapamycin kinase	Homo sapiens	436-440
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	14-17	vascular endothelial growth factor A	Homo sapiens	249-283
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	14-17	vascular endothelial growth factor A	Homo sapiens	285-289
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	14-17	fibroblast growth factor 2	Homo sapiens	292-322
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	14-17	fibroblast growth factor 2	Homo sapiens	324-328
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	14-17	kinase insert domain receptor	Homo sapiens	331-376
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	14-17	kinase insert domain receptor	Homo sapiens	378-384
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	14-17	mechanistic target of rapamycin kinase	Homo sapiens	405-434
29068216-1	2017	Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile, has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting multiple angiogenic stimulatory signals and pathways, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and mammalian target of rapamycin (mTOR).	Itraconazole	14-17	mechanistic target of rapamycin kinase	Homo sapiens	436-440
29181306-6	2017	The itraconazole group showed reduced expression of VEGF-A, VEGFR-2, TNF-alpha, IL-6 than the PBS group (all P&lt;0.05).	Itraconazole	4-16	vascular endothelial growth factor A	Mus musculus	52-58
29181306-6	2017	The itraconazole group showed reduced expression of VEGF-A, VEGFR-2, TNF-alpha, IL-6 than the PBS group (all P&lt;0.05).	Itraconazole	4-16	kinase insert domain protein receptor	Mus musculus	60-67
29181306-6	2017	The itraconazole group showed reduced expression of VEGF-A, VEGFR-2, TNF-alpha, IL-6 than the PBS group (all P&lt;0.05).	Itraconazole	4-16	tumor necrosis factor	Mus musculus	69-78
29181306-6	2017	The itraconazole group showed reduced expression of VEGF-A, VEGFR-2, TNF-alpha, IL-6 than the PBS group (all P&lt;0.05).	Itraconazole	4-16	interleukin 6	Mus musculus	80-84
29022838-6	2017	Expert opinion: Currently studies demonstrating the pharmacogenomic influences on itraconazole, posaconazole and isavuconazole are minimal and limited to their inhibitory effects on CYP3A4 in expressors of CYP3A5 variants.	Itraconazole	82-94	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	206-212
28993551-11	2017	DDIs perpetrated by FLV and itraconazole were successfully predicted by use of the present method where two DDI predictors [perpetrator-specific inhibitory activities toward CYP isoforms (pAi, CYPs) and victim-specific fractional CYP-isoform contributions to the clearance (vfm, CYPs)] are determined successively as shown in the graphical abstract.	Itraconazole	28-40	serpin family E member 1	Homo sapiens	188-191
28679023-2	2017	The effect of itraconazole (a strong CYP3A inhibitor) on the pharmacokinetics of etizolam (a substrate of CYP2C19 and CYP3A) was assessed in both extensive metabolizers (EMs) and poor metabolizers (PMs) of CYP2C19.	Itraconazole	14-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-42
28679023-2	2017	The effect of itraconazole (a strong CYP3A inhibitor) on the pharmacokinetics of etizolam (a substrate of CYP2C19 and CYP3A) was assessed in both extensive metabolizers (EMs) and poor metabolizers (PMs) of CYP2C19.	Itraconazole	14-26	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	106-113
30108741-5	2017	4 mug mL-1 for itraconazole).	Itraconazole	15-27	L1 cell adhesion molecule	Mus musculus	6-10
28789339-1	2017	Itraconazole, a common anti-fungal agent, has demonstrated potential anticancer activity, including reversing chemoresistance mediated by P-glycoprotein, modulating the signal transduction pathways of Hedgehog, mechanistic target of rapamycin and Wnt/beta-catenin in cancer cells, inhibiting angiogenesis and lymphangiogenesis, and possibly interfering with cancer-stromal cell interactions.	Itraconazole	0-12	mechanistic target of rapamycin kinase	Homo sapiens	211-242
27858342-6	2017	RESULTS: The statin models reasonably predicted the observed exposure change due to Organic Anion Transporting Polypeptide (OATP) 1B1 polymorphism or clinical DDIs with itraconazole, erythromycin, and gemfibrozil, while under-predicted the observed DDIs caused by rifampin and cyclosporine.	Itraconazole	169-181	solute carrier organic anion transporter family member 1B1	Homo sapiens	84-133
28495568-4	2017	DDIs with rifampicin and itraconazole were simulated using in vivo Rdif (ratio of diffusional uptake to active uptake) and beta (the fraction of the sum of intrinsic clearances for metabolism and biliary excretion in all possible itineraries of intracellular drugs including basolateral efflux) estimated by static analyses based on the extended clearance concept, in vivo inhibition constant (Ki) for hepatic OATPs reported previously, and in vivo Ki for CYP3A determined from DDI data with midazolam and itraconazole.	Itraconazole	25-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	456-461
28823259-6	2017	CONCLUSION: Arsenic trioxide combined with itraconazole can inhibit the KG1a cell proliferation and induce apoptosis, which may be related with the inhibition of Hh signaling pathway and upregulation of both Caspase-3 and BAX protein expression, and provided experimental data of arsenic trioxide combined with itraconazole for the treatment of refractory AML.	Itraconazole	43-55	caspase 3	Homo sapiens	208-217
28823259-6	2017	CONCLUSION: Arsenic trioxide combined with itraconazole can inhibit the KG1a cell proliferation and induce apoptosis, which may be related with the inhibition of Hh signaling pathway and upregulation of both Caspase-3 and BAX protein expression, and provided experimental data of arsenic trioxide combined with itraconazole for the treatment of refractory AML.	Itraconazole	43-55	BCL2 associated X, apoptosis regulator	Homo sapiens	222-225
28789339-1	2017	Itraconazole, a common anti-fungal agent, has demonstrated potential anticancer activity, including reversing chemoresistance mediated by P-glycoprotein, modulating the signal transduction pathways of Hedgehog, mechanistic target of rapamycin and Wnt/beta-catenin in cancer cells, inhibiting angiogenesis and lymphangiogenesis, and possibly interfering with cancer-stromal cell interactions.	Itraconazole	0-12	catenin beta 1	Homo sapiens	251-263
28747628-9	2017	These results suggest that itraconazole selectively inhibits endothelial cells rather than cancer cells by targeting multiple pathways including hedgehog, and mTOR pathways and angiogenesis.	Itraconazole	27-39	mechanistic target of rapamycin kinase	Homo sapiens	159-163
28668841-0	2017	Itraconazole Modulates Hedgehog, WNT/beta-catenin, as well as Akt Signalling, and Inhibits Proliferation of Cervical Cancer Cells.	Itraconazole	0-12	catenin beta 1	Homo sapiens	37-49
28668841-0	2017	Itraconazole Modulates Hedgehog, WNT/beta-catenin, as well as Akt Signalling, and Inhibits Proliferation of Cervical Cancer Cells.	Itraconazole	0-12	AKT serine/threonine kinase 1	Homo sapiens	62-65
28668841-7	2017	The microarray analysis showed an 8-fold down-regulation in the expression of GLI1, WNT4 and WNT10A among itraconazole-treated CaSki cells.	Itraconazole	106-118	GLI family zinc finger 1	Homo sapiens	78-82
28666022-10	2017	Quantitative RT-PCR showed significantly lower expression of VEGFR2 mRNA in the RPE-choroid complexes of itraconazole-injected eyes than those of BSS-injected eyes on days 7 and 14 (p = 0.003 and p = 0.006).	Itraconazole	105-117	kinase insert domain receptor	Rattus norvegicus	61-67
28668841-7	2017	The microarray analysis showed an 8-fold down-regulation in the expression of GLI1, WNT4 and WNT10A among itraconazole-treated CaSki cells.	Itraconazole	106-118	Wnt family member 4	Homo sapiens	84-88
28668841-7	2017	The microarray analysis showed an 8-fold down-regulation in the expression of GLI1, WNT4 and WNT10A among itraconazole-treated CaSki cells.	Itraconazole	106-118	Wnt family member 10A	Homo sapiens	93-99
28666022-11	2017	Western blots indicated that VEGFR2 was downregulated after itraconazole treatment.	Itraconazole	60-72	kinase insert domain receptor	Rattus norvegicus	29-35
28666022-12	2017	ELISA showed a significant difference in VEGF level between itraconazole-injected and BSS-injected eyes on days 7 and 14 (p = 0.04 and p = 0.001).	Itraconazole	60-72	vascular endothelial growth factor A	Rattus norvegicus	41-45
28666022-14	2017	Itraconazole had anti-angiogenic activity along with the reduction of VEGFR2 and VEGF levels.	Itraconazole	0-12	kinase insert domain receptor	Rattus norvegicus	70-76
28666022-14	2017	Itraconazole had anti-angiogenic activity along with the reduction of VEGFR2 and VEGF levels.	Itraconazole	0-12	vascular endothelial growth factor A	Rattus norvegicus	70-74
28390928-0	2017	Itraconazole cis-diastereoisomers activate aryl hydrocarbon receptor AhR and pregnane X receptor PXR and induce CYP1A1 in human cell lines and human hepatocytes.	Itraconazole	0-12	aryl hydrocarbon receptor	Homo sapiens	69-72
28390928-0	2017	Itraconazole cis-diastereoisomers activate aryl hydrocarbon receptor AhR and pregnane X receptor PXR and induce CYP1A1 in human cell lines and human hepatocytes.	Itraconazole	0-12	nuclear receptor subfamily 1 group I member 2	Homo sapiens	97-100
28390928-0	2017	Itraconazole cis-diastereoisomers activate aryl hydrocarbon receptor AhR and pregnane X receptor PXR and induce CYP1A1 in human cell lines and human hepatocytes.	Itraconazole	0-12	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	112-118
28390928-4	2017	Therefore, we have prepared 4 pure cis-diastereoisomers of itraconazole and investigated their effects on transcriptional activities of xenoreceptors aryl hydrocarbon receptor AhR and pregnane X receptor PXR.	Itraconazole	59-71	aryl hydrocarbon receptor	Homo sapiens	176-179
28390928-4	2017	Therefore, we have prepared 4 pure cis-diastereoisomers of itraconazole and investigated their effects on transcriptional activities of xenoreceptors aryl hydrocarbon receptor AhR and pregnane X receptor PXR.	Itraconazole	59-71	nuclear receptor subfamily 1 group I member 2	Homo sapiens	204-207
28390928-5	2017	Gene reporter assays showed that itraconazole dose-dependently activated both AhR and PXR, and the activation of AhR but not of PXR was enantiospecific.	Itraconazole	33-45	aryl hydrocarbon receptor	Homo sapiens	78-81
28390928-5	2017	Gene reporter assays showed that itraconazole dose-dependently activated both AhR and PXR, and the activation of AhR but not of PXR was enantiospecific.	Itraconazole	33-45	nuclear receptor subfamily 1 group I member 2	Homo sapiens	86-89
28390928-5	2017	Gene reporter assays showed that itraconazole dose-dependently activated both AhR and PXR, and the activation of AhR but not of PXR was enantiospecific.	Itraconazole	33-45	aryl hydrocarbon receptor	Homo sapiens	113-116
28390928-6	2017	Itraconazole diastereoisomers transformed AhR and PXR into their DNA-binding forms, as demonstrated by electromobility shift assays.	Itraconazole	0-12	aryl hydrocarbon receptor	Homo sapiens	42-45
28390928-6	2017	Itraconazole diastereoisomers transformed AhR and PXR into their DNA-binding forms, as demonstrated by electromobility shift assays.	Itraconazole	0-12	nuclear receptor subfamily 1 group I member 2	Homo sapiens	50-53
28390928-7	2017	Cytochrome P450 CYP1A1 mRNA and protein were induced by itraconazole diastereoisomers in human hepatoma cells HepG2, human skin cells HaCaT, and in primary human hepatocytes.	Itraconazole	56-68	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	0-22
28390928-9	2017	Collectively, we show that itraconazole is a dual activator of AhR and PXR, with differential effects on the target genes for xenoreceptors.	Itraconazole	27-39	aryl hydrocarbon receptor	Homo sapiens	63-66
28390928-9	2017	Collectively, we show that itraconazole is a dual activator of AhR and PXR, with differential effects on the target genes for xenoreceptors.	Itraconazole	27-39	nuclear receptor subfamily 1 group I member 2	Homo sapiens	71-74
28131847-7	2017	The most potent 11beta-HSD2 inhibition, using cell lysates expressing recombinant human 11beta-HSD2, was obtained for itraconazole (IC50 139+-14nM), its active metabolite hydroxyitraconazole (IC50 223+-31nM) and posaconazole (IC50 460+-98nM).	Itraconazole	118-130	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	16-27
28212537-0	2017	Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways.	Itraconazole	0-12	mechanistic target of rapamycin kinase	Mus musculus	84-88
28212537-8	2017	Moreover, we demonstrate that itraconazole significantly down-regulates Gli-1, Gli-2, Wnt3A, beta-catenin and cyclin D1, while it up-regulates Gli-3 and Axin-1, indicating potent inhibitory effects of itraconazole on Hedgehog (Hh) and Wnt signaling pathways.	Itraconazole	30-42	GLI-Kruppel family member GLI1	Mus musculus	72-77
28212537-8	2017	Moreover, we demonstrate that itraconazole significantly down-regulates Gli-1, Gli-2, Wnt3A, beta-catenin and cyclin D1, while it up-regulates Gli-3 and Axin-1, indicating potent inhibitory effects of itraconazole on Hedgehog (Hh) and Wnt signaling pathways.	Itraconazole	30-42	GLI-Kruppel family member GLI2	Mus musculus	79-84
28212537-8	2017	Moreover, we demonstrate that itraconazole significantly down-regulates Gli-1, Gli-2, Wnt3A, beta-catenin and cyclin D1, while it up-regulates Gli-3 and Axin-1, indicating potent inhibitory effects of itraconazole on Hedgehog (Hh) and Wnt signaling pathways.	Itraconazole	30-42	wingless-type MMTV integration site family, member 3A	Mus musculus	86-91
28212537-8	2017	Moreover, we demonstrate that itraconazole significantly down-regulates Gli-1, Gli-2, Wnt3A, beta-catenin and cyclin D1, while it up-regulates Gli-3 and Axin-1, indicating potent inhibitory effects of itraconazole on Hedgehog (Hh) and Wnt signaling pathways.	Itraconazole	30-42	catenin (cadherin associated protein), beta 1	Mus musculus	93-105
28212537-8	2017	Moreover, we demonstrate that itraconazole significantly down-regulates Gli-1, Gli-2, Wnt3A, beta-catenin and cyclin D1, while it up-regulates Gli-3 and Axin-1, indicating potent inhibitory effects of itraconazole on Hedgehog (Hh) and Wnt signaling pathways.	Itraconazole	30-42	cyclin D1	Mus musculus	110-119
28212537-8	2017	Moreover, we demonstrate that itraconazole significantly down-regulates Gli-1, Gli-2, Wnt3A, beta-catenin and cyclin D1, while it up-regulates Gli-3 and Axin-1, indicating potent inhibitory effects of itraconazole on Hedgehog (Hh) and Wnt signaling pathways.	Itraconazole	30-42	GLI-Kruppel family member GLI3	Mus musculus	143-148
28212537-8	2017	Moreover, we demonstrate that itraconazole significantly down-regulates Gli-1, Gli-2, Wnt3A, beta-catenin and cyclin D1, while it up-regulates Gli-3 and Axin-1, indicating potent inhibitory effects of itraconazole on Hedgehog (Hh) and Wnt signaling pathways.	Itraconazole	30-42	axin 1	Mus musculus	153-159
28212537-9	2017	Furthermore, itraconazole significantly suppresses the PI3K/mTOR signaling pathway - indicated by the down-regulated phosphorylation of p70S6K, 4E-BP1 and AKT - but has no effect on the phosphorylation of MEK or ERK.	Itraconazole	13-25	mechanistic target of rapamycin kinase	Mus musculus	60-64
28212537-9	2017	Furthermore, itraconazole significantly suppresses the PI3K/mTOR signaling pathway - indicated by the down-regulated phosphorylation of p70S6K, 4E-BP1 and AKT - but has no effect on the phosphorylation of MEK or ERK.	Itraconazole	13-25	thymoma viral proto-oncogene 1	Mus musculus	155-158
28212537-9	2017	Furthermore, itraconazole significantly suppresses the PI3K/mTOR signaling pathway - indicated by the down-regulated phosphorylation of p70S6K, 4E-BP1 and AKT - but has no effect on the phosphorylation of MEK or ERK.	Itraconazole	13-25	midkine	Mus musculus	205-208
28212537-9	2017	Furthermore, itraconazole significantly suppresses the PI3K/mTOR signaling pathway - indicated by the down-regulated phosphorylation of p70S6K, 4E-BP1 and AKT - but has no effect on the phosphorylation of MEK or ERK.	Itraconazole	13-25	mitogen-activated protein kinase 1	Mus musculus	212-215
28212537-10	2017	Our data suggest that itraconazole inhibits melanoma growth through an interacting regulatory network that includes Hh, Wnt, and PI3K/mTOR signaling pathways.	Itraconazole	22-34	mechanistic target of rapamycin kinase	Mus musculus	134-138
28159723-8	2017	This covalent binding of apolipoproteinE to the surface of a drug delivery system enables targeting of low density lipoprotein receptor (LDLR) expressed on endothelial brain capillary cell membranes, making our novel highly loaded itraconazole poly(butyl cyanoacrylate) nanocapsules a promising drug delivery system for treatment of cryptococcal meningitis.	Itraconazole	231-243	low density lipoprotein receptor	Homo sapiens	103-135
28159723-8	2017	This covalent binding of apolipoproteinE to the surface of a drug delivery system enables targeting of low density lipoprotein receptor (LDLR) expressed on endothelial brain capillary cell membranes, making our novel highly loaded itraconazole poly(butyl cyanoacrylate) nanocapsules a promising drug delivery system for treatment of cryptococcal meningitis.	Itraconazole	231-243	low density lipoprotein receptor	Homo sapiens	137-141
28131847-7	2017	The most potent 11beta-HSD2 inhibition, using cell lysates expressing recombinant human 11beta-HSD2, was obtained for itraconazole (IC50 139+-14nM), its active metabolite hydroxyitraconazole (IC50 223+-31nM) and posaconazole (IC50 460+-98nM).	Itraconazole	118-130	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	88-99
27822915-4	2017	Multiple regression analysis showed that concomitant use of oral itraconazole or voriconazole significantly increased the (C/Dpo)/(C/Div) of tacrolimus (p = 0.002), probably owing to the inhibition of enterohepatic cytochrome P450 3A4.	Itraconazole	65-77	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	215-234
28399898-10	2017	In vitro, studies showed that the expression of glioma-associated zinc finger transcription factor 1 (Gli1) was decreased at both transcriptional and translational levels after treatment with itraconazole.	Itraconazole	192-204	GLI family zinc finger 1	Homo sapiens	102-106
28399898-11	2017	Dual luciferase assay also indicated that itraconazole could inhibit the transcription of Gli1.	Itraconazole	42-54	GLI family zinc finger 1	Homo sapiens	90-94
28399898-13	2017	CONCLUSIONS: Hh signaling is activated in gastric tumor and itraconazole can inhibit the growth of gastric cancer cells by inhibiting Gli1 expression.	Itraconazole	60-72	GLI family zinc finger 1	Homo sapiens	134-138
28281345-1	2017	Photoinduced dehalogenation of the antifungal drug itraconazole (ITR) in acetonitrile (ACN) and ACN/water mixed solutions was investigated using femtosecond and nanosecond time-resolved transient absorption (fs-TA and ns-TA, respectively) and nanosecond time-resolved resonance Raman spectroscopy (ns-TR3) experiments.	Itraconazole	51-63	nuclear receptor subfamily 4 group A member 1	Homo sapiens	301-304
28281345-1	2017	Photoinduced dehalogenation of the antifungal drug itraconazole (ITR) in acetonitrile (ACN) and ACN/water mixed solutions was investigated using femtosecond and nanosecond time-resolved transient absorption (fs-TA and ns-TA, respectively) and nanosecond time-resolved resonance Raman spectroscopy (ns-TR3) experiments.	Itraconazole	65-68	nuclear receptor subfamily 4 group A member 1	Homo sapiens	301-304
28179296-0	2017	Itraconazole Inhibits AKT/mTOR Signaling and Proliferation in Endometrial Cancer Cells.	Itraconazole	0-12	AKT serine/threonine kinase 1	Homo sapiens	22-25
28179296-0	2017	Itraconazole Inhibits AKT/mTOR Signaling and Proliferation in Endometrial Cancer Cells.	Itraconazole	0-12	mechanistic target of rapamycin kinase	Homo sapiens	26-30
28179296-5	2017	Itraconazole did not suppress GLI1 or GLI2 transcription but did inhibit the expression of mammalian target of rapamycin (mTOR) signaling components in AN3-CA and HEC-1A cells, while inducing that of microtubule-associated protein 1A/1B-light chain 3-II, a marker of autophagy.	Itraconazole	0-12	mechanistic target of rapamycin kinase	Homo sapiens	91-120
28179296-5	2017	Itraconazole did not suppress GLI1 or GLI2 transcription but did inhibit the expression of mammalian target of rapamycin (mTOR) signaling components in AN3-CA and HEC-1A cells, while inducing that of microtubule-associated protein 1A/1B-light chain 3-II, a marker of autophagy.	Itraconazole	0-12	mechanistic target of rapamycin kinase	Homo sapiens	122-126
28179296-7	2017	CONCLUSION: Itraconazole treatment suppresses the growth of EC cells by inhibiting AKT/mTOR signalling.	Itraconazole	12-24	AKT serine/threonine kinase 1	Homo sapiens	83-86
28179296-7	2017	CONCLUSION: Itraconazole treatment suppresses the growth of EC cells by inhibiting AKT/mTOR signalling.	Itraconazole	12-24	mechanistic target of rapamycin kinase	Homo sapiens	87-91
28103683-0	2017	Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis.	Itraconazole	44-56	NPC intracellular cholesterol transporter 1	Homo sapiens	26-30
27810405-4	2017	Itraconazole treatment inhibited hedgehog pathway key molecular expression, such as SHH and Gli1, resulting in promotion of apoptosis and autophagy.	Itraconazole	0-12	GLI family zinc finger 1	Homo sapiens	92-96
27810405-5	2017	The anti-proliferation effect of itraconazole-induced apoptosis and autophagy via hedgehog pathway inhibition was confirmed with Gli1 inhibitor GANT61 and SHH siRNA, GANT61 and SHH siRNA synergistically enhanced cytotoxicity induced by itraconazole.	Itraconazole	33-45	GLI family zinc finger 1	Homo sapiens	129-133
27810405-5	2017	The anti-proliferation effect of itraconazole-induced apoptosis and autophagy via hedgehog pathway inhibition was confirmed with Gli1 inhibitor GANT61 and SHH siRNA, GANT61 and SHH siRNA synergistically enhanced cytotoxicity induced by itraconazole.	Itraconazole	33-45	sonic hedgehog signaling molecule	Homo sapiens	155-158
27810405-5	2017	The anti-proliferation effect of itraconazole-induced apoptosis and autophagy via hedgehog pathway inhibition was confirmed with Gli1 inhibitor GANT61 and SHH siRNA, GANT61 and SHH siRNA synergistically enhanced cytotoxicity induced by itraconazole.	Itraconazole	33-45	sonic hedgehog signaling molecule	Homo sapiens	177-180
27810405-2	2017	We report that itraconazole was cytotoxic to MCF-7 and SKBR-3 breast cancer cell lines via apoptosis by altering mitochondria membrane potential, reducing BCL-2 expression and elevating caspase-3 activity.	Itraconazole	15-27	BCL2 apoptosis regulator	Homo sapiens	155-160
27810405-2	2017	We report that itraconazole was cytotoxic to MCF-7 and SKBR-3 breast cancer cell lines via apoptosis by altering mitochondria membrane potential, reducing BCL-2 expression and elevating caspase-3 activity.	Itraconazole	15-27	caspase 3	Homo sapiens	186-195
27810405-3	2017	Itraconazole also induced autophagic cell death via LC3-II expression upregulation, P62/SQSTM1 degradation, autophagosome formation and increases in autophagic puncta.	Itraconazole	0-12	sequestosome 1	Homo sapiens	84-87
27810405-3	2017	Itraconazole also induced autophagic cell death via LC3-II expression upregulation, P62/SQSTM1 degradation, autophagosome formation and increases in autophagic puncta.	Itraconazole	0-12	sequestosome 1	Homo sapiens	88-94
27810405-4	2017	Itraconazole treatment inhibited hedgehog pathway key molecular expression, such as SHH and Gli1, resulting in promotion of apoptosis and autophagy.	Itraconazole	0-12	sonic hedgehog signaling molecule	Homo sapiens	84-87
28103683-0	2017	Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis.	Itraconazole	44-56	voltage dependent anion channel 1	Homo sapiens	35-40
28103683-0	2017	Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis.	Itraconazole	44-56	mechanistic target of rapamycin kinase	Homo sapiens	92-96
28103683-2	2017	Itraconazole has been shown to exert its antiangiogenic activity through inhibition of the mTOR signaling pathway, but the molecular mechanism of action was unknown.	Itraconazole	0-12	mechanistic target of rapamycin kinase	Homo sapiens	91-95
28103683-3	2017	We recently identified the mitochondrial protein VDAC1 as a target of itraconazole and a mediator of its activation of AMPK, an upstream regulator of mTOR.	Itraconazole	70-82	voltage dependent anion channel 1	Homo sapiens	49-54
28103683-5	2017	In this study, we demonstrate that cholesterol trafficking inhibition by itraconazole is due to direct inhibition of the lysosomal protein NPC1.	Itraconazole	73-85	NPC intracellular cholesterol transporter 1	Homo sapiens	139-143
28103683-6	2017	We further map the binding site of itraconazole to the sterol-sensing domain of NPC1 using mutagenesis, competition with U18666A, and molecular docking.	Itraconazole	35-47	NPC intracellular cholesterol transporter 1	Homo sapiens	80-84
27449014-5	2017	In particular, the first x-ray co-crystal structures of fungal CYP51 complexed with lanosterol and itraconazole are compared with co-crystal structures of other protozoal CYP51 enzymes.	Itraconazole	99-111	cytochrome P450 family 51 subfamily A member 1	Homo sapiens	63-68
27449014-5	2017	In particular, the first x-ray co-crystal structures of fungal CYP51 complexed with lanosterol and itraconazole are compared with co-crystal structures of other protozoal CYP51 enzymes.	Itraconazole	99-111	cytochrome P450 family 51 subfamily A member 1	Homo sapiens	171-176
27225997-2	2016	A clinical drug-drug interaction (DDI) study with the potent CYP3A4 inhibitor itraconazole resulted in an approximately sevenfold increase in cobimetinib exposure.	Itraconazole	78-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-67
27812353-17	2016	In conclusion, INK128 could enhance the in vitro antifungal activity of voriconazole, itraconazole and posaconazole against Exophiala spp.	Itraconazole	86-98	histocompatibility minor 13	Homo sapiens	134-137
28124646-6	2016	Th1 and Th2 type cells were differentiated in the presence of varying concentrations of itraconazole.	Itraconazole	88-100	negative elongation factor complex member C/D	Homo sapiens	0-3
27852416-5	2016	Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group.	Itraconazole	75-87	BCL2 associated X, apoptosis regulator	Homo sapiens	237-240
27852416-5	2016	Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group.	Itraconazole	75-87	caspase 3	Homo sapiens	250-259
27852416-5	2016	Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group.	Itraconazole	75-87	ceramide synthase 1	Homo sapiens	287-292
27852416-5	2016	Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group.	Itraconazole	75-87	BCL2 apoptosis regulator	Homo sapiens	360-365
27852416-5	2016	Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group.	Itraconazole	75-87	AKT serine/threonine kinase 1	Homo sapiens	498-501
27852416-5	2016	Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group.	Itraconazole	75-87	CREB regulated transcription coactivator 1	Mus musculus	508-514
27852416-5	2016	Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group.	Itraconazole	75-87	AKT serine/threonine kinase 1	Homo sapiens	584-587
27852416-5	2016	Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group.	Itraconazole	75-87	CREB regulated transcription coactivator 1	Mus musculus	594-600
27852416-5	2016	Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group.	Itraconazole	75-87	ceramide synthase 1	Homo sapiens	618-624
27852416-5	2016	Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group.	Itraconazole	98-110	BCL2 associated X, apoptosis regulator	Homo sapiens	237-240
27852416-5	2016	Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group.	Itraconazole	98-110	BCL2 associated X, apoptosis regulator	Homo sapiens	237-240
27852416-6	2016	Conclusion: Itraconazole induces apoptosis of PC-3 cell through increasing the intracellular ceramide content, which might relate to upregulation of cleavage-caspase 3 and Bax, downregulation of Bcl-2 and inactivation of Akt-mTORC signal pathway.	Itraconazole	12-24	caspase 3	Homo sapiens	158-167
27852416-6	2016	Conclusion: Itraconazole induces apoptosis of PC-3 cell through increasing the intracellular ceramide content, which might relate to upregulation of cleavage-caspase 3 and Bax, downregulation of Bcl-2 and inactivation of Akt-mTORC signal pathway.	Itraconazole	12-24	BCL2 associated X, apoptosis regulator	Homo sapiens	172-175
27852416-6	2016	Conclusion: Itraconazole induces apoptosis of PC-3 cell through increasing the intracellular ceramide content, which might relate to upregulation of cleavage-caspase 3 and Bax, downregulation of Bcl-2 and inactivation of Akt-mTORC signal pathway.	Itraconazole	12-24	BCL2 apoptosis regulator	Homo sapiens	195-200
27852416-6	2016	Conclusion: Itraconazole induces apoptosis of PC-3 cell through increasing the intracellular ceramide content, which might relate to upregulation of cleavage-caspase 3 and Bax, downregulation of Bcl-2 and inactivation of Akt-mTORC signal pathway.	Itraconazole	12-24	AKT serine/threonine kinase 1	Homo sapiens	221-224
27852416-5	2016	Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group.	Itraconazole	75-87	BCL2 associated X, apoptosis regulator	Homo sapiens	38-41
27852416-5	2016	Western blot analysis showed that the Bax, cleaved-caspase 3 expression of itraconazole group and itraconazole+ PDMP group was significantly higher than control group, while Bcl-2 expression was significantly lower than the control; the Bax, cleaved-caspase 3 expression ofitraconazole+ CerS1-shRNA group was significantly lower than itraconazole group, while Bcl-2 expression was significantly higher than the itraconazole group.After 5, 10, 20 mumol/L itraconazole treatment, the expression of p-Akt and p-mTORC1 were significantly lower than the control group; the expression of p-Akt and p-mTORC1 in itraconazole+ CerS-1-shRNA group were significantly higher than itraconazole group.	Itraconazole	75-87	caspase 3	Homo sapiens	51-60
33597793-2	2016	Recent studies indicate that itraconazole can also inhibit the growth of basal cell carcinoma (BCC) through suppression of the Sonic Hedgehog (SHH) signaling pathway.	Itraconazole	29-41	sonic hedgehog signaling molecule	Homo sapiens	127-141
27112167-7	2016	The antifungal azoles, posaconazole, itraconazole, and ketoconazole, significantly inhibited MDR3-mediated phosphatidylcholine secretion.	Itraconazole	37-49	ATP binding cassette subfamily B member 4	Homo sapiens	93-97
25670260-9	2016	DISCUSSION: Itraconazole has been shown to have many mechanisms by which it could potentially suppress tumor cell growth, which includes inhibition of the Hedgehog pathway, vascular endothelial growth factor receptor-2, and P-glycoprotein efflux pump.	Itraconazole	12-24	kinase insert domain receptor	Homo sapiens	173-218
25670260-9	2016	DISCUSSION: Itraconazole has been shown to have many mechanisms by which it could potentially suppress tumor cell growth, which includes inhibition of the Hedgehog pathway, vascular endothelial growth factor receptor-2, and P-glycoprotein efflux pump.	Itraconazole	12-24	ATP binding cassette subfamily B member 1	Homo sapiens	224-238
27001813-4	2016	Fifty percent inhibitory concentrations (IC50s) for P-gp and BCRP were both 2 muM for itraconazole, 5 and 12 muM for hydroxyitraconazole, 3 and 6 muM for posaconazole, and 3 and 11 muM for isavuconazole, respectively.	Itraconazole	86-98	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
27001813-4	2016	Fifty percent inhibitory concentrations (IC50s) for P-gp and BCRP were both 2 muM for itraconazole, 5 and 12 muM for hydroxyitraconazole, 3 and 6 muM for posaconazole, and 3 and 11 muM for isavuconazole, respectively.	Itraconazole	86-98	BCR pseudogene 1	Homo sapiens	61-65
27001813-4	2016	Fifty percent inhibitory concentrations (IC50s) for P-gp and BCRP were both 2 muM for itraconazole, 5 and 12 muM for hydroxyitraconazole, 3 and 6 muM for posaconazole, and 3 and 11 muM for isavuconazole, respectively.	Itraconazole	86-98	latexin	Homo sapiens	78-81
27001813-5	2016	BSEP was strongly inhibited by itraconazole and hydroxyitraconazole (3 and 17 muM, respectively).	Itraconazole	31-43	ATP binding cassette subfamily B member 11	Homo sapiens	0-4
27001813-5	2016	BSEP was strongly inhibited by itraconazole and hydroxyitraconazole (3 and 17 muM, respectively).	Itraconazole	31-43	latexin	Homo sapiens	78-81
27784375-7	2016	qPCR and Western blot results confirmed that the ATO combined with ITRA could significantly down-regulated expression of Gli1, leading to significantly decrease of cyclinD1 and BCL-2 expression levels.	Itraconazole	67-71	GLI-Kruppel family member GLI1	Mus musculus	121-125
27784375-7	2016	qPCR and Western blot results confirmed that the ATO combined with ITRA could significantly down-regulated expression of Gli1, leading to significantly decrease of cyclinD1 and BCL-2 expression levels.	Itraconazole	67-71	cyclin D1	Mus musculus	164-172
27784375-7	2016	qPCR and Western blot results confirmed that the ATO combined with ITRA could significantly down-regulated expression of Gli1, leading to significantly decrease of cyclinD1 and BCL-2 expression levels.	Itraconazole	67-71	B cell leukemia/lymphoma 2	Mus musculus	177-182
27105861-0	2016	Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.	Itraconazole	103-115	androgen receptor	Homo sapiens	51-68
26823493-4	2016	The antifungal itraconazole was demonstrated to be a potent SMO antagonist with a distinct mechanism of action from that of current SMO inhibitors.	Itraconazole	15-27	smoothened, frizzled class receptor	Homo sapiens	60-63
26823493-4	2016	The antifungal itraconazole was demonstrated to be a potent SMO antagonist with a distinct mechanism of action from that of current SMO inhibitors.	Itraconazole	15-27	smoothened, frizzled class receptor	Homo sapiens	132-135
26765315-3	2016	OBJECTIVE: To determine whether administration of intravenous arsenic trioxide and oral itraconazole in patients with metastatic BCC is associated with a reduction in GLI1 messenger RNA expression in tumor and/or normal skin biopsy samples.	Itraconazole	88-100	GLI family zinc finger 1	Homo sapiens	167-171
26765315-11	2016	Overall, arsenic trioxide and itraconazole reduced GLI1 messenger RNA levels by 75% from baseline (P &lt; .001).	Itraconazole	30-42	GLI family zinc finger 1	Homo sapiens	51-55
33597793-2	2016	Recent studies indicate that itraconazole can also inhibit the growth of basal cell carcinoma (BCC) through suppression of the Sonic Hedgehog (SHH) signaling pathway.	Itraconazole	29-41	sonic hedgehog signaling molecule	Homo sapiens	143-146
26722041-5	2016	Itraconazole also suppressed monocyte chemoattractant protein-1 secretion and the growth of CAFs.	Itraconazole	0-12	C-C motif chemokine ligand 2	Homo sapiens	29-63
26668209-8	2016	The results indicate that, like ketoconazole, the alternative clinical CYP3A4/5 inhibitors ritonavir, clarithromycin, and itraconazole each have unique transporter inhibition profiles.	Itraconazole	122-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-77
26171880-8	2015	Encapsulation efficiency (EE (%)), absolute drug loading (AL (%)) and release rate of itraconazole from PBCA-NSP in vitro were measured by reversed phase high-performance liquid chromatography (RP-HPLC).	Itraconazole	86-98	PBCA	Homo sapiens	104-108
26467209-0	2016	Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.	Itraconazole	156-168	ATP binding cassette subfamily B member 1	Homo sapiens	41-55
28057172-3	2016	The effects of five azole antifungal agents, fluconazole, itraconazole, ketoconazole, miconazole, and voriconazole, on the aminopyrine N-demethylation activity by CYP2C8 were investigated.	Itraconazole	58-70	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	163-169
26655341-0	2015	Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells.	Itraconazole	16-28	voltage dependent anion channel 1	Homo sapiens	37-42
26655341-0	2015	Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells.	Itraconazole	16-28	mechanistic target of rapamycin kinase	Homo sapiens	64-68
26655341-2	2015	Previous mechanistic studies have shown that itraconazole inhibits the mechanistic target of rapamycin (mTOR) signaling pathway, which is known to be a critical regulator of endothelial cell function and angiogenesis.	Itraconazole	45-57	mechanistic target of rapamycin kinase	Homo sapiens	71-102
26655341-2	2015	Previous mechanistic studies have shown that itraconazole inhibits the mechanistic target of rapamycin (mTOR) signaling pathway, which is known to be a critical regulator of endothelial cell function and angiogenesis.	Itraconazole	45-57	mechanistic target of rapamycin kinase	Homo sapiens	104-108
26655341-4	2015	Here we identify the major target of itraconazole in endothelial cells as the mitochondrial protein voltage-dependent anion channel 1 (VDAC1), which regulates mitochondrial metabolism by controlling the passage of ions and small metabolites through the outer mitochondrial membrane.	Itraconazole	37-49	voltage dependent anion channel 1	Homo sapiens	100-133
26655341-4	2015	Here we identify the major target of itraconazole in endothelial cells as the mitochondrial protein voltage-dependent anion channel 1 (VDAC1), which regulates mitochondrial metabolism by controlling the passage of ions and small metabolites through the outer mitochondrial membrane.	Itraconazole	37-49	voltage dependent anion channel 1	Homo sapiens	135-140
26655341-6	2015	Inhibition of VDAC1 by itraconazole disrupts mitochondrial metabolism, leading to an increase in the cellular AMP:ATP ratio and activation of the AMP-activated protein kinase (AMPK), an upstream regulator of mTOR.	Itraconazole	23-35	voltage dependent anion channel 1	Homo sapiens	14-19
26655341-6	2015	Inhibition of VDAC1 by itraconazole disrupts mitochondrial metabolism, leading to an increase in the cellular AMP:ATP ratio and activation of the AMP-activated protein kinase (AMPK), an upstream regulator of mTOR.	Itraconazole	23-35	mechanistic target of rapamycin kinase	Homo sapiens	208-212
26655341-7	2015	VDAC1-knockout cells are resistant to AMPK activation and mTOR inhibition by itraconazole, demonstrating that VDAC1 is the mediator of this activity.	Itraconazole	77-89	voltage dependent anion channel 1	Homo sapiens	0-5
26655341-7	2015	VDAC1-knockout cells are resistant to AMPK activation and mTOR inhibition by itraconazole, demonstrating that VDAC1 is the mediator of this activity.	Itraconazole	77-89	mechanistic target of rapamycin kinase	Homo sapiens	58-62
26617583-6	2015	Chemical inhibition of Hsp90 resulted in increased susceptibility of the fungus to itraconazole and micafungin, and decreased its growth in human nails in vitro.	Itraconazole	83-95	heat shock protein 90 alpha family class A member 1	Homo sapiens	23-28
26549342-4	2015	Prednisolone 0.5 mg/kg/day and Itraconazole improved his symptoms and IgE levels.	Itraconazole	31-43	immunoglobulin heavy constant epsilon	Homo sapiens	70-73
26171880-3	2015	Therefore, poly(butyl cyanoacrylate) nanospheres (PBCA-NSP) have been developed as a potential delivery system for transport of itraconazole.	Itraconazole	128-140	PBCA	Homo sapiens	50-54
26171880-4	2015	One possible application of itraconazole loaded PBCA-NSP could be to treat cryptococcal meningitis.	Itraconazole	28-40	PBCA	Homo sapiens	48-52
26171880-10	2015	Lyophilization of itraconazole loaded PBCA-NSP was needed to increase the stability of formulations, which was achieved by evaluating different sugar cryoprotectants.	Itraconazole	18-30	PBCA	Homo sapiens	38-42
26171880-11	2015	In this study, PBCA-NSPs were successfully generated as a delivery system for itraconazole providing a promising approach to improve the therapy of fungal infections of specific organs such as the brain infection cryptococcal meningitis.	Itraconazole	78-90	PBCA	Homo sapiens	15-19
26045286-5	2015	Presumably, itraconazole by inhibiting CYP3A4 enzyme caused an increase in plasma methylprednisolone levels.	Itraconazole	12-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-45
26710539-6	2015	Amphotericin B, itraconazole and voriconazole were the most potent antifungal drugs against Paracoccidioides spp (CMI: 0.03-1 microg/mL).	Itraconazole	16-28	histocompatibility minor 13	Homo sapiens	109-112
26184414-0	2015	Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease.	Itraconazole	83-95	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	10-16
26184414-0	2015	Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease.	Itraconazole	83-95	ATP binding cassette subfamily B member 1	Homo sapiens	21-26
26184414-1	2015	PURPOSE: The aim of this study was to investigate the effect of itraconazole (ITCZ), a potent inhibitor of CYP3A4 and P-glycoprotein, on the blood concentration 12 h after tacrolimus administration (C 12h) in relation to CYP3A5 6986A&gt;G and ABCB1 3435C&gt;T genotype status in patients with connective tissue disease (CTD).	Itraconazole	64-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	107-113
26184414-1	2015	PURPOSE: The aim of this study was to investigate the effect of itraconazole (ITCZ), a potent inhibitor of CYP3A4 and P-glycoprotein, on the blood concentration 12 h after tacrolimus administration (C 12h) in relation to CYP3A5 6986A&gt;G and ABCB1 3435C&gt;T genotype status in patients with connective tissue disease (CTD).	Itraconazole	64-76	ATP binding cassette subfamily B member 1	Homo sapiens	118-132
26184414-1	2015	PURPOSE: The aim of this study was to investigate the effect of itraconazole (ITCZ), a potent inhibitor of CYP3A4 and P-glycoprotein, on the blood concentration 12 h after tacrolimus administration (C 12h) in relation to CYP3A5 6986A&gt;G and ABCB1 3435C&gt;T genotype status in patients with connective tissue disease (CTD).	Itraconazole	64-76	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	221-227
26184414-1	2015	PURPOSE: The aim of this study was to investigate the effect of itraconazole (ITCZ), a potent inhibitor of CYP3A4 and P-glycoprotein, on the blood concentration 12 h after tacrolimus administration (C 12h) in relation to CYP3A5 6986A&gt;G and ABCB1 3435C&gt;T genotype status in patients with connective tissue disease (CTD).	Itraconazole	64-76	ATP binding cassette subfamily B member 1	Homo sapiens	243-248
25907295-0	2015	Itraconazole and clarithromycin inhibit P-glycoprotein activity in primary human sinonasal epithelial cells.	Itraconazole	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	40-54
25907295-9	2015	RESULTS: Both itraconazole and clarithromycin demonstrated a dose-response curve for P-gp inhibition similar to that of Zosuquidar.	Itraconazole	14-26	ATP binding cassette subfamily B member 1	Homo sapiens	85-89
26126827-5	2015	Moreover calcitriol strongly synergizes with itraconazole (ITZ) in Smo inhibition, which did not result from elevated calcitriol bioavailability due to ITZ-mediated 24-hydroxylase inhibition but rather from a direct interaction of the compounds at the level of Smo.	Itraconazole	45-57	smoothened, frizzled class receptor	Homo sapiens	67-70
26126827-5	2015	Moreover calcitriol strongly synergizes with itraconazole (ITZ) in Smo inhibition, which did not result from elevated calcitriol bioavailability due to ITZ-mediated 24-hydroxylase inhibition but rather from a direct interaction of the compounds at the level of Smo.	Itraconazole	45-57	smoothened, frizzled class receptor	Homo sapiens	261-264
26126827-5	2015	Moreover calcitriol strongly synergizes with itraconazole (ITZ) in Smo inhibition, which did not result from elevated calcitriol bioavailability due to ITZ-mediated 24-hydroxylase inhibition but rather from a direct interaction of the compounds at the level of Smo.	Itraconazole	59-62	smoothened, frizzled class receptor	Homo sapiens	67-70
26126827-5	2015	Moreover calcitriol strongly synergizes with itraconazole (ITZ) in Smo inhibition, which did not result from elevated calcitriol bioavailability due to ITZ-mediated 24-hydroxylase inhibition but rather from a direct interaction of the compounds at the level of Smo.	Itraconazole	59-62	smoothened, frizzled class receptor	Homo sapiens	261-264
26065977-2	2015	Recently, it has been discovered that itraconazole, a widely used systemic antifungal drug, has an effect on cell morphology, acting as an inhibitor of the morphogen Sonic Hedgehog (Shh) and of the mammalian target of rapamycin mTOR pathways.	Itraconazole	38-50	sonic hedgehog signaling molecule	Homo sapiens	166-180
26065977-2	2015	Recently, it has been discovered that itraconazole, a widely used systemic antifungal drug, has an effect on cell morphology, acting as an inhibitor of the morphogen Sonic Hedgehog (Shh) and of the mammalian target of rapamycin mTOR pathways.	Itraconazole	38-50	sonic hedgehog signaling molecule	Homo sapiens	182-185
26065977-2	2015	Recently, it has been discovered that itraconazole, a widely used systemic antifungal drug, has an effect on cell morphology, acting as an inhibitor of the morphogen Sonic Hedgehog (Shh) and of the mammalian target of rapamycin mTOR pathways.	Itraconazole	38-50	mechanistic target of rapamycin kinase	Homo sapiens	228-232
26065977-5	2015	Our results show for the first time a strong alteration of neurons morphology and an inhibitory effect of differentiation by itraconazole, probably due to cholesterol trafficking reduction, mTOR and Shh pathways inhibition.	Itraconazole	125-137	mechanistic target of rapamycin kinase	Mus musculus	190-194
26065977-5	2015	Our results show for the first time a strong alteration of neurons morphology and an inhibitory effect of differentiation by itraconazole, probably due to cholesterol trafficking reduction, mTOR and Shh pathways inhibition.	Itraconazole	125-137	sonic hedgehog	Mus musculus	199-202
26124377-1	2015	BACKGROUND: We evaluated chemotherapy with itraconazole (a common anti-fungal agent that is a potent inhibitor of the Hedgehog pathway, P-glycoprotein, and angiogenesis) for treating progressive pancreatic cancer.	Itraconazole	43-55	ATP binding cassette subfamily B member 1	Homo sapiens	136-150
26071720-2	2015	The pressure coefficients of the glass transition temperature (dT(g)/dp) for itraconazole and ketoconazole were determined to be equal to 183 and 228 K/GPa, respectively.	Itraconazole	77-89	glycophorin A (MNS blood group)	Homo sapiens	152-155
26071720-3	2015	However, for itraconazole, the additional transition to the nematic phase was observed and characterized by the pressure coefficient dT(n)/dp = 258 K/GPa.	Itraconazole	13-25	glycophorin A (MNS blood group)	Homo sapiens	150-153
25907295-10	2015	The respective maximal inhibitory concentrations of Zosuquidar, itraconazole, and clarithromycin prior to induction of cytotoxicity were 0.31, 3.13, and 1.56 muM, respectively, as demonstrated by a statistically significant increase in total intracellular fluorescence (p &lt; 0.05 in all groups).	Itraconazole	64-76	latexin	Homo sapiens	158-161
25907295-11	2015	CONCLUSION: Both itraconazole and clarithromycin are capable of inhibiting sinonasal epithelial cell associated P-gp.	Itraconazole	17-29	ATP binding cassette subfamily B member 1	Homo sapiens	112-116
25907295-3	2015	Both itraconazole and clarithromycin have also been shown to have P-gp inhibitory properties in other tissues, suggesting a novel explanation for their immunomodulatory effects in CRS.	Itraconazole	5-17	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
25907295-7	2015	A dose-response curve was generated for itraconazole and clarithromycin (maximal concentration 100 muM) and compared to that of Zosuquidar, a highly specific known P-gp inhibitor.	Itraconazole	40-52	latexin	Homo sapiens	99-102
25515245-7	2015	The interaction between 3A3 and 3A4 with itraconazole proved to be synergistic and indifferent, respectively.	Itraconazole	41-53	DNA segment, 3a4	Mus musculus	32-35
25640182-0	2015	Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein.	Itraconazole	0-12	oxysterol binding protein	Homo sapiens	63-88
24952675-14	2014	Itraconazole may induce a resistant hypertension with low renin.	Itraconazole	0-12	renin	Homo sapiens	58-63
26736983-1	2015	The mechanism of drug-drug interaction between saquinavir, a protease inhibitor used effectively for HIV/AIDS treatment, and itraconazole, an azole antifungal agent, is hypothesized to involve competitive inhibition at CYP3A4 enzyme, an important drug metabolizing enzyme in humans.	Itraconazole	125-137	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	219-225
26736984-1	2015	BACKGROUND: Concomitant use of simvastatin, a HMG-CoA reductase inhibitor, with a potent CYP3A4 inhibitor, itraconazole, can result in a serious drug-drug interaction induced severe adverse event, rhabdomyolysis.	Itraconazole	107-119	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95
25216238-8	2014	Possible alternatives to ketoconazole as prototype CYP3A inhibitors include ritonavir and potentially itraconazole, but not clarithromycin.	Itraconazole	102-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-56
24905460-5	2014	Functional studies revealed that itraconazole retarded the trafficking of cholesterol from late endosomes and lysosomes to the plasma membrane by reducing the levels of SCP2, resulting in repression of AKT1-MTOR signaling, induction of autophagy, and finally inhibition of cell proliferation.	Itraconazole	33-45	sterol carrier protein 2	Homo sapiens	169-173
24905460-5	2014	Functional studies revealed that itraconazole retarded the trafficking of cholesterol from late endosomes and lysosomes to the plasma membrane by reducing the levels of SCP2, resulting in repression of AKT1-MTOR signaling, induction of autophagy, and finally inhibition of cell proliferation.	Itraconazole	33-45	AKT serine/threonine kinase 1	Homo sapiens	202-206
24905460-5	2014	Functional studies revealed that itraconazole retarded the trafficking of cholesterol from late endosomes and lysosomes to the plasma membrane by reducing the levels of SCP2, resulting in repression of AKT1-MTOR signaling, induction of autophagy, and finally inhibition of cell proliferation.	Itraconazole	33-45	mechanistic target of rapamycin kinase	Homo sapiens	207-211
25385095-8	2015	We then characterized 19 distinct ERG11 alleles by introducing them into the wild-type azole-susceptible C. albicans SC5314 strain and testing them for susceptibilities to FLC, itraconazole (ITC), and voriconazole (VRC).	Itraconazole	191-194	cytochrome P450 lanosterol 14-alpha -demethylase	Candida albicans SC5314	34-39
24495175-0	2015	Itraconazole inhibits TNF-alpha-induced CXCL10 expression in oral fibroblasts.	Itraconazole	0-12	tumor necrosis factor	Homo sapiens	22-31
24495175-0	2015	Itraconazole inhibits TNF-alpha-induced CXCL10 expression in oral fibroblasts.	Itraconazole	0-12	C-X-C motif chemokine ligand 10	Homo sapiens	40-46
24495175-3	2015	We examined the anti-inflammatory potential of ICZ against TNF-alpha-induced chemokines in oral fibroblasts.	Itraconazole	47-50	tumor necrosis factor	Homo sapiens	59-68
24495175-4	2015	MATERIALS AND METHODS: We investigated the effects of ICZ on mRNA expressions of various TNF-alpha-induced chemokines in immortalized oral keratinocytes (RT7) and oral fibroblasts (GT1) using quantitative PCR analysis.	Itraconazole	54-57	tumor necrosis factor	Homo sapiens	89-98
24495175-5	2015	Subsequently, the effects of ICZ and fluconazole (FLZ) on TNF-alpha-induced CXCL10 proteins in GT1 and primary fibroblasts were examined using enzyme-linked immunosorbent assays (ELISA).	Itraconazole	29-32	tumor necrosis factor	Homo sapiens	58-67
24495175-11	2015	CONCLUSION: ICZ may be useful as therapy for Th1-mediated oral inflammatory disease.	Itraconazole	12-15	negative elongation factor complex member C/D	Homo sapiens	45-48
24972669-10	2014	Here, it down-regulates vitamin D receptor expression which following itraconazole therapy is rescued concurrent with decreased Th2 cytokine (IL-5 and IL-13) concentrations in the CF airway.	Itraconazole	70-82	vitamin D receptor	Homo sapiens	24-42
25106415-0	2014	Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1.	Itraconazole	74-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	9-14
25106415-1	2014	Ketoconazole is no longer available for clinical determination of worst-case victim drug-drug interaction (DDI) potential for cytochrome P450 3A (CYP3A)-substrate drugs; clarithromycin and itraconazole are the proposed replacements.	Itraconazole	189-201	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-151
25106415-3	2014	At present, transport of clarithromycin, itraconazole, and hydroxyitraconazole by hepatic organic anion transporting polypeptides (OATPs) and organic cation transporter 1 (OCT1) was examined in vitro and in vivo.	Itraconazole	41-53	solute carrier family 22 member 1	Homo sapiens	172-176
25106415-4	2014	As for ketoconazole, uptake of clarithromycin, itraconazole, and hydroxyitraconazole into OATP1B1, OATP1B3, OATP2B1, and OCT1 expressing human embryonic kidney 293 (HEK293) cells was not greater than in vector controls.	Itraconazole	47-59	solute carrier organic anion transporter family member 1B1	Homo sapiens	90-97
25359648-7	2014	However, patients taking anticoagulants or cytochrome P450 3A4 substrates (such as clarithromycin, erythromycin, ketoconazole, itraconazole, midazolam and triazolam) in addition to specific vitamin or mineral supplements (vitamins D, E, K, calcium, fluoride, iron, magnesium, selenium or zinc) may face additional challenges.	Itraconazole	127-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-62
24212378-4	2014	From a set of potential P-gp inhibitors, clarithromycin, cyclosporin A, itraconazole, ketoconazole, quinidine, and ritonavir inhibited P-gp-mediated transport of dabigatran etexilate over a concentration range that may hypothetically occur in the intestine.	Itraconazole	72-84	ATP binding cassette subfamily B member 1	Homo sapiens	24-28
24405193-0	2014	Longitudinal monitoring of CYP3A activity in patients receiving 3 cycles of itraconazole pulse therapy for onychomycosis.	Itraconazole	76-88	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-32
24405193-1	2014	WHAT IS KNOWN AND OBJECTIVE: Itraconazole, a CYP3A inhibitor, is used for the treatment for onychomycosis with a three-cycle pulse therapy over 3 months, but its effects on in vivo CYP3A activity during the entire course remain unknown.	Itraconazole	29-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-50
24405193-1	2014	WHAT IS KNOWN AND OBJECTIVE: Itraconazole, a CYP3A inhibitor, is used for the treatment for onychomycosis with a three-cycle pulse therapy over 3 months, but its effects on in vivo CYP3A activity during the entire course remain unknown.	Itraconazole	29-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	181-186
24405193-5	2014	WHAT IS NEW AND CONCLUSION: The inhibitory effect of itraconazole pulse therapy on the in vivo CYP3A activity appears clinically relevant at the end of each cycle, but the inhibition resolves, on average, within 3 weeks.	Itraconazole	53-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-100
24386966-13	2014	Co-administration of itraconazole and indomethacin as P-gp and MRP2 inhibitors, respectively revealed the potential of S-SNEDDS in reducing the efflux activities.	Itraconazole	21-33	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
24386966-13	2014	Co-administration of itraconazole and indomethacin as P-gp and MRP2 inhibitors, respectively revealed the potential of S-SNEDDS in reducing the efflux activities.	Itraconazole	21-33	ATP binding cassette subfamily C member 2	Homo sapiens	63-67
24599432-6	2014	Voriconazole was replaced with itraconazole, and after 3 weeks, the patient stopped complaining of bone pain concomitant with the decrease in ALP.	Itraconazole	31-43	alkaline phosphatase, placental	Homo sapiens	142-145
24212378-4	2014	From a set of potential P-gp inhibitors, clarithromycin, cyclosporin A, itraconazole, ketoconazole, quinidine, and ritonavir inhibited P-gp-mediated transport of dabigatran etexilate over a concentration range that may hypothetically occur in the intestine.	Itraconazole	72-84	ATP binding cassette subfamily B member 1	Homo sapiens	135-139
24114622-10	2013	Moreover, concomitant use with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, ritonavir, telithromycin, etc.)	Itraconazole	79-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
24471457-14	2014	The antimycotics itraconazole, ketoconazole, luliconazole, terbinafine, butenafine and amorolfine may suppress the M. restricta-induced production of CXCL10 by inhibiting STAT1 through an increase in 15d-PGJ2 production in keratinocytes.	Itraconazole	17-29	C-X-C motif chemokine ligand 10	Homo sapiens	150-156
24471457-14	2014	The antimycotics itraconazole, ketoconazole, luliconazole, terbinafine, butenafine and amorolfine may suppress the M. restricta-induced production of CXCL10 by inhibiting STAT1 through an increase in 15d-PGJ2 production in keratinocytes.	Itraconazole	17-29	signal transducer and activator of transcription 1	Homo sapiens	171-176
24127168-2	2013	Cohort data were used to determine whether primary prophylaxis with 100 mg itraconazole for patients with CD4 counts &lt; 150/mm(3) was cost-effective with different scenarios.	Itraconazole	75-87	CD4 molecule	Homo sapiens	106-109
24471457-10	2014	The antimycotics itraconazole, ketoconazole, luliconazole, terbinafine, butenafine and amorolfine suppressed M. restricta extract-induced CXCL10 mRNA and protein expression and STAT1 activity and phosphorylation.	Itraconazole	17-29	C-X-C motif chemokine ligand 10	Homo sapiens	138-144
24471457-10	2014	The antimycotics itraconazole, ketoconazole, luliconazole, terbinafine, butenafine and amorolfine suppressed M. restricta extract-induced CXCL10 mRNA and protein expression and STAT1 activity and phosphorylation.	Itraconazole	17-29	signal transducer and activator of transcription 1	Homo sapiens	177-182
25429674-2	2014	In in vitro interaction studies, itraconazole, ketoconazole, and miconazole were found to have higher inhibitory effects on cytochrome P450 (P450 or CYP) 3A4 and 3A5 activities than the other azoles or echinocandins did.	Itraconazole	33-45	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	141-157
25429674-3	2014	Fluconazole, itraconazole, and voriconazole were relatively less potent inhibitors of CYP3A5 than of CYP3A4.	Itraconazole	13-25	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	86-92
25429674-3	2014	Fluconazole, itraconazole, and voriconazole were relatively less potent inhibitors of CYP3A5 than of CYP3A4.	Itraconazole	13-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-107
25429674-4	2014	The inhibitory effects of fluconazole, itraconazole, ketoconazole, and voriconazole against CYP3A4 and CYP3A5 seemed to be correlated with their dissociation constants for CYP51 (lanosterol 14alpha-demethylase) from Candida albicans.	Itraconazole	39-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-98
25429674-4	2014	The inhibitory effects of fluconazole, itraconazole, ketoconazole, and voriconazole against CYP3A4 and CYP3A5 seemed to be correlated with their dissociation constants for CYP51 (lanosterol 14alpha-demethylase) from Candida albicans.	Itraconazole	39-51	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	103-109
25429674-5	2014	In in vivo pharmacokinetic studies, itraconazole was found to be a potent clinically important inhibitor of CYP3A4/5 substrates, and fluconazole and voriconazole increased the blood/plasma concentrations of not only CYP3A4/5 substrates but also CYP2C9 substrates.	Itraconazole	36-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-114
25429674-5	2014	In in vivo pharmacokinetic studies, itraconazole was found to be a potent clinically important inhibitor of CYP3A4/5 substrates, and fluconazole and voriconazole increased the blood/plasma concentrations of not only CYP3A4/5 substrates but also CYP2C9 substrates.	Itraconazole	36-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	216-222
25429674-5	2014	In in vivo pharmacokinetic studies, itraconazole was found to be a potent clinically important inhibitor of CYP3A4/5 substrates, and fluconazole and voriconazole increased the blood/plasma concentrations of not only CYP3A4/5 substrates but also CYP2C9 substrates.	Itraconazole	36-48	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	245-251
24484539-5	2014	Among the substrates that are preferably metabolized by CYP3A4, including carebastine, itraconazole, haloperidol, and fluvastatin, the former three compounds were found to closely dock to the heme region of CYP3A4 but not to that of CYP3A5.	Itraconazole	87-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
24484539-5	2014	Among the substrates that are preferably metabolized by CYP3A4, including carebastine, itraconazole, haloperidol, and fluvastatin, the former three compounds were found to closely dock to the heme region of CYP3A4 but not to that of CYP3A5.	Itraconazole	87-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	207-213
24484539-5	2014	Among the substrates that are preferably metabolized by CYP3A4, including carebastine, itraconazole, haloperidol, and fluvastatin, the former three compounds were found to closely dock to the heme region of CYP3A4 but not to that of CYP3A5.	Itraconazole	87-99	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	233-239
23598928-3	2013	Additional therapy with itraconazole leads to the decrease of total IgE to the limits recommended for proper omalizumab dosing (30-1500 kUA/l).	Itraconazole	24-36	immunoglobulin heavy constant epsilon	Homo sapiens	68-71
23688403-10	2013	The antimycotics itraconazole, ketoconazole, luliconazole, terbinafine, butenafine, and amorolfine suppressed the secretion and mRNA expression of TSLP, NF-kappaB activity, and IkappaBalpha degradation induced by poly I:C plus IL-4.	Itraconazole	17-29	thymic stromal lymphopoietin	Homo sapiens	147-151
23688403-10	2013	The antimycotics itraconazole, ketoconazole, luliconazole, terbinafine, butenafine, and amorolfine suppressed the secretion and mRNA expression of TSLP, NF-kappaB activity, and IkappaBalpha degradation induced by poly I:C plus IL-4.	Itraconazole	17-29	NFKB inhibitor alpha	Homo sapiens	177-189
23688403-10	2013	The antimycotics itraconazole, ketoconazole, luliconazole, terbinafine, butenafine, and amorolfine suppressed the secretion and mRNA expression of TSLP, NF-kappaB activity, and IkappaBalpha degradation induced by poly I:C plus IL-4.	Itraconazole	17-29	interleukin 4	Homo sapiens	227-231
23688403-14	2013	CONCLUSIONS: Antimycotics itraconazole, ketoconazole, luliconazole, terbinafine, butenafine, and amorolfine may suppress poly I:C plus IL-4-induced production of TSLP by inhibiting NF-kappaB via increasing 15d-PGJ2 production in keratinocytes.	Itraconazole	26-38	interleukin 4	Homo sapiens	135-139
23688403-14	2013	CONCLUSIONS: Antimycotics itraconazole, ketoconazole, luliconazole, terbinafine, butenafine, and amorolfine may suppress poly I:C plus IL-4-induced production of TSLP by inhibiting NF-kappaB via increasing 15d-PGJ2 production in keratinocytes.	Itraconazole	26-38	thymic stromal lymphopoietin	Homo sapiens	162-166
23598928-4	2013	Itraconazole, used as bridge therapy, provided us the opportunity to start anti-IgE treatment in a patient with high levels of total IgE, beyond the upper limits recommended for proper prescription of omalizumab.	Itraconazole	0-12	immunoglobulin heavy constant epsilon	Homo sapiens	80-83
23598928-4	2013	Itraconazole, used as bridge therapy, provided us the opportunity to start anti-IgE treatment in a patient with high levels of total IgE, beyond the upper limits recommended for proper prescription of omalizumab.	Itraconazole	0-12	immunoglobulin heavy constant epsilon	Homo sapiens	133-136
23462027-8	2013	Other antibiotics that are strong CYP3A4 inhibitors include itraconazole and telithromycin, whereas erythromycin and fluconazole are moderate inhibitors of the isoenzyme CYP3A4.	Itraconazole	60-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
23099620-1	2013	PURPOSE: We assessed possible drug interactions of tramadol given concomitantly with the potent CYP2B6 inhibitor ticlopidine, alone or together with the potent CYP3A4 and P-glycoprotein inhibitor itraconazole.	Itraconazole	196-208	ATP binding cassette subfamily B member 1	Homo sapiens	171-185
23291299-0	2013	Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.	Itraconazole	0-12	smoothened, frizzled class receptor	Mus musculus	126-136
23089896-5	2013	Coadministration of the inhibitor itraconazole reduced the skin and plasma concentrations of Rho123 in the wild-type mice, but not in mdr1a/1b/bcrp-/- mice, and a marked decrease of Rho123 concentration was seen in the dermis, demonstrating that the functional activities of these transporters can be modulated in vivo.	Itraconazole	34-46	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	134-139
23139378-4	2013	The plasma concentration profiles of repaglinide were then analyzed by a PBPK model, together with those of the inhibitors, assuming a competitive inhibition of CYP3A4 by itraconazole, mechanism-based inhibition of CYP2C8 by gemfibrozil glucuronide, and inhibition of organic anion transporting polypeptide (OATP) 1B1 by gemfibrozil and its glucuronide.	Itraconazole	171-183	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	161-167
23291299-4	2013	Here, we report that itraconazole and arsenic trioxide, two agents in clinical use that inhibit Hedgehog signaling by mechanisms distinct from that of current Smoothened antagonists, retain inhibitory activity in vitro in the context of all reported resistance-conferring Smoothened mutants and GLI2 overexpression.	Itraconazole	21-33	smoothened, frizzled class receptor	Mus musculus	159-169
23291299-4	2013	Here, we report that itraconazole and arsenic trioxide, two agents in clinical use that inhibit Hedgehog signaling by mechanisms distinct from that of current Smoothened antagonists, retain inhibitory activity in vitro in the context of all reported resistance-conferring Smoothened mutants and GLI2 overexpression.	Itraconazole	21-33	smoothened, frizzled class receptor	Mus musculus	272-282
23291299-4	2013	Here, we report that itraconazole and arsenic trioxide, two agents in clinical use that inhibit Hedgehog signaling by mechanisms distinct from that of current Smoothened antagonists, retain inhibitory activity in vitro in the context of all reported resistance-conferring Smoothened mutants and GLI2 overexpression.	Itraconazole	21-33	GLI-Kruppel family member GLI2	Mus musculus	295-299
23291299-5	2013	Itraconazole and arsenic trioxide, alone or in combination, inhibit the growth of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mice with intracranial drug-resistant SMO(D477G) medulloblastoma.	Itraconazole	0-12	smoothened, frizzled class receptor	Mus musculus	194-197
23419354-2	2013	Pretreatment with itraconazole (ICZ, P-gp inhibitor, 50 mg/kg) for 30 min before oral administration of NDL (10 mg/kg) significantly increased the area under the plasma concentration-time curve (AUC0- )of NDL by 1.7-fold compared with control.	Itraconazole	18-30	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	37-41
23054991-1	2012	Cocrystals of itraconazole, an antifungal drug with poor bioavailability, and succinic acid, a water-soluble dicarboxylic acid, were formed by gas antisolvent (GAS) cocrystallization using pressurized CO(2) to improve itraconazole dissolution.	Itraconazole	14-26	gastrin	Homo sapiens	143-146
23729559-6	2013	RESULTS: Mean IC50 values of ketoconazole, itraconazole and verapamil were 0.056, 0.061 and 23 muM (conventional method) compared to 0.05, 0.057 and 26 muM (column-switching method), respectively.	Itraconazole	43-55	latexin	Homo sapiens	95-98
22894166-0	2013	Improved antifungal activity of itraconazole-loaded PEG/PLA nanoparticles.	Itraconazole	32-44	progestagen associated endometrial protein	Homo sapiens	52-55
22894166-1	2013	Poly(ethylene glycol)/polylactic acid (PEG/PLA) nanoparticles (NPs) containing the hydrophobic antifungal itraconazole (ITZ) were developed to provide a controlled release pattern of ITZ as well as to improve its aqueous dispersibility and hence enhance its antifungal action.	Itraconazole	106-118	progestagen associated endometrial protein	Homo sapiens	39-42
22894166-1	2013	Poly(ethylene glycol)/polylactic acid (PEG/PLA) nanoparticles (NPs) containing the hydrophobic antifungal itraconazole (ITZ) were developed to provide a controlled release pattern of ITZ as well as to improve its aqueous dispersibility and hence enhance its antifungal action.	Itraconazole	120-123	progestagen associated endometrial protein	Homo sapiens	39-42
23054991-1	2012	Cocrystals of itraconazole, an antifungal drug with poor bioavailability, and succinic acid, a water-soluble dicarboxylic acid, were formed by gas antisolvent (GAS) cocrystallization using pressurized CO(2) to improve itraconazole dissolution.	Itraconazole	218-230	gastrin	Homo sapiens	143-146
23054991-1	2012	Cocrystals of itraconazole, an antifungal drug with poor bioavailability, and succinic acid, a water-soluble dicarboxylic acid, were formed by gas antisolvent (GAS) cocrystallization using pressurized CO(2) to improve itraconazole dissolution.	Itraconazole	218-230	gastrin	Homo sapiens	160-163
23054991-6	2012	The dissolution profile of itraconazole was significantly enhanced through GAS cocrystallization with succinic acid, achieving over 90% dissolution in less than 2 h. The cocrystals appeared stable against thermal stress for up to 4 weeks under accelerated stability conditions, showing only moderate decreases in their degree of crystallinity but no change in their crystalline structure.	Itraconazole	27-39	gastrin	Homo sapiens	75-78
23054991-1	2012	Cocrystals of itraconazole, an antifungal drug with poor bioavailability, and succinic acid, a water-soluble dicarboxylic acid, were formed by gas antisolvent (GAS) cocrystallization using pressurized CO(2) to improve itraconazole dissolution.	Itraconazole	14-26	gastrin	Homo sapiens	160-163
21832990-4	2011	The pharmacokinetics of this cocktail was observed at baseline, after an oral dose of 600 mg rifampicin (an inhibitor of OATPs), and after an intravenous dose of 200 mg itraconazole (a CYP3A4 inhibitor).	Itraconazole	169-181	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	185-191
23175341-6	2012	The purpose of the study is to evaluate the levels of selected inflammatory cytokines, IL-2, IL-4, IFN-gamma and TNF-alpha, in the serum after treatment with itraconazole.	Itraconazole	158-170	interleukin 2	Homo sapiens	87-91
23175341-6	2012	The purpose of the study is to evaluate the levels of selected inflammatory cytokines, IL-2, IL-4, IFN-gamma and TNF-alpha, in the serum after treatment with itraconazole.	Itraconazole	158-170	interleukin 4	Homo sapiens	93-97
23175341-6	2012	The purpose of the study is to evaluate the levels of selected inflammatory cytokines, IL-2, IL-4, IFN-gamma and TNF-alpha, in the serum after treatment with itraconazole.	Itraconazole	158-170	interferon gamma	Homo sapiens	99-108
23175341-6	2012	The purpose of the study is to evaluate the levels of selected inflammatory cytokines, IL-2, IL-4, IFN-gamma and TNF-alpha, in the serum after treatment with itraconazole.	Itraconazole	158-170	tumor necrosis factor	Homo sapiens	113-122
22564244-6	2012	We found that itraconazole inhibits angiogenesis markers such as VEGF, AAMP and e-NOS.	Itraconazole	14-26	angio associated migratory cell protein	Homo sapiens	71-75
22564244-6	2012	We found that itraconazole inhibits angiogenesis markers such as VEGF, AAMP and e-NOS.	Itraconazole	14-26	nitric oxide synthase 3	Homo sapiens	80-85
22564244-7	2012	mTOR and ERK1/2 phosphorylation as well as the expression of Gli1, one of the main controllers of the Shh pathway, were also inhibited by itraconazole.	Itraconazole	138-150	mechanistic target of rapamycin kinase	Homo sapiens	0-4
22564244-7	2012	mTOR and ERK1/2 phosphorylation as well as the expression of Gli1, one of the main controllers of the Shh pathway, were also inhibited by itraconazole.	Itraconazole	138-150	mitogen-activated protein kinase 3	Homo sapiens	9-15
22564244-7	2012	mTOR and ERK1/2 phosphorylation as well as the expression of Gli1, one of the main controllers of the Shh pathway, were also inhibited by itraconazole.	Itraconazole	138-150	GLI family zinc finger 1	Homo sapiens	61-65
22564244-7	2012	mTOR and ERK1/2 phosphorylation as well as the expression of Gli1, one of the main controllers of the Shh pathway, were also inhibited by itraconazole.	Itraconazole	138-150	sonic hedgehog signaling molecule	Homo sapiens	102-105
22025615-0	2011	The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells.	Itraconazole	20-32	kinase insert domain receptor	Homo sapiens	42-87
22025615-0	2011	The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells.	Itraconazole	20-32	kinase insert domain receptor	Homo sapiens	89-95
22025615-4	2011	We report here that itraconazole significantly inhibited the binding of vascular endothelial growth factor (VEGF) to VEGF receptor 2 (VEGFR2) and that both VEGFR2 and an immediate downstream substrate, phospholipase C gamma1, failed to become activated after VEGF stimulation.	Itraconazole	20-32	vascular endothelial growth factor A	Homo sapiens	72-106
22025615-4	2011	We report here that itraconazole significantly inhibited the binding of vascular endothelial growth factor (VEGF) to VEGF receptor 2 (VEGFR2) and that both VEGFR2 and an immediate downstream substrate, phospholipase C gamma1, failed to become activated after VEGF stimulation.	Itraconazole	20-32	vascular endothelial growth factor A	Homo sapiens	108-112
22025615-4	2011	We report here that itraconazole significantly inhibited the binding of vascular endothelial growth factor (VEGF) to VEGF receptor 2 (VEGFR2) and that both VEGFR2 and an immediate downstream substrate, phospholipase C gamma1, failed to become activated after VEGF stimulation.	Itraconazole	20-32	kinase insert domain receptor	Homo sapiens	117-132
22025615-4	2011	We report here that itraconazole significantly inhibited the binding of vascular endothelial growth factor (VEGF) to VEGF receptor 2 (VEGFR2) and that both VEGFR2 and an immediate downstream substrate, phospholipase C gamma1, failed to become activated after VEGF stimulation.	Itraconazole	20-32	kinase insert domain receptor	Homo sapiens	134-140
22025615-4	2011	We report here that itraconazole significantly inhibited the binding of vascular endothelial growth factor (VEGF) to VEGF receptor 2 (VEGFR2) and that both VEGFR2 and an immediate downstream substrate, phospholipase C gamma1, failed to become activated after VEGF stimulation.	Itraconazole	20-32	kinase insert domain receptor	Homo sapiens	156-162
22025615-4	2011	We report here that itraconazole significantly inhibited the binding of vascular endothelial growth factor (VEGF) to VEGF receptor 2 (VEGFR2) and that both VEGFR2 and an immediate downstream substrate, phospholipase C gamma1, failed to become activated after VEGF stimulation.	Itraconazole	20-32	phospholipase C gamma 1	Homo sapiens	202-224
22025615-4	2011	We report here that itraconazole significantly inhibited the binding of vascular endothelial growth factor (VEGF) to VEGF receptor 2 (VEGFR2) and that both VEGFR2 and an immediate downstream substrate, phospholipase C gamma1, failed to become activated after VEGF stimulation.	Itraconazole	20-32	vascular endothelial growth factor A	Homo sapiens	117-121
22025615-8	2011	Repletion of cellular cholesterol levels, which was known to rescue the effects of itraconazole on mTOR and cholesterol trafficking, was also able to restore VEGFR2 glycosylation and signaling.	Itraconazole	83-95	mechanistic target of rapamycin kinase	Homo sapiens	99-103
22025615-10	2011	We also demonstrated that itraconazole globally reduced poly-N-acetyllactosamine and tetra-antennary complex N-glycans in endothelial cells and induced hypoglycosylation of the epidermal growth factor receptor in a renal cell carcinoma line, suggesting that itraconazole"s effects extend beyond VEGFR2.	Itraconazole	26-38	kinase insert domain receptor	Homo sapiens	295-301
21896639-5	2011	In vivo, using primary xenograft models of human NSCLC, oral itraconazole showed single-agent growth-inhibitory activity associated with induction of tumor hypoxia-inducible factor 1 alpha expression and marked inhibition of tumor vascularity.	Itraconazole	61-73	hypoxia inducible factor 1 subunit alpha	Homo sapiens	156-188
21771587-1	2011	BACKGROUND: Itraconazole is a potent inhibitor of CYP3A4 and P-glycoprotein, but not CYP2C9.	Itraconazole	12-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
21771587-1	2011	BACKGROUND: Itraconazole is a potent inhibitor of CYP3A4 and P-glycoprotein, but not CYP2C9.	Itraconazole	12-24	ATP binding cassette subfamily B member 1	Homo sapiens	61-75
21771587-2	2011	Herein, we report a case study in which the plasma concentration of the CYP2C9 substrate (S)-warfarin, and not the CYP3A4 substrate (R)-warfarin, increased with itraconazole coadministration.	Itraconazole	161-173	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	72-78
22088546-6	2011	Intravenous itraconazole was given at a dose of 200 mg bid (intravenous infusion every 12 hours) for the first two days, 200 mg qd for the subsequent 12 days.	Itraconazole	12-24	BH3 interacting domain death agonist	Homo sapiens	55-58
22088546-7	2011	Sequential oral itraconazole solution was given at a dose of 100 mg bid for 4 weeks.	Itraconazole	16-28	BH3 interacting domain death agonist	Homo sapiens	68-71
25787325-9	2012	Microemulsion-based itraconazole gel (MBGI) showed better penetration and retention in human skin as well as bovine hoof as compared to commercial preparation (market formulation, MFI).	Itraconazole	20-32	MFI	Bos taurus	180-183
22106171-0	2012	Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.	Itraconazole	29-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
22106171-1	2012	Itraconazole (ITZ) is a mixture of four cis-stereoisomers that inhibit CYP3A4 potently and coordinate CYP3A4 heme via the triazole nitrogen.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-77
22106171-1	2012	Itraconazole (ITZ) is a mixture of four cis-stereoisomers that inhibit CYP3A4 potently and coordinate CYP3A4 heme via the triazole nitrogen.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	102-108
22106171-1	2012	Itraconazole (ITZ) is a mixture of four cis-stereoisomers that inhibit CYP3A4 potently and coordinate CYP3A4 heme via the triazole nitrogen.	Itraconazole	14-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-77
22106171-1	2012	Itraconazole (ITZ) is a mixture of four cis-stereoisomers that inhibit CYP3A4 potently and coordinate CYP3A4 heme via the triazole nitrogen.	Itraconazole	14-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	102-108
21838784-5	2012	Plasma concentrations of montelukast, gemfibrozil, itraconazole and their metabolites were measured up to 72 h. RESULTS: The CYP2C8 inhibitor gemfibrozil increased the AUC(0, ) of montelukast 4.3-fold and its t(1/2) 2.1-fold (P &lt; 0.001).	Itraconazole	51-63	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	125-131
21838784-7	2012	The CYP3A4 inhibitor itraconazole had no significant effect on the pharmacokinetic variables of montelukast or its M6 and M4 metabolites, but markedly reduced the AUC and C(max) of M5a and M5b (P &lt; 0.05).	Itraconazole	21-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
22589709-7	2012	In vitro assays confirmed that five old drugs, namely montelukast, diclofenac, simvastatin, ketoconazole, and itraconazole, showed polypharmacological features on estrogen receptors or dipeptidyl peptidase-IV with half maximal inhibitory or effective concentration ranged from 0.2 to 10 microM.	Itraconazole	110-122	dipeptidyl peptidase 4	Homo sapiens	185-208
22119069-15	2011	Some causes have been recently described: familial hyponatraemia via X-linked recessive disease caused by an activating mutation of the vasopressin 2 receptor; and corticotropin insufficiency related to drug interference between some inhaled glucocorticoids and cytochrome p450 inhibitors, such as the antiretroviral drugs and itraconazole, etc.	Itraconazole	327-339	arginine vasopressin	Homo sapiens	136-147
21936514-0	2011	Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling.	Itraconazole	0-12	kinase insert domain receptor	Homo sapiens	125-170
21936514-0	2011	Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling.	Itraconazole	0-12	kinase insert domain receptor	Homo sapiens	172-178
21936514-3	2011	Through this analysis, we have identified analogues with increased potency for inhibiting endothelial cell proliferation and the Hh pathway, as well as VEGFR2 glycosylation that was recently found to be inhibited by itraconazole.	Itraconazole	216-228	kinase insert domain receptor	Homo sapiens	152-158
22090300-23	2011	Resistance rates for both fluconazole and itraconazole were higher in biofilm-producers (39.5% and 52.6%, respectively), than those of non-producers (10.6% and 29.8%, respectively), representing a statistical significance (p= 0.002 and p= 0.03, respectively) for Candida spp.	Itraconazole	42-54	histocompatibility minor 13	Homo sapiens	271-274
22215390-3	2011	AIM: To evaluate the results of oral prophylaxis with high dose itraconazole, 400 mg bid, among patients with adult acute leukemia.	Itraconazole	64-76	BH3 interacting domain death agonist	Homo sapiens	85-88
21490593-7	2011	Given the significant decrease in CL(f) of 6beta-hydroxycortisone and 6beta-hydroxycortisol after 200-mg and 400-mg single doses of itraconazole, this endogenous probe can be used to detect moderate and potent CYP3A4 inhibition in vivo.	Itraconazole	132-144	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	210-216
21716267-1	2011	This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole.	Itraconazole	143-155	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-132
21484807-5	2011	The inhibition of P-gp-mediated efflux of these two fluorescent substrates by several drugs, including quinidine and itraconazole, was found to be substrate- and/or species-dependent.	Itraconazole	117-129	ATP binding cassette subfamily B member 1	Homo sapiens	18-22
21420575-8	2011	Moreover, itraconazole and posaconazole are substrates and inhibitors of the transporter protein, P-glycoprotein.	Itraconazole	10-22	ATP binding cassette subfamily B member 1	Homo sapiens	98-112
21360715-10	2011	CONCLUSION: Ciprofloxacin decreases the metabolism of itraconazole, most likely through inhibition of CYP3A4.	Itraconazole	54-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	102-108
21212239-0	2011	Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.	Itraconazole	41-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-91
21212239-3	2011	In this study, we quantitatively investigated the inhibition kinetics of two typical inhibitors, itraconazole (ITCZ) and cimetidine (CMD), on CYP3A4 variants and evaluated whether the genetic variation leads to interindividual differences in the extent of CYP3A4-mediated drug interactions.	Itraconazole	97-109	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-148
21212239-3	2011	In this study, we quantitatively investigated the inhibition kinetics of two typical inhibitors, itraconazole (ITCZ) and cimetidine (CMD), on CYP3A4 variants and evaluated whether the genetic variation leads to interindividual differences in the extent of CYP3A4-mediated drug interactions.	Itraconazole	111-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-148
20875690-0	2011	The antimycotic drugs itraconazole and terbinafine hydrochloride induce the production of human beta-defensin-3 in human keratinocytes.	Itraconazole	22-34	defensin beta 103B	Homo sapiens	96-111
20875690-6	2011	Antimycotics itraconazole and terbinafine hydrochloride increased hBD-3 secretion and mRNA levels in parallel to the enhanced activity of activator protein-1, expression and phosphorylation of activator protein-1 component, c-Fos, but fluconazole was ineffective.	Itraconazole	13-25	defensin beta 103B	Homo sapiens	66-71
20875690-6	2011	Antimycotics itraconazole and terbinafine hydrochloride increased hBD-3 secretion and mRNA levels in parallel to the enhanced activity of activator protein-1, expression and phosphorylation of activator protein-1 component, c-Fos, but fluconazole was ineffective.	Itraconazole	13-25	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	138-157
20875690-6	2011	Antimycotics itraconazole and terbinafine hydrochloride increased hBD-3 secretion and mRNA levels in parallel to the enhanced activity of activator protein-1, expression and phosphorylation of activator protein-1 component, c-Fos, but fluconazole was ineffective.	Itraconazole	13-25	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	193-212
20875690-6	2011	Antimycotics itraconazole and terbinafine hydrochloride increased hBD-3 secretion and mRNA levels in parallel to the enhanced activity of activator protein-1, expression and phosphorylation of activator protein-1 component, c-Fos, but fluconazole was ineffective.	Itraconazole	13-25	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	224-229
20875690-9	2011	The conditioned medium from itraconazole or terbinafine hydrochloride-treated keratinocytes inhibited the growth of Candida albicans dependently on hBD-3.	Itraconazole	28-40	defensin beta 103B	Homo sapiens	148-153
20875690-10	2011	These results suggest that itraconazole and terbinafine hydrochloride may enhance c-Fos expression and phosphorylation, activator protein-1 activity and hBD-3 production by increasing prostaglandin D(2) release from keratinocytes.	Itraconazole	27-39	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	82-87
20875690-10	2011	These results suggest that itraconazole and terbinafine hydrochloride may enhance c-Fos expression and phosphorylation, activator protein-1 activity and hBD-3 production by increasing prostaglandin D(2) release from keratinocytes.	Itraconazole	27-39	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	120-139
20875690-10	2011	These results suggest that itraconazole and terbinafine hydrochloride may enhance c-Fos expression and phosphorylation, activator protein-1 activity and hBD-3 production by increasing prostaglandin D(2) release from keratinocytes.	Itraconazole	27-39	defensin beta 103B	Homo sapiens	153-158
20400651-0	2011	Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-41
20400651-0	2011	Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.	Itraconazole	0-12	renin	Homo sapiens	112-117
20400651-5	2011	Plasma renin activity 24 hours after aliskiren intake was 68% lower during the itraconazole phase than during the placebo phase (P = .011).	Itraconazole	79-91	renin	Homo sapiens	7-12
20400651-6	2011	In conclusion, itraconazole markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.	Itraconazole	15-27	renin	Homo sapiens	87-92
21219398-3	2011	Treatment of patients with strong inducers of CYP3A enzymes, e.g. anti-epileptic drugs, resulted in 10-fold increased concentrations of plasma 4beta-OHC, while treatment with CYP3A inhibitors such as ritonavir or itraconazole resulted in decreased plasma concentrations.	Itraconazole	213-225	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-51
21147222-9	2011	Studies using itraconazole, a CYP3A4 inhibitor, established its role in curcumin metabolism.	Itraconazole	14-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36
21142269-3	2011	The aim of this study was to determine whether inhibition of CYP2D6 alone by paroxetine or inhibition of both CYP2D6 and CYP3A4 by a combination of paroxetine and itraconazole alters the pharmacokinetics of and pharmacological response to intravenous oxycodone.	Itraconazole	163-175	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	110-116
21056966-0	2011	Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4.	Itraconazole	0-12	ATP binding cassette subfamily B member 4	Homo sapiens	110-114
21056966-0	2011	Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4.	Itraconazole	0-12	ATP binding cassette subfamily B member 4	Homo sapiens	115-120
21142269-3	2011	The aim of this study was to determine whether inhibition of CYP2D6 alone by paroxetine or inhibition of both CYP2D6 and CYP3A4 by a combination of paroxetine and itraconazole alters the pharmacokinetics of and pharmacological response to intravenous oxycodone.	Itraconazole	163-175	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
20739919-0	2010	Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.	Itraconazole	59-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
21410294-3	2011	OBJECTIVE: The aim of this study was to investigate the effects of a potent CYP3A4 inducer, rifampicin (Study A), and a potent CYP3A4 inhibitor, itraconazole (Study B), on the pharmacokinetics of a single 300 mg dose of vandetanib in healthy subjects.	Itraconazole	145-157	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-133
21410294-18	2011	Vandetanib exposure was increased by about 9% when it was taken in combination with the CYP3A4 inhibitor itraconazole.	Itraconazole	105-117	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
21141064-6	2010	Following the administration of micafungin and itraconazole, the cavity lesion diminished in size, and his eosinophil and serum IgE levels decreased.	Itraconazole	47-59	immunoglobulin heavy constant epsilon	Homo sapiens	128-131
20860661-0	2010	Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2.	Itraconazole	36-48	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	163-171
20860661-10	2010	The metabolism of itraconazole and metformin was significantly inhibited by each other via CYP3A1 and 3A2 in rat and 3A4 in human microsomes.	Itraconazole	18-30	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	91-105
20739919-2	2010	The aim of this study was to determine the importance of inhibitory metabolites of itraconazole (ITZ) in in vivo cytochrome P450 (CYP) 3A4 inhibition.	Itraconazole	83-95	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-138
20739919-2	2010	The aim of this study was to determine the importance of inhibitory metabolites of itraconazole (ITZ) in in vivo cytochrome P450 (CYP) 3A4 inhibition.	Itraconazole	97-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-138
20739919-6	2010	The metabolites of ITZ were estimated to account for ~50% of the total CYP3A4 inhibition, with the relative contribution increasing with time after ITZ dosing.	Itraconazole	19-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-77
20568249-0	2010	Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3.	Itraconazole	15-27	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	121-127
20952738-4	2010	Itraconazoles dose-dependently increased the production of prostaglandin E2 (PGE2) and tumor necrosis factor-alpha (TNF-alpha) without affecting the production of interleukin-1beta (IL-1beta) and nitric oxide (NO).	Itraconazole	0-13	tumor necrosis factor	Mus musculus	87-114
20952738-4	2010	Itraconazoles dose-dependently increased the production of prostaglandin E2 (PGE2) and tumor necrosis factor-alpha (TNF-alpha) without affecting the production of interleukin-1beta (IL-1beta) and nitric oxide (NO).	Itraconazole	0-13	tumor necrosis factor	Mus musculus	116-125
20952738-6	2010	The addition of itraconazoles to LPS-stimulated RAW264.7 cells significantly reduced the production of NO, but rather enhanced the production of PGE2, TNF-alpha and IL-1beta.	Itraconazole	16-29	tumor necrosis factor	Mus musculus	151-160
20952738-6	2010	The addition of itraconazoles to LPS-stimulated RAW264.7 cells significantly reduced the production of NO, but rather enhanced the production of PGE2, TNF-alpha and IL-1beta.	Itraconazole	16-29	interleukin 1 beta	Mus musculus	165-173
20621721-0	2010	TGF-beta plasma levels in chromoblastomycosis patients during itraconazole treatment.	Itraconazole	62-74	transforming growth factor beta 1	Homo sapiens	0-8
20621721-4	2010	AIM: To quantify Transforming Growth Factor-beta (TGF-beta) plasma levels of CBM patients during itraconazole (ITZ) treatment.	Itraconazole	97-109	transforming growth factor beta 1	Homo sapiens	17-48
20621721-4	2010	AIM: To quantify Transforming Growth Factor-beta (TGF-beta) plasma levels of CBM patients during itraconazole (ITZ) treatment.	Itraconazole	97-109	transforming growth factor beta 1	Homo sapiens	50-58
20621721-4	2010	AIM: To quantify Transforming Growth Factor-beta (TGF-beta) plasma levels of CBM patients during itraconazole (ITZ) treatment.	Itraconazole	111-114	transforming growth factor beta 1	Homo sapiens	17-48
20621721-4	2010	AIM: To quantify Transforming Growth Factor-beta (TGF-beta) plasma levels of CBM patients during itraconazole (ITZ) treatment.	Itraconazole	111-114	transforming growth factor beta 1	Homo sapiens	50-58
20575631-10	2010	We further assessed whether a drug interaction between bortezomib and itraconazole and/or lansoprazole had occurred involving the CYP3A4 and/or the CYP2C19 pathways, respectively-resulting in increased severity of the bortezomib-induced peripheral neuropathy and thrombocytopenia-by using the Horn drug interaction probability scale.	Itraconazole	70-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	130-136
20642550-5	2010	AIM: The aim of this study was to find out whether the inhibition of cytochrome P450 2D6 (CYP2D6) with paroxetine or concomitant inhibition of CYP2D6 and CYP3A4 with paroxetine and itraconazole, altered the pharmacokinetics and pharmacological response of orally administered oxycodone.	Itraconazole	181-193	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	90-96
20642550-5	2010	AIM: The aim of this study was to find out whether the inhibition of cytochrome P450 2D6 (CYP2D6) with paroxetine or concomitant inhibition of CYP2D6 and CYP3A4 with paroxetine and itraconazole, altered the pharmacokinetics and pharmacological response of orally administered oxycodone.	Itraconazole	181-193	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	143-149
20642550-5	2010	AIM: The aim of this study was to find out whether the inhibition of cytochrome P450 2D6 (CYP2D6) with paroxetine or concomitant inhibition of CYP2D6 and CYP3A4 with paroxetine and itraconazole, altered the pharmacokinetics and pharmacological response of orally administered oxycodone.	Itraconazole	181-193	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	154-160
20575631-10	2010	We further assessed whether a drug interaction between bortezomib and itraconazole and/or lansoprazole had occurred involving the CYP3A4 and/or the CYP2C19 pathways, respectively-resulting in increased severity of the bortezomib-induced peripheral neuropathy and thrombocytopenia-by using the Horn drug interaction probability scale.	Itraconazole	70-82	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	148-155
20304965-12	2010	In terms of UGT1A4 metabolism, itraconazole showed kinetic features characteristic of imidazole rather than triazole antifungals.	Itraconazole	31-43	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	12-18
20460536-0	2010	Antifungal therapy with itraconazole impairs the anti-lymphoma effects of rituximab by inhibiting recruitment of CD20 to cell surface lipid rafts.	Itraconazole	24-36	keratin 20	Homo sapiens	113-117
20460536-6	2010	At the molecular level, recruitment of CD20 to lipid rafts is inhibited in the presence of itraconazole.	Itraconazole	91-103	keratin 20	Homo sapiens	39-43
20460536-9	2010	The finding that itraconazole also abolished the cytotoxic effects of other therapeutic antibodies directed against lipid raft-associated molecules (i.e., CD20 and CD52) but not those against the non-raft-associated molecule CD33 further supported our proposed mechanism of action.	Itraconazole	17-29	keratin 20	Homo sapiens	155-159
20460536-9	2010	The finding that itraconazole also abolished the cytotoxic effects of other therapeutic antibodies directed against lipid raft-associated molecules (i.e., CD20 and CD52) but not those against the non-raft-associated molecule CD33 further supported our proposed mechanism of action.	Itraconazole	17-29	CD52 molecule	Homo sapiens	164-168
20497744-1	2010	OBJECTIVE: Itraconazole is a potent inhibitor of cytochrome P450 (CYP) 3A with an elimination half-life of more than 30 hours.	Itraconazole	11-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-73
20497744-2	2010	Therefore, itraconazole may cause persistent CYP3A inhibition.	Itraconazole	11-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-50
19818023-5	2009	Using gas chromatography, we showed that Sre1 and Stp1 are required for both normoxic and hypoxic ergosterol biosynthesis, and therefore cells lacking SRE1 or STP1 are defective for growth in the presence of low levels of the ergosterol biosynthesis inhibitors, itraconazole and 25-thialanosterol.	Itraconazole	262-274	transition protein 1	Homo sapiens	50-54
20385363-3	2010	Mechanistically, itraconazole appears to act on the essential Hh pathway component Smoothened (SMO) by a mechanism distinct from that of cyclopamine and other known SMO antagonists, and prevents the ciliary accumulation of SMO normally caused by Hh stimulation.	Itraconazole	17-29	smoothened, frizzled class receptor	Homo sapiens	83-93
20385363-3	2010	Mechanistically, itraconazole appears to act on the essential Hh pathway component Smoothened (SMO) by a mechanism distinct from that of cyclopamine and other known SMO antagonists, and prevents the ciliary accumulation of SMO normally caused by Hh stimulation.	Itraconazole	17-29	smoothened, frizzled class receptor	Homo sapiens	95-98
20385363-3	2010	Mechanistically, itraconazole appears to act on the essential Hh pathway component Smoothened (SMO) by a mechanism distinct from that of cyclopamine and other known SMO antagonists, and prevents the ciliary accumulation of SMO normally caused by Hh stimulation.	Itraconazole	17-29	smoothened, frizzled class receptor	Homo sapiens	165-168
20385363-3	2010	Mechanistically, itraconazole appears to act on the essential Hh pathway component Smoothened (SMO) by a mechanism distinct from that of cyclopamine and other known SMO antagonists, and prevents the ciliary accumulation of SMO normally caused by Hh stimulation.	Itraconazole	17-29	smoothened, frizzled class receptor	Homo sapiens	165-168
20176935-3	2010	We report that blockade of cholesterol trafficking through lysosome by a newly identified inhibitor of angiogenesis, itraconazole, leads to inhibition of mTOR activity in endothelial cells.	Itraconazole	117-129	mechanistic target of rapamycin kinase	Homo sapiens	154-158
20176935-4	2010	Inhibition of mTOR by itraconazole but not rapamycin can be partially restored by extracellular cholesterol delivered by cyclodextrin.	Itraconazole	22-34	mechanistic target of rapamycin kinase	Homo sapiens	14-18
20176935-6	2010	In addition, both the accumulation of cholesterol in the lysosome and inhibition of mTOR caused by itraconazole can be reversed by thapsigarin.	Itraconazole	99-111	mechanistic target of rapamycin kinase	Homo sapiens	84-88
19954708-1	2009	OBJECTIVE: Itraconazole, a triazole antifungal agent, has been demonstrated to act as an inhibitor of the ligand induced pregnane X receptor-mediated transcriptional regulation of the CYP3A4 gene.	Itraconazole	11-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	184-190
19954708-2	2009	Here, we study the potential endogenous serum marker of CYP3A4 activity, 4beta-hydroxycholesterol, during therapy with itraconazole.	Itraconazole	119-131	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
19954708-11	2009	CONCLUSIONS: In conclusion, 4beta-hydroxycholesterol appears to be a sensitive endogenous surrogate marker in human serum for inhibition of CYP3A4 by itraconazole.	Itraconazole	150-162	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	140-146
20076952-1	2010	BACKGROUND: The aim of this study was to investigate the effects of the cytochrome P450 3A4 (CYP34A) inhibitor itraconazole on the pharmacokinetics and pharmacodynamics of orally and intravenously administered oxycodone.	Itraconazole	111-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-91
20000889-4	2010	OBJECTIVES: To accomplish a semi-mechanistic DDI model for a long-elimination-half-life drug substrate, tesofensine, and the cytochrome P450 (CYP) 3A4 inhibitor itraconazole, and to compare the results of the semi-mechanistic model with the results obtained from the standard NCA approach.	Itraconazole	161-173	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-150
20000889-12	2010	Inhibition resulted in reduced clearances and prolonged elimination half-lives for tesofensine and itraconazole: using NCA, the actual study revealed an approximately 9% increase in exposure for the timeframe of the coadministration with itraconazole (the area under the plasma concentration-time curve (AUC) from 0 to 144 hours [AUC(144h)]), and the impact on exposure estimated to infinity (AUC(infinity)) was approximately 26%.	Itraconazole	99-111	CEA cell adhesion molecule 4	Homo sapiens	119-122
20000889-12	2010	Inhibition resulted in reduced clearances and prolonged elimination half-lives for tesofensine and itraconazole: using NCA, the actual study revealed an approximately 9% increase in exposure for the timeframe of the coadministration with itraconazole (the area under the plasma concentration-time curve (AUC) from 0 to 144 hours [AUC(144h)]), and the impact on exposure estimated to infinity (AUC(infinity)) was approximately 26%.	Itraconazole	238-250	CEA cell adhesion molecule 4	Homo sapiens	119-122
19947891-4	2010	Both in vitro and in vivo studies have demonstrated that both itraconazole and verapamil are potent P-glycoprotein inhibitors.	Itraconazole	62-74	ATP binding cassette subfamily B member 1	Homo sapiens	100-114
19947891-7	2010	Co-administration of itraconazole and/or verapamil significantly increased the AUC(0 - 24) of both enantiomers; their influence on the P-glycoprotein-mediated transport of (S)-fexofenadine was greater than that of the (R)-enantiomer.	Itraconazole	21-33	ATP binding cassette subfamily B member 1	Homo sapiens	135-149
19455959-1	2009	We report the case of a 75-year-old woman with mucoid impaction of the bronchi (MIB) due to Schizophyllum commune who improved with itraconazole (ITCZ) administration and relapsed after discontinuation of the drug.	Itraconazole	132-144	MIB E3 ubiquitin protein ligase 1	Homo sapiens	80-83
19309762-3	2009	Since both itraconazole and hydroxyitraconazole are effective inhibitors of cytochrome P450 (CYP) 3A4 and p-glycoprotein (pgp)-mediated efflux transporters, they have the potential to elicit drug-drug interaction with a number of CYP3A4 and/or pgp substrates.	Itraconazole	11-23	ATP binding cassette subfamily B member 1	Homo sapiens	106-120
19309762-3	2009	Since both itraconazole and hydroxyitraconazole are effective inhibitors of cytochrome P450 (CYP) 3A4 and p-glycoprotein (pgp)-mediated efflux transporters, they have the potential to elicit drug-drug interaction with a number of CYP3A4 and/or pgp substrates.	Itraconazole	11-23	ATP binding cassette subfamily B member 1	Homo sapiens	122-125
19309762-3	2009	Since both itraconazole and hydroxyitraconazole are effective inhibitors of cytochrome P450 (CYP) 3A4 and p-glycoprotein (pgp)-mediated efflux transporters, they have the potential to elicit drug-drug interaction with a number of CYP3A4 and/or pgp substrates.	Itraconazole	11-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	230-236
19309762-3	2009	Since both itraconazole and hydroxyitraconazole are effective inhibitors of cytochrome P450 (CYP) 3A4 and p-glycoprotein (pgp)-mediated efflux transporters, they have the potential to elicit drug-drug interaction with a number of CYP3A4 and/or pgp substrates.	Itraconazole	11-23	ATP binding cassette subfamily B member 1	Homo sapiens	244-247
19414590-3	2009	We have found that incubation of macrophages with itraconazole (ICZ), an azole antifungal commonly used in humans, altered both the expression and glycosylation of CD14.	Itraconazole	50-62	CD14 molecule	Homo sapiens	164-168
19414590-3	2009	We have found that incubation of macrophages with itraconazole (ICZ), an azole antifungal commonly used in humans, altered both the expression and glycosylation of CD14.	Itraconazole	64-67	CD14 molecule	Homo sapiens	164-168
20209351-8	2009	The Cryptococcus gattii isolate from an HIV-positive patient showed resistance to fluconazole (MIC &gt; or = 256 (1/4)g/ml) and itraconazole (MIC = 3 (1/4)microg/ml).	Itraconazole	128-140	CD9 molecule	Homo sapiens	142-149
20130764-7	2009	In vitro incubation of hepatocytes with itraconazole revealed significantly lower viability when compared to fluconazole as assessed by lactate dehydrogenase, aspartate aminotransferase and alanine aminotransferase activities.	Itraconazole	40-52	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	159-185
20230761-7	2009	A drug-drug interaction study with itraconazole confirmed in vitro metabolic results implicating CYP3A enzymes as the major contributors to in vivo oxidative metabolism.	Itraconazole	35-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-102
19025521-0	2008	Itraconazole, a potent inhibitor of P-glycoprotein, moderately increases plasma concentrations of oral morphine.	Itraconazole	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	36-50
18725258-2	2008	The distribution of P-gp substrates (rhodamine 123 and itraconazole) to the skin after administration from the epidermal side was lower in P-gp gene knockout (mdr1a/1b(-/-)) mice than that in wild-type mice.	Itraconazole	55-67	phosphoglycolate phosphatase	Mus musculus	20-24
18725258-2	2008	The distribution of P-gp substrates (rhodamine 123 and itraconazole) to the skin after administration from the epidermal side was lower in P-gp gene knockout (mdr1a/1b(-/-)) mice than that in wild-type mice.	Itraconazole	55-67	phosphoglycolate phosphatase	Mus musculus	139-143
18725258-2	2008	The distribution of P-gp substrates (rhodamine 123 and itraconazole) to the skin after administration from the epidermal side was lower in P-gp gene knockout (mdr1a/1b(-/-)) mice than that in wild-type mice.	Itraconazole	55-67	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	159-164
18725258-3	2008	Coadministration of propranolol, a P-gp inhibitor, decreased the distribution of itraconazole to the skin in wild-type mice, but not in mdr1a/1b(-/-) mice.	Itraconazole	81-93	phosphoglycolate phosphatase	Mus musculus	35-39
18725258-6	2008	Distribution of itraconazole after intravenous administration, on the other hand, was higher in mdr1a/1b(-/-) mice than that in wild-type mice, suggesting that P-gp transports this drug from the skin to the circulation.	Itraconazole	16-28	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	96-101
18725258-6	2008	Distribution of itraconazole after intravenous administration, on the other hand, was higher in mdr1a/1b(-/-) mice than that in wild-type mice, suggesting that P-gp transports this drug from the skin to the circulation.	Itraconazole	16-28	phosphoglycolate phosphatase	Mus musculus	160-164
19025521-4	2008	The aim of this study was to evaluate whether itraconazole, which is a potent inhibitor of P-glycoprotein and CYP3A4, would change the pharmacokinetics or the pharmacodynamics of oral morphine.	Itraconazole	46-58	ATP binding cassette subfamily B member 1	Homo sapiens	91-105
19025521-4	2008	The aim of this study was to evaluate whether itraconazole, which is a potent inhibitor of P-glycoprotein and CYP3A4, would change the pharmacokinetics or the pharmacodynamics of oral morphine.	Itraconazole	46-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-116
19025521-11	2008	CONCLUSIONS: Itraconazole moderately increases plasma concentrations of oral morphine, probably by enhancing its absorption by inhibiting intestinal wall P-glycoprotein.	Itraconazole	13-25	ATP binding cassette subfamily B member 1	Homo sapiens	154-168
18755176-2	2008	DESIGN AND METHODS: A representative analyte (itraconazole) was extracted from plasma samples using small quantities of C18-modified ferromagnetic micro-particles.	Itraconazole	46-58	Bardet-Biedl syndrome 9	Homo sapiens	120-123
19356088-2	2008	Itraconazole (ITZ) functions as an inhibitor of both the P-gp and CYP3A and is used as a fungistatic/fungicidal agent in human and veterinary medicine.	Itraconazole	0-12	phosphoglycolate phosphatase	Homo sapiens	57-61
18656535-7	2008	Due to the lower miscibility degree between the longer PEG types and HPMC 2910 E5, the ternary amorphous phase was further separated, leading to a more rapid decrease of the ternary amorphous phase glass transition as a function of PEG and itraconazole weight percentage and hence, itraconazole recrystallization.	Itraconazole	240-252	progestagen associated endometrial protein	Homo sapiens	55-58
18656535-7	2008	Due to the lower miscibility degree between the longer PEG types and HPMC 2910 E5, the ternary amorphous phase was further separated, leading to a more rapid decrease of the ternary amorphous phase glass transition as a function of PEG and itraconazole weight percentage and hence, itraconazole recrystallization.	Itraconazole	240-252	progestagen associated endometrial protein	Homo sapiens	232-235
18656535-7	2008	Due to the lower miscibility degree between the longer PEG types and HPMC 2910 E5, the ternary amorphous phase was further separated, leading to a more rapid decrease of the ternary amorphous phase glass transition as a function of PEG and itraconazole weight percentage and hence, itraconazole recrystallization.	Itraconazole	282-294	progestagen associated endometrial protein	Homo sapiens	55-58
18656535-7	2008	Due to the lower miscibility degree between the longer PEG types and HPMC 2910 E5, the ternary amorphous phase was further separated, leading to a more rapid decrease of the ternary amorphous phase glass transition as a function of PEG and itraconazole weight percentage and hence, itraconazole recrystallization.	Itraconazole	282-294	progestagen associated endometrial protein	Homo sapiens	232-235
18656535-8	2008	In terms of release, an advantage of the shorter chain length PEG types (2000, 6000) over the longer chain length PEG types (10,000, 20,000) was observed for the polymer blends with 5% of PEG with respect to the binary itraconazole/HPMC 2910 E5 solid dispersion.	Itraconazole	219-231	progestagen associated endometrial protein	Homo sapiens	62-65
18817631-1	2008	AIM: To evaluate the effects of cyclosporin A and itraconazole, which were used as inhibitors of P-glycoprotein (P-gp) and/or cytochrome P450 (CYP) 3A4 on the pharmacokinetics of atorvastatin in rats.	Itraconazole	50-62	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	97-111
18817631-1	2008	AIM: To evaluate the effects of cyclosporin A and itraconazole, which were used as inhibitors of P-glycoprotein (P-gp) and/or cytochrome P450 (CYP) 3A4 on the pharmacokinetics of atorvastatin in rats.	Itraconazole	50-62	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	113-117
18630936-8	2008	At a loading of 30 wt %, itraconazole exhibited intermolecular interactions inside the mesopores revealed by UV spectroscopy and endothermic events traced with DSC.	Itraconazole	25-37	desmocollin 3	Homo sapiens	160-163
19356088-2	2008	Itraconazole (ITZ) functions as an inhibitor of both the P-gp and CYP3A and is used as a fungistatic/fungicidal agent in human and veterinary medicine.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-71
19356088-2	2008	Itraconazole (ITZ) functions as an inhibitor of both the P-gp and CYP3A and is used as a fungistatic/fungicidal agent in human and veterinary medicine.	Itraconazole	14-17	phosphoglycolate phosphatase	Homo sapiens	57-61
19356088-2	2008	Itraconazole (ITZ) functions as an inhibitor of both the P-gp and CYP3A and is used as a fungistatic/fungicidal agent in human and veterinary medicine.	Itraconazole	14-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-71
18294330-2	2008	Although itraconazole co-administration is known to increase the bioavailability of a racemic mixture of fexofenadine, little is known about the stereoselective inhibition of P-gp activity by itraconazole.	Itraconazole	192-204	ATP binding cassette subfamily B member 1	Homo sapiens	175-179
18520601-1	2008	An open-label, clinical pilot study was performed to study the effect of cyclosporine A (CsA) on single-dose pharmacokinetics of itraconazole in patients with a hematologic malignancy.	Itraconazole	129-141	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	89-92
18520601-8	2008	In contrast, exposure to OH-itraconazole was significantly increased when itraconazole was coadministered with CsA (median increase of AUC[0-24h] 49%) with significant prolongation of T(max) and T1/2 (median increase of T(max) 37% and T1/2 176%).	Itraconazole	28-40	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	111-114
18520601-9	2008	These differences may be the result of variability in affinity of itraconazole, OH-itraconazole, and CsA for the cytochrome P450 3A4 metabolic system and the occurrence of P-glycoprotein polymorphisms.	Itraconazole	66-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-132
18339815-0	2008	Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats.	Itraconazole	7-19	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	121-126
18339815-0	2008	Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats.	Itraconazole	71-83	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	121-126
18339815-1	2008	Itraconazole (ITZ) is a substrate of CYP3A and both ITZ and hydroxyitraconazole (OH-ITZ), a major metabolite formed by CYP3A, are potent inhibitors of CYP3A.	Itraconazole	0-12	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	37-42
18339815-1	2008	Itraconazole (ITZ) is a substrate of CYP3A and both ITZ and hydroxyitraconazole (OH-ITZ), a major metabolite formed by CYP3A, are potent inhibitors of CYP3A.	Itraconazole	0-12	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	119-124
18339815-1	2008	Itraconazole (ITZ) is a substrate of CYP3A and both ITZ and hydroxyitraconazole (OH-ITZ), a major metabolite formed by CYP3A, are potent inhibitors of CYP3A.	Itraconazole	0-12	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	119-124
18339815-1	2008	Itraconazole (ITZ) is a substrate of CYP3A and both ITZ and hydroxyitraconazole (OH-ITZ), a major metabolite formed by CYP3A, are potent inhibitors of CYP3A.	Itraconazole	14-17	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	37-42
18339815-1	2008	Itraconazole (ITZ) is a substrate of CYP3A and both ITZ and hydroxyitraconazole (OH-ITZ), a major metabolite formed by CYP3A, are potent inhibitors of CYP3A.	Itraconazole	14-17	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	119-124
18339815-1	2008	Itraconazole (ITZ) is a substrate of CYP3A and both ITZ and hydroxyitraconazole (OH-ITZ), a major metabolite formed by CYP3A, are potent inhibitors of CYP3A.	Itraconazole	14-17	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	119-124
18520601-10	2008	In conclusion, exposure to OH-itraconazole, but not to itraconazole, is increased when itraconazole is coadministered with CsA.	Itraconazole	30-42	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	123-126
18520601-11	2008	Although the interaction profile of itraconazole and CsA remains complex, these findings may be of importance in patients in whom monitoring of itraconazole serum levels is warranted, for example, in those with life-threatening fungal infections or in those who receive concurrent cytochrome inducers or inhibitors.	Itraconazole	144-156	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	53-56
18294330-3	2008	WHAT THIS STUDY ADDS: This study indicates that the stereoselective pharmacokinetics of fexofenadine are due to P-gp-mediated transport and its stereoselectivity is altered by itraconazole, a an inhibitor of P-gp.	Itraconazole	176-188	ATP binding cassette subfamily B member 1	Homo sapiens	112-116
18294330-4	2008	AIMS: The aim of this study was to determine the inhibitory effect of itraconazole, a P-glycoprotein (P-gp) inhibitor, on the stereoselective pharmacokinetics of fexofenadine.	Itraconazole	70-82	ATP binding cassette subfamily B member 1	Homo sapiens	86-100
18294330-4	2008	AIMS: The aim of this study was to determine the inhibitory effect of itraconazole, a P-glycoprotein (P-gp) inhibitor, on the stereoselective pharmacokinetics of fexofenadine.	Itraconazole	70-82	ATP binding cassette subfamily B member 1	Homo sapiens	102-106
18294330-11	2008	CONCLUSIONS: This study indicates that the stereoselective pharmacokinetics of fexofenadine are due to P-gp-mediated transport and its stereoselectivity is altered by itraconazole, a P-gp inhibitor.	Itraconazole	167-179	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
17998298-3	2008	In the present study, we examined effects of azole antimycotics clotrimazole, ketoconazole, econazole, oxiconazole, miconazole, fluconazole, and itraconazole on PXR-mediated expression of CYP3A4.	Itraconazole	145-157	nuclear receptor subfamily 1 group I member 2	Homo sapiens	161-164
18218784-8	2008	In conclusion, itraconazole increases the plasma concentrations of imidafenacin by inhibiting CYP3A4.	Itraconazole	15-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	94-100
18783297-10	2008	The CRCYP3A4 was calculated for 22 substrates on the basis of the previously reported method from inhibitory DDI studies using a potent CYP3A4 inhibitor such as itraconazole or ketoconazole.	Itraconazole	161-173	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-12
18033783-7	2008	Exposure to fluconazole led to significant increases in GFP-SAP4 and -SAP6 fluorescence in the filaments; itraconazole exposure also significantly increased GFP-SAP4 fluorescence, whereas flucytosine had no effect on any of the constructs.	Itraconazole	106-118	Sap4p	Saccharomyces cerevisiae S288C	161-165
17495874-0	2008	Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.	Itraconazole	16-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-64
17495874-6	2008	A 3.9-fold decrease in the hepatic intrinsic clearance of a CYP3A4 substrate was predicted using the average unbound steady-state concentrations (C(ss,ave,u)) and liver microsomal inhibition constants for ITZ, OH-ITZ, keto-ITZ, and ND-ITZ.	Itraconazole	212-216	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
17495874-7	2008	Accounting for circulating metabolites of ITZ significantly improved the in vitro to in vivo extrapolation of CYP3A4 inhibition compared to a consideration of ITZ exposure alone.	Itraconazole	42-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-116
17283379-0	2007	Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines.	Itraconazole	53-65	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	13-32
17923278-0	2007	Induction of the NAD(P)H:quinone oxidoreductase 1 by ketoconazole and itraconazole: a mechanism of cancer chemoprotection.	Itraconazole	70-82	NAD(P)H dehydrogenase, quinone 1	Mus musculus	17-49
17923278-3	2007	Therefore, we examined the ability of three structurally different antifungal drugs, ketoconazole (KTZ), itraconazole (ITZ), and fluconazole (FLZ) to induce the expression of NAD(P)H:quinone oxidoreductase 1 (Nqo1), an enzyme known to play an important role in xenobiotic and carcinogen detoxifications.	Itraconazole	105-117	NAD(P)H dehydrogenase, quinone 1	Mus musculus	175-207
17923278-3	2007	Therefore, we examined the ability of three structurally different antifungal drugs, ketoconazole (KTZ), itraconazole (ITZ), and fluconazole (FLZ) to induce the expression of NAD(P)H:quinone oxidoreductase 1 (Nqo1), an enzyme known to play an important role in xenobiotic and carcinogen detoxifications.	Itraconazole	119-122	NAD(P)H dehydrogenase, quinone 1	Mus musculus	175-207
17518356-11	2007	These results suggest that BCRP could play a significant role in the pharmacokinetic interactions of ketoconazole or itraconazole with BCRP substrate drugs.	Itraconazole	117-129	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	27-31
17518356-11	2007	These results suggest that BCRP could play a significant role in the pharmacokinetic interactions of ketoconazole or itraconazole with BCRP substrate drugs.	Itraconazole	117-129	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	135-139
17518356-2	2007	The goal of this study was to investigate the interactions of azole antifungal agents, ketoconazole, itraconazole, fluconazole, and voriconazole, with BCRP.	Itraconazole	101-113	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	151-155
17518356-4	2007	We found that keotoconazole and itraconazole significantly inhibited BCRP-mediated efflux of PhA at low microM concentrations.	Itraconazole	32-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	69-73
17518356-4	2007	We found that keotoconazole and itraconazole significantly inhibited BCRP-mediated efflux of PhA at low microM concentrations.	Itraconazole	32-44	lamin B receptor	Homo sapiens	93-96
17518356-7	2007	Ketoconazole and itraconazole also effectively reversed BCRP-mediated resistance of HEK cells to topotecan.	Itraconazole	17-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	56-60
17518356-10	2007	Taken together, ketoconazole and itraconazole are BCRP inhibitors, but fluconazole and voriconazole are not.	Itraconazole	33-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	50-54
17517842-4	2007	Consistent with the role of CYP3A4 in the biotransformation of itraconazole, a substantial degree of variability was observed in the pharmacokinetics of this drug after IV administration.	Itraconazole	63-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34
17725244-7	2007	RESULTS: During itraconazole treatment total cholesterol and LDL-C decreased on average by 12% (p &lt; 0.001) and 17% (p &lt; 0.001), respectively, whereas HDL-C increased by 21% (p &lt; 0.001).	Itraconazole	16-28	component of oligomeric golgi complex 2	Homo sapiens	61-66
17725244-9	2007	Incubation of Caco-2 cells in the presence of itraconazole and hydroxyitraconazole for 3 hours resulted in a significant increase in apoA-I concentration in the medium (913 and 412%, respectively) compared with control.	Itraconazole	46-58	apolipoprotein A1	Homo sapiens	133-139
17725244-10	2007	CONCLUSION: In addition to its inhibitory effect on cholesterol synthesis, high-dose itraconazole (400 mg/d) causes a significant decrease in serum LDL-C and, in contrast to ketoconazole, a significant increase in HDL-C.	Itraconazole	85-97	component of oligomeric golgi complex 2	Homo sapiens	148-153
17472656-2	2007	The comparative effect of the itraconazole (ITZ)-mediated modulation of P-glycoprotein (P-gp) activity on the in vivo kinetic behaviour of ivermectin (IVM) administered by the intravenous (i.v.)	Itraconazole	30-42	multidrug resistance protein 1	Ovis aries	72-86
17472656-2	2007	The comparative effect of the itraconazole (ITZ)-mediated modulation of P-glycoprotein (P-gp) activity on the in vivo kinetic behaviour of ivermectin (IVM) administered by the intravenous (i.v.)	Itraconazole	30-42	multidrug resistance protein 1	Ovis aries	88-92
17472656-2	2007	The comparative effect of the itraconazole (ITZ)-mediated modulation of P-glycoprotein (P-gp) activity on the in vivo kinetic behaviour of ivermectin (IVM) administered by the intravenous (i.v.)	Itraconazole	44-47	multidrug resistance protein 1	Ovis aries	72-86
17472656-2	2007	The comparative effect of the itraconazole (ITZ)-mediated modulation of P-glycoprotein (P-gp) activity on the in vivo kinetic behaviour of ivermectin (IVM) administered by the intravenous (i.v.)	Itraconazole	44-47	multidrug resistance protein 1	Ovis aries	88-92
17472656-15	2007	An ITZ-induced reduction on the P-gp efflux activity at the intestinal lining may have accounted for the greater absorption and enhanced systemic availability observed for IVM in the intraruminally treated animals.	Itraconazole	3-6	multidrug resistance protein 1	Ovis aries	32-36
17283379-2	2007	Therefore, we examined here the ability of three structurally different antifungal drugs, ketoconazole (KTZ), itraconazole (ITZ), and fluconazole (FLZ) to induce the CYP1A1, an enzyme known to play an important role in chemical activation of xenobiotics to toxic metabolites.	Itraconazole	110-122	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	166-172
17283379-2	2007	Therefore, we examined here the ability of three structurally different antifungal drugs, ketoconazole (KTZ), itraconazole (ITZ), and fluconazole (FLZ) to induce the CYP1A1, an enzyme known to play an important role in chemical activation of xenobiotics to toxic metabolites.	Itraconazole	124-127	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	166-172
17283379-6	2007	Inhibition studies showed that KTZ and ITZ, in addition to being CYP1A1 inducers, are substrates and competitive inhibitors.	Itraconazole	39-42	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	65-71
17432820-5	2007	In attempts to delineate the mechanism of action of itraconazole, we found that human lanosterol 14alpha-demethylase (14DM) is essential for endothelial cell proliferation and may partially mediate the inhibition of endothelial cells by itraconazole.	Itraconazole	52-64	cytochrome P450 family 51 subfamily A member 1	Homo sapiens	86-116
17432820-5	2007	In attempts to delineate the mechanism of action of itraconazole, we found that human lanosterol 14alpha-demethylase (14DM) is essential for endothelial cell proliferation and may partially mediate the inhibition of endothelial cells by itraconazole.	Itraconazole	237-249	cytochrome P450 family 51 subfamily A member 1	Homo sapiens	86-116
17304149-3	2007	The aim of this study was to examine the effects of itraconazole, a P-glycoprotein inhibitor, on the pharmacokinetics of paroxetine.	Itraconazole	52-64	ATP binding cassette subfamily B member 1	Homo sapiens	68-82
17386084-0	2007	Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.	Itraconazole	77-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
17304149-9	2007	The present study demonstrated that the bioavailability of paroxetine was increased by itraconazole, suggesting a possible involvement of P-glycoprotein in the pharmacokinetics of paroxetine.	Itraconazole	87-99	ATP binding cassette subfamily B member 1	Homo sapiens	138-152
17178259-4	2006	Simvastatin, lovastatin, and atorvastatin are metabolized by cytochrome P450 (CYP) 3A4 (simvastatin acid is also metabolized by CYP2C8); their plasma concentrations and risk of myotoxicity are greatly increased by strong inhibitors of CYP3A4 (eg, itraconazole and ritonavir).	Itraconazole	247-259	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-86
17484517-5	2007	Clinically established CYP3A4 inhibitors including itraconazole, ketoconazole, erythromycin and clarithromycin inhibited the elimination of IM in HLM.	Itraconazole	51-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
17003527-11	2007	CONCLUSIONS: Itraconazole comedication substantially increases systemic levels of inhaled fluticasone, most likely by inhibiting the cytochrome P450 3A4 enzyme system and thus the clearance of fluticasone.	Itraconazole	13-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	133-152
17178259-4	2006	Simvastatin, lovastatin, and atorvastatin are metabolized by cytochrome P450 (CYP) 3A4 (simvastatin acid is also metabolized by CYP2C8); their plasma concentrations and risk of myotoxicity are greatly increased by strong inhibitors of CYP3A4 (eg, itraconazole and ritonavir).	Itraconazole	247-259	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	128-134
17022761-0	2006	Fluconazole and itraconazole susceptibilities of Candida spp.	Itraconazole	16-28	histocompatibility minor 13	Homo sapiens	57-60
16989930-10	2006	For the inhibition of hCYP51, IC(50) values split into two classes: the newer drugs fluconazole and itraconazole showed little inhibition (&gt; or = 30 microM) while the older drugs were even more potent than the agricultural fungicides, with miconazole being the most potent (0.057 microM).	Itraconazole	100-112	cytochrome P450 family 51 subfamily A member 1	Homo sapiens	22-28
17022761-2	2006	This study examined the in vitro susceptibilities to fluconazole and itraconazole of isolates of Candida spp.	Itraconazole	69-81	histocompatibility minor 13	Homo sapiens	105-108
16872551-5	2006	The sex-related influence on the itraconazole (ITZ) modulation of P-gp-mediated IVM intestinal transport was also assessed.	Itraconazole	33-45	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	66-70
16872551-5	2006	The sex-related influence on the itraconazole (ITZ) modulation of P-gp-mediated IVM intestinal transport was also assessed.	Itraconazole	47-50	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	66-70
16556082-7	2006	The systemic azoles, such as ketoconazole, itraconazole, fluconazole and voriconazole, are inhibitors of CYP isoenzymes, such as CYP3A4, CYP2C9 and CYP2C19, to varying degrees.	Itraconazole	43-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135
16700545-3	2006	However, CYP3A4 also slowly oxidizes the antifungal itraconazole (ITZ) at a site that is approximately 25 A from the triazole nitrogens, suggesting that large antifungal azoles can adopt multiple orientations within the CYP3A4 active site.	Itraconazole	52-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	9-15
16700545-3	2006	However, CYP3A4 also slowly oxidizes the antifungal itraconazole (ITZ) at a site that is approximately 25 A from the triazole nitrogens, suggesting that large antifungal azoles can adopt multiple orientations within the CYP3A4 active site.	Itraconazole	52-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	220-226
16700545-3	2006	However, CYP3A4 also slowly oxidizes the antifungal itraconazole (ITZ) at a site that is approximately 25 A from the triazole nitrogens, suggesting that large antifungal azoles can adopt multiple orientations within the CYP3A4 active site.	Itraconazole	66-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	9-15
16700545-3	2006	However, CYP3A4 also slowly oxidizes the antifungal itraconazole (ITZ) at a site that is approximately 25 A from the triazole nitrogens, suggesting that large antifungal azoles can adopt multiple orientations within the CYP3A4 active site.	Itraconazole	66-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	220-226
16556082-7	2006	The systemic azoles, such as ketoconazole, itraconazole, fluconazole and voriconazole, are inhibitors of CYP isoenzymes, such as CYP3A4, CYP2C9 and CYP2C19, to varying degrees.	Itraconazole	43-55	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	137-143
16556082-7	2006	The systemic azoles, such as ketoconazole, itraconazole, fluconazole and voriconazole, are inhibitors of CYP isoenzymes, such as CYP3A4, CYP2C9 and CYP2C19, to varying degrees.	Itraconazole	43-55	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	148-155
16633141-7	2006	In the presence of itraconazole, subjects with CYP2D6*10/*10 showed 3-fold higher AUC of haloperidol compared to that of placebo pretreated subjects with CYP2D6*1/*1 genotype (21.7 +/- 11.3 vs 66.7 +/- 62.1 ng h/mL; P &lt; 0.05).	Itraconazole	19-31	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	47-53
16633141-10	2006	Barnes Akathisia Rating Scale (BARS) of subjects with CYP2D6*10/*10 in the presence of itraconazole pretreatment was significantly higher than that of subjects with CYP2D6*1/*1 genotype in the period of placebo pretreatment.	Itraconazole	87-99	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
16633141-12	2006	The moderate effect of CYP2D6*10 genotype on the pharmacokinetics and pharmacodynamics of haloperidol seems to be augmented by the presence of itraconazole pretreatment.	Itraconazole	143-155	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	23-29
18360572-6	2005	Itraconazole works by inhibiting ergosterol synthesis via cytochrome P-450 (CYP450)-dependent demethylation step.	Itraconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-74
16418697-3	2006	In this study, the authors investigated the effects of itraconazole, which is a specific inhibitor of CYP3A4, or tandospirone, which is mainly metabolized by CYP3A4 and is expected to competitively inhibit the activity of this enzyme, on single oral dose pharmacokinetics of perospirone.	Itraconazole	55-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	102-108
16418697-3	2006	In this study, the authors investigated the effects of itraconazole, which is a specific inhibitor of CYP3A4, or tandospirone, which is mainly metabolized by CYP3A4 and is expected to competitively inhibit the activity of this enzyme, on single oral dose pharmacokinetics of perospirone.	Itraconazole	55-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	158-164
18360572-6	2005	Itraconazole works by inhibiting ergosterol synthesis via cytochrome P-450 (CYP450)-dependent demethylation step.	Itraconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-82
16141569-1	2005	The effects of five antifungal drugs, fluconazole, itraconazole, micafungin, miconazole, and voriconazole, on cytochrome P450 (CYP) 1A2-mediated 7-ethoxyresorufin O-deethylation, CYP2D6-mediated debrisoquine 4-hydroxylation, and CYP2E1-mediated chlorzoxazone 6-hydroxylation activities in human liver microsomes were compared.	Itraconazole	51-63	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	110-135
16321618-2	2005	The aim of this study was to evaluate the effect of itraconazole, a CYP3A inhibitor, on the plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients in relation to CYP2D6 genotype.	Itraconazole	52-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-73
16321618-2	2005	The aim of this study was to evaluate the effect of itraconazole, a CYP3A inhibitor, on the plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients in relation to CYP2D6 genotype.	Itraconazole	52-64	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	195-201
16321618-7	2005	Itraconazole increased the concentrations of risperidone by 69% (P &lt; .001) and 75% (P &lt; .01) in CYP2D6 extensive and poor metabolizers, respectively.	Itraconazole	0-12	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	102-108
16321618-8	2005	In addition, the active moiety (risperidone plus 9-hydroxyrisperidone) also increased similarly, by 71% (P &lt; .001) and 73% (P &lt; .05), respectively, with itraconazole, without a significant difference between CYP2D6 genotypes.	Itraconazole	159-171	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	214-220
16321618-11	2005	In addition to CYP2D6, treatment with CYP3A inhibitor(s) including itraconazole may influence clinical symptoms and risperidone side effects.	Itraconazole	67-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-43
16205037-4	2005	In in vivo pharmacokinetic studies, it is well known that itraconazole is a potent clinically important inhibitor of the clearance of CYP3A4 substrates, and fluconazole and voriconazole are reported to increase the blood or plasma concentrations of not only midazolam and cyclosporine (CYP3A4 substrates) but also of phenytoin (CYP2C9 substrate) and/or omeprazole (CYP2C19/CYP3A4 substrate).	Itraconazole	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	134-140
16205037-4	2005	In in vivo pharmacokinetic studies, it is well known that itraconazole is a potent clinically important inhibitor of the clearance of CYP3A4 substrates, and fluconazole and voriconazole are reported to increase the blood or plasma concentrations of not only midazolam and cyclosporine (CYP3A4 substrates) but also of phenytoin (CYP2C9 substrate) and/or omeprazole (CYP2C19/CYP3A4 substrate).	Itraconazole	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	286-292
16205037-4	2005	In in vivo pharmacokinetic studies, it is well known that itraconazole is a potent clinically important inhibitor of the clearance of CYP3A4 substrates, and fluconazole and voriconazole are reported to increase the blood or plasma concentrations of not only midazolam and cyclosporine (CYP3A4 substrates) but also of phenytoin (CYP2C9 substrate) and/or omeprazole (CYP2C19/CYP3A4 substrate).	Itraconazole	58-70	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	328-334
16205037-4	2005	In in vivo pharmacokinetic studies, it is well known that itraconazole is a potent clinically important inhibitor of the clearance of CYP3A4 substrates, and fluconazole and voriconazole are reported to increase the blood or plasma concentrations of not only midazolam and cyclosporine (CYP3A4 substrates) but also of phenytoin (CYP2C9 substrate) and/or omeprazole (CYP2C19/CYP3A4 substrate).	Itraconazole	58-70	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	365-372
16205037-4	2005	In in vivo pharmacokinetic studies, it is well known that itraconazole is a potent clinically important inhibitor of the clearance of CYP3A4 substrates, and fluconazole and voriconazole are reported to increase the blood or plasma concentrations of not only midazolam and cyclosporine (CYP3A4 substrates) but also of phenytoin (CYP2C9 substrate) and/or omeprazole (CYP2C19/CYP3A4 substrate).	Itraconazole	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	286-292
16042675-0	2005	Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.	Itraconazole	36-48	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	104-110
16042675-0	2005	Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.	Itraconazole	36-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-121
16042675-1	2005	BACKGROUND AND AIMS: Gemfibrozil, and particularly its combination with itraconazole, greatly increases the area under the plasma concentration-time curve [AUC(0, infinity)] and response to the cytochrome P450 (CYP) 2C8 and 3A4 substrate repaglinide.	Itraconazole	72-84	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	194-219
16042675-3	2005	Our aim was to investigate the effects of the gemfibrozil-itraconazole combination on the pharmacokinetics and pharmacodynamics of another meglitinide analogue, nateglinide, which is metabolized by CYP2C9 and CYP3A4.	Itraconazole	58-70	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	198-204
16042675-3	2005	Our aim was to investigate the effects of the gemfibrozil-itraconazole combination on the pharmacokinetics and pharmacodynamics of another meglitinide analogue, nateglinide, which is metabolized by CYP2C9 and CYP3A4.	Itraconazole	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	209-215
16012077-4	2005	The formation of 4-hydroxyestazolam from estazolam in pooled human liver microsomes was significantly inhibited by itraconazole and erythromycin, specific CYP3A4 inhibitors, in a dose-dependent manner, with IC50 values of 1.1 and 12.8 microM, respectively.	Itraconazole	115-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	155-161
15969931-3	2005	An inhibitory effect on CYP3A4 activity was found for ketoconazole, itraconazole and miconazole, with 50% inhibitory concentrations of 11.7, 32.6 and 74.2 nM, respectively.	Itraconazole	68-80	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
15900215-2	2005	Some patients who take atorvastatin along with concomitant medications known to inhibit CYP3A enzyme activity (e.g. itraconazole) develop rhabdomyolysis secondary to a severe drug-induced myopathy.	Itraconazole	116-128	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-93
15829804-10	2005	In keratitis due to Fusarium spp, 19 (79%) of 24 patients showed a favorable response to natamycin, which was significantly greater than the 8 (44%) of 18 patients who showed a favorable response to itraconazole (P &lt; 0.02).	Itraconazole	199-211	histocompatibility minor 13	Homo sapiens	29-32
15829804-13	2005	CONCLUSIONS: Topical natamycin should continue to be considered as the treatment of choice for filamentous fungal keratitis; when natamycin is unavailable, topical itraconazole therapy could be used, particularly if the infections are due to Aspergillus or Curvularia spp.	Itraconazole	164-176	histocompatibility minor 13	Homo sapiens	268-271
15969931-5	2005	The MDR1-mediated transport of [3H]digoxin was inhibited by ketoconazole and itraconazole, and slightly by miconazole.	Itraconazole	77-89	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
15905803-11	2005	Drug interactions can occur with itraconazole because it is both an inhibitor and substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and P-glycoprotein transporter systems.	Itraconazole	33-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-118
15905803-11	2005	Drug interactions can occur with itraconazole because it is both an inhibitor and substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and P-glycoprotein transporter systems.	Itraconazole	33-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-126
15770075-2	2005	The objective of the present study was to investigate the influence of itraconazole (hereafter referred to as ITZ) co-administration (CYP3A4 inhibition) on the pharmacokinetics of ARIPIPRAZOLE administered to 24 healthy adult male volunteers in a fasting condition.	Itraconazole	71-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	134-140
15684493-3	2005	This might be because concomitant drugs such as itraconazole inhibit cytochrome P450 3A4 (CYP3A4), the enzyme responsible for the degradation of terfenadine and astemizole, and thus the blood concentrations of the drugs are abnormally increased.	Itraconazole	48-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-88
15684493-3	2005	This might be because concomitant drugs such as itraconazole inhibit cytochrome P450 3A4 (CYP3A4), the enzyme responsible for the degradation of terfenadine and astemizole, and thus the blood concentrations of the drugs are abnormally increased.	Itraconazole	48-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
15770075-12	2005	The urinary 6beta-hydroxycortisol/cortisol concentration ratio following ITZ administration for 7 consecutive days was about half of that before the start of ITZ administration, indicating that CYP3A4 metabolic activity was inhibited by administration of ITZ.	Itraconazole	73-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	194-200
15770075-12	2005	The urinary 6beta-hydroxycortisol/cortisol concentration ratio following ITZ administration for 7 consecutive days was about half of that before the start of ITZ administration, indicating that CYP3A4 metabolic activity was inhibited by administration of ITZ.	Itraconazole	158-161	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	194-200
15770075-12	2005	The urinary 6beta-hydroxycortisol/cortisol concentration ratio following ITZ administration for 7 consecutive days was about half of that before the start of ITZ administration, indicating that CYP3A4 metabolic activity was inhibited by administration of ITZ.	Itraconazole	158-161	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	194-200
16122280-16	2005	Inhibition of CYP3A4 by potent inhibitors such as itraconazole and ketoconazole results in a 54% and 95% increase in telithromycin area under the plasma concentration-time curve, respectively.	Itraconazole	50-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
15726880-1	2005	OBJECTIVE: The present study evaluates the acute effect of a single-dose itraconazole administration on CYP3A phenotype, as measured by cortisol MR ratio in urine.	Itraconazole	73-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	104-109
15447735-3	2004	We have studied the effect of a potent CYP3A4 inhibitor, itraconazole, on the pharmacokinetics of inhaled lidocaine in ten healthy volunteers using a randomized, two-phase cross-over study design.	Itraconazole	57-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-45
15865259-2	2005	Itraconazole is an inhibitor of CYP3A4, a metabolic enzyme of sildenafil.	Itraconazole	0-12	cytochrome P450 3A12	Canis lupus familiaris	32-38
15521894-7	2004	CONCLUSIONS: Itraconazole increases plasma concentrations of brotizolam probably via its inhibitory effect on CYP3A4 brotizolam metabolism.	Itraconazole	13-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-116
15242978-0	2004	Role of itraconazole metabolites in CYP3A4 inhibition.	Itraconazole	8-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42
15242978-1	2004	Itraconazole (ITZ) is a potent inhibitor of CYP3A in vivo.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-49
15242978-1	2004	Itraconazole (ITZ) is a potent inhibitor of CYP3A in vivo.	Itraconazole	14-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-49
15242978-10	2004	Both ITZ and OH-ITZ were competitive inhibitors of CYP3A4, with unbound Ki (1.3 nM for ITZ and 14.4 nM for OH-ITZ) close to their respective Km.	Itraconazole	5-8	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-57
15242978-10	2004	Both ITZ and OH-ITZ were competitive inhibitors of CYP3A4, with unbound Ki (1.3 nM for ITZ and 14.4 nM for OH-ITZ) close to their respective Km.	Itraconazole	16-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-57
15552648-9	2004	However, itraconazole which targets Erg11p (lanosterol demethylase) increased ERG27 expression 10-fold and zaragozic acid A which targets the Erg9p (squalene synthase) increased ERG27 expression fivefold.	Itraconazole	9-21	3-keto-steroid reductase	Saccharomyces cerevisiae S288C	78-83
15289787-10	2004	However, during cytochrome P450 (CYP) 3A inhibition by itraconazole, individuals carrying the CYP3A5*1 allele were found to be less susceptible to changes in systemic clearance and showed higher 1"-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratios, probably resulting from the relatively CYP3A4-specific inhibition caused by itraconazole.	Itraconazole	55-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-40
15289787-10	2004	However, during cytochrome P450 (CYP) 3A inhibition by itraconazole, individuals carrying the CYP3A5*1 allele were found to be less susceptible to changes in systemic clearance and showed higher 1"-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratios, probably resulting from the relatively CYP3A4-specific inhibition caused by itraconazole.	Itraconazole	55-67	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	94-100
15289787-10	2004	However, during cytochrome P450 (CYP) 3A inhibition by itraconazole, individuals carrying the CYP3A5*1 allele were found to be less susceptible to changes in systemic clearance and showed higher 1"-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratios, probably resulting from the relatively CYP3A4-specific inhibition caused by itraconazole.	Itraconazole	359-371	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	94-100
15289787-10	2004	However, during cytochrome P450 (CYP) 3A inhibition by itraconazole, individuals carrying the CYP3A5*1 allele were found to be less susceptible to changes in systemic clearance and showed higher 1"-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratios, probably resulting from the relatively CYP3A4-specific inhibition caused by itraconazole.	Itraconazole	55-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	322-328
15204103-0	2004	In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin.	Itraconazole	98-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
15232663-2	2004	METHODS: The effects of itraconazole, a potent and specific inhibitor of CYP3A4, on the single oral dose pharmacokinetics and pharmacodynamics of etizolam were examined.	Itraconazole	24-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-79
15232663-9	2004	CONCLUSION: The present study suggests that itraconazole inhibits the metabolism of etizolam, providing evidence that CYP3A4 is at least partly involved in etizolam metabolism.	Itraconazole	44-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-124
15286096-2	2004	The purpose of this study was to evaluate the effect of itraconazole, a known P-gp inhibitor, on the renal tubular secretion of cimetidine in healthy volunteers who received intravenous cimetidine alone and following 3 days of oral itraconazole (400 mg/day) administration.	Itraconazole	56-68	ATP binding cassette subfamily B member 1	Homo sapiens	78-82
15286096-10	2004	The increased systemic exposure of cimetidine during coadministration with itraconazole was likely due to inhibition of P-gp-mediated renal tubular secretion.	Itraconazole	75-87	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
15286096-11	2004	Further evaluation of renal P-gp-modulating drugs such as itraconazole that may alter the renal excretion of coadministered drugs is warranted.	Itraconazole	58-70	ATP binding cassette subfamily B member 1	Homo sapiens	28-32
15204103-3	2004	In vitro assays were performed to assess whether cytochrome P450 (CYP450) enzymes were affected by combinations of cytarabine or idarubicin with itraconazole or caspofungin.	Itraconazole	145-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	49-64
15204103-3	2004	In vitro assays were performed to assess whether cytochrome P450 (CYP450) enzymes were affected by combinations of cytarabine or idarubicin with itraconazole or caspofungin.	Itraconazole	145-157	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-72
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Itraconazole	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	136-142
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Itraconazole	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-185
15204103-4	2004	METHODS: The high throughput microtiter assay was used to determine whether cytarabine, idarubicin and itraconazole or caspofungin were CYP450 isoenzyme substrates, inhibitors of CYP450 isoenzymes, and to determine potential CYP450 metabolism interactions between these agents.	Itraconazole	103-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-185
15133245-3	2004	This might be because concomitant drugs such as itraconazole inhibit cytochrome P450 3A4 (CYP3A4), the enzyme responsible for degradation of terfenadine and astemizole, and thus the blood concentrations of the drugs are abnormally increased.	Itraconazole	48-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-88
15133245-3	2004	This might be because concomitant drugs such as itraconazole inhibit cytochrome P450 3A4 (CYP3A4), the enzyme responsible for degradation of terfenadine and astemizole, and thus the blood concentrations of the drugs are abnormally increased.	Itraconazole	48-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
14517708-3	2003	The purpose of this study was to examine whether the inhibition of CYP3A4 produced by itraconazole alters the pharmacokinetics and pharmacodynamics of bromazepam.	Itraconazole	86-98	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73
15370674-0	2004	Modulation of the human interleukin-12p40 response by a triazole antifungal derivative, itraconazole.	Itraconazole	88-100	interleukin 12B	Homo sapiens	24-41
15370674-2	2004	We investigated whether itraconazole (ITCZ) can modulate the serum cytokine levels (tumor necrosis factor (TNF-alpha, interleukin (IL)-10, IL-12p40) in both patients and healthy subjects.	Itraconazole	24-36	tumor necrosis factor	Homo sapiens	84-105
15370674-2	2004	We investigated whether itraconazole (ITCZ) can modulate the serum cytokine levels (tumor necrosis factor (TNF-alpha, interleukin (IL)-10, IL-12p40) in both patients and healthy subjects.	Itraconazole	38-42	tumor necrosis factor	Homo sapiens	84-105
15284827-4	2004	Azole derivatives, ketoconazole, itraconazole, miconazole and non-azole terbinafine hydrochloride and tolnaftate reduced IL-4 and IL-5 secretion without altering that of IFN-gamma and IL-2 in anti-CD3/CD28-stimulated T cells from both AD patients and normal donors.	Itraconazole	33-45	interleukin 4	Homo sapiens	121-125
15284827-4	2004	Azole derivatives, ketoconazole, itraconazole, miconazole and non-azole terbinafine hydrochloride and tolnaftate reduced IL-4 and IL-5 secretion without altering that of IFN-gamma and IL-2 in anti-CD3/CD28-stimulated T cells from both AD patients and normal donors.	Itraconazole	33-45	interleukin 5	Homo sapiens	130-134
12684380-7	2003	Dap1p also directs resistance to itraconazole and fluconazole, inhibitors of sterol synthesis.	Itraconazole	33-45	death associated protein	Homo sapiens	0-5
12883232-1	2003	The effects of itraconazole, a potent inhibitor of cytochrome P450 (CYP) 3A4, on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug were studied.	Itraconazole	15-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-76
12743557-8	2003	Itraconazole reduced systemic immune activation, leading to a decrease in serum IgE levels (310 IU/mL) compared with levels seen in the placebo group (increase of 18 IU/mL, P &lt;.01) and a decrease in IgG levels to A fumigatu s (15.4 IU/mL) compared with levels seen in the placebo group (increase of 3.7 IU/mL, P =.03).	Itraconazole	0-12	immunoglobulin heavy constant epsilon	Homo sapiens	80-83
12709722-2	2003	Itraconazole, an inhibitor of cytochrome P450 (CYP) 3A4 and the transport protein P-glycoprotein, is known to interact with other HMG-CoA reductase inhibitors.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-55
12709722-2	2003	Itraconazole, an inhibitor of cytochrome P450 (CYP) 3A4 and the transport protein P-glycoprotein, is known to interact with other HMG-CoA reductase inhibitors.	Itraconazole	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	82-96
12595750-0	2003	Effect of interleukin 6 on the hepatic metabolism of itraconazole and its metabolite hydroxyitraconazole using primary human hepatocytes.	Itraconazole	53-65	interleukin 6	Homo sapiens	10-23
12654681-0	2003	In vitro synergy of caspofungin and itraconazole against Aspergillus spp.	Itraconazole	36-48	histocompatibility minor 13	Homo sapiens	69-72
12166560-2	2002	Itraconazole can inhibit CYP3A, thus interfering with synthesis of gluco- and mineralocorticoids, androgens and oestradiol as well as the metabolism of budesonide.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-30
12619051-5	2003	Itraconazole was reported to be metabolized via CYP3A4 to several metabolites, including hydroxyitraconazole, in human subjects.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
12388057-6	2003	We found that in high endothelial venular cells (SVEC4-10), multiple inhibitors of CYP450 monooxygenases (SKF-525a, ketoconazole, troleandomycin, itraconazole) attenuated TNF-alpha induction of MAdCAM-1, whereas NADPH oxidase inhibition (PR-39) did not.	Itraconazole	146-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	83-89
12949438-6	2003	Serious cases by coadministration of CYP3A inhibitors resulting in acute hepatitis, hypotension, rhabdomyolyis, torsade de pointes, sedation, or ergotism are presented: interactions with azole antifungals (ketoconazole, itraconazole, fluconazole), HIV protease inhibitors (ritonavir, indinavir, saquinavir, nelfinavir), macrolide antibiotics (clarithromycin, erythromycin), and grapefruit juice.	Itraconazole	220-232	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-42
12237270-0	2002	P-glycoprotein as the mediator of itraconazole-digoxin interaction.	Itraconazole	34-46	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
12069997-3	2002	The in vitro MICs of posaconazole and itraconazole for the strains of Mucor spp.	Itraconazole	38-50	sphingosine-1-phosphate phosphatase 1	Mus musculus	76-79
12412882-8	2002	CONCLUSION: This observation suggests that the metabolic clearance of buDesonide was compromised by itraconazole"s inhibition of cytochrome P450 enzymes, especially the CYP3A isoforms, causing an elevation in systemic budesonide concentration.	Itraconazole	100-112	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	169-174
12134942-5	2002	RESULTS: Amiodarone (10 microM) inhibited slightly the transcellular transport of digoxin in LLC-GA5-COL150 monolayers, whereas itraconazole (10 microM), a potent Pgp inhibitor, markedly blocked the transport.	Itraconazole	128-140	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	163-166
11740718-8	2002	Primary prophylaxis with oral itraconazole is well tolerated and prevents cryptococcosis and penicilliosis marneffei in patients with advanced HIV infection, especially those with CD4+ lymphocyte counts of &lt;100 cells/microL.	Itraconazole	30-42	CD4 molecule	Homo sapiens	180-183
15618678-8	2002	Correspondingly, the content of CYP3A2 was significantly altered by single or repeated itraconazole administration.	Itraconazole	87-99	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	32-38
11751127-6	2002	In a cell line presenting an overexpressed amount of the human P-gp transporter, itraconazole and ketoconazole inhibited P-gp function with 50% inhibitory concentrations (IC(50)s) of approximately 2 and approximately 6 microM, respectively.	Itraconazole	81-93	ATP binding cassette subfamily B member 1	Homo sapiens	63-67
11751127-6	2002	In a cell line presenting an overexpressed amount of the human P-gp transporter, itraconazole and ketoconazole inhibited P-gp function with 50% inhibitory concentrations (IC(50)s) of approximately 2 and approximately 6 microM, respectively.	Itraconazole	81-93	ATP binding cassette subfamily B member 1	Homo sapiens	121-125
11836874-6	2001	The concomitant use of statins with drugs that inhibit CYP3A4 (cyclosporin, erythromycin, clarithromycin, itraconazole, and ketoconazole), may result in increased plasma concentrations of HMG-CoA reductase inhibitors leading occasionally to myotoxicity.	Itraconazole	106-118	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-61
11808341-6	2002	The ATP-driven efflux pump P-glycoprotein appeared to be an interaction site between digoxin and clarithromycin or itraconazole in the kidney.	Itraconazole	115-127	ATP binding cassette subfamily B member 1	Homo sapiens	27-41
11886533-4	2001	Azole derivatives, ketoconazole, itraconazole, miconazole, and nonazole terbinafine hydrochloride, and tolnaftate reduced interleukin-4 and interleukin-5 secretion without altering that of interferon-gamma and interleukin-2 in anti-CD3/CD28-stimulated T cells from both atopic dermatitis patients and normal donors.	Itraconazole	33-45	interleukin 4	Homo sapiens	122-135
11886533-4	2001	Azole derivatives, ketoconazole, itraconazole, miconazole, and nonazole terbinafine hydrochloride, and tolnaftate reduced interleukin-4 and interleukin-5 secretion without altering that of interferon-gamma and interleukin-2 in anti-CD3/CD28-stimulated T cells from both atopic dermatitis patients and normal donors.	Itraconazole	33-45	interleukin 5	Homo sapiens	140-153
11516940-4	2001	The activities of posaconazole for all the fungal species far surpassed those of fluconazole and were even superior to those of itraconazole for Aspergillus spp.	Itraconazole	128-140	histocompatibility minor 13	Homo sapiens	157-160
11531835-9	2001	With itraconazole 200 mg d(-1) or 400 mg d(-1) for 1 week each month for 3-4 months, EP1 was 37% at 18 months, and 53% at 2 years; EP2 was 76% at 4 years.	Itraconazole	5-17	prostaglandin E receptor 1	Homo sapiens	85-88
11531835-11	2001	In the only study planned to compare the long-term efficacy of terbinafine and itraconazole, EP1 at 18 months was significantly higher with continuous terbinafine than with intermittent itraconazole (66% vs. 37%, P &lt; 0.001).	Itraconazole	79-91	prostaglandin E receptor 1	Homo sapiens	93-96
11531835-11	2001	In the only study planned to compare the long-term efficacy of terbinafine and itraconazole, EP1 at 18 months was significantly higher with continuous terbinafine than with intermittent itraconazole (66% vs. 37%, P &lt; 0.001).	Itraconazole	186-198	prostaglandin E receptor 1	Homo sapiens	93-96
11558564-6	2001	Itraconazole was found to have potent reversal effect on the resistance to VLB and TXL, but the others had no such effect.	Itraconazole	0-12	thioredoxin like 1	Homo sapiens	83-86
11737382-2	2001	METHODS: HIV-1 infected patients with CD4 counts &lt; 300 cells/microL were treated with itraconazole (200 mg per day) or matching placebo and followed for 2 years.	Itraconazole	89-101	CD4 molecule	Homo sapiens	38-41
11408375-4	2001	Therefore, the sex difference in the inhibition of simvastatin metabolism by itraconazole seems to be caused by a difference in the P450 isozymes responsible for the metabolism of simvastatin in male and female rats and the different ability of itraconazole to inhibit CYP3A and CYP2C11.	Itraconazole	77-89	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	269-274
11408375-4	2001	Therefore, the sex difference in the inhibition of simvastatin metabolism by itraconazole seems to be caused by a difference in the P450 isozymes responsible for the metabolism of simvastatin in male and female rats and the different ability of itraconazole to inhibit CYP3A and CYP2C11.	Itraconazole	77-89	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	279-286
11422002-1	2001	AIMS: Itraconazole is a potent inhibitor of CYP3A4 activity and is often used in combination with corticosteroids.	Itraconazole	6-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-50
11422002-9	2001	The pharmacokinetic interaction between methylprednisolone and itraconazole is probably related to inhibition of hepatic CYP3A4 activity by itraconazole.	Itraconazole	63-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
11422002-9	2001	The pharmacokinetic interaction between methylprednisolone and itraconazole is probably related to inhibition of hepatic CYP3A4 activity by itraconazole.	Itraconazole	140-152	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127
11465417-4	2001	RESULTS: Itraconazole competitively inhibited the metabolism of simvastatin to M-1 and M-2 with Ki values in the nM range.	Itraconazole	9-21	cholinergic receptor muscarinic 1	Homo sapiens	79-82
11465417-9	2001	CONCLUSIONS: It was demonstrated that the competitive inhibition of CYP3A4-mediated simvastatin metabolism by itraconazole is the main cause of the drug interaction and that a Ki value corrected for drug adsorption to microsomes is the key factor in quantitatively predicting the maximum in vivo drug interactions.	Itraconazole	110-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-74
11372588-1	2001	OBJECTIVE: To characterise the effects of itraconazole, a potent inhibitor of CYP3A4, on the pharmacokinetics of selegiline in healthy volunteers.	Itraconazole	42-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	78-84
11799844-3	2001	The present study was carried out to determine whether oxatomide and terfenadine have effects on QT interval as a single drug or in combination with itraconazole (CAS 84625-61-6), an antifungal agent with a CYP3A4 inhibitory effect, in conscious dogs.	Itraconazole	149-161	cytochrome P450 3A12	Canis lupus familiaris	207-213
11322176-7	2001	Both clarithromycin and itraconazole inhibit the CYP3A4 mediated formation of (S)-2",6"-pipecoloxylidide from ropivacaine.	Itraconazole	24-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
11061579-5	2000	OBJECTIVE: To determine the comparative effect of itraconazole, a potent CYP3A4 inhibitor, on the pharmacokinetics of cerivastatin, atorvastatin, and pravastatin.	Itraconazole	50-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-79
11687098-16	2001	REVIEWER"S CONCLUSIONS: Itraconazole modifies the immunologic activation associated with ABPA and improves clinical outcome in ABPA at least over the period of 16 weeks.	Itraconazole	24-36	filamin C	Homo sapiens	89-93
11687098-16	2001	REVIEWER"S CONCLUSIONS: Itraconazole modifies the immunologic activation associated with ABPA and improves clinical outcome in ABPA at least over the period of 16 weeks.	Itraconazole	24-36	filamin C	Homo sapiens	127-131
11103751-0	2000	The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.	Itraconazole	34-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-23
11103751-10	2000	A careful follow-up is recommended when itraconazole or other potent inhibitors of the cytochrome P450 3A4 are added to the drug regimen of patients receiving dexamethasone.	Itraconazole	40-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	87-106
10926350-9	2000	Similarly, azole antifungal agents such as fluconazole, itraconazole and ketoconazole are CYP3A4 inhibitors and their concomitant use with cisapride should be avoided.	Itraconazole	56-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
11007866-0	2000	Tacrolimus/itraconazole interactions: a case report of ABO-incompatible living-related renal transplantation.	Itraconazole	11-23	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	55-58
10786463-7	2000	Three weeks into the puerperium, she developed generalised seizures and investigations indicated systemic fungal infection with positive cultures for Aureobasidium spp which responded to appropriate antifungal therapy of flucytosine and itraconazole.	Itraconazole	237-249	histocompatibility minor 13	Homo sapiens	164-167
10731517-2	2000	IC(50) values for ketoconazole and itraconazole CYP3A4 inhibition were 0.25 and 0.	Itraconazole	35-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
10722490-14	2000	The higher level of distribution of SYN-2869 into lung tissue was considered to contribute to the potent efficacy in respiratory tract infection models compared with the potency of itraconazole.	Itraconazole	181-193	joined toes	Mus musculus	36-39
10853878-8	2000	The susceptibility of prednisolone to interact with CYP3A4 inhibitors is considerably smaller than that of methylprednisolone, and itraconazole and probably also other inhibitors of CYP3A4 can be used concomitantly with prednisolone without marked changes in the effects of this corticosteroid.	Itraconazole	131-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	182-188
10885336-7	2000	He responded to fluconazole, and was given itraconazole as secondary prophylaxis because of persistent low CD4 counts.	Itraconazole	43-55	CD4 molecule	Homo sapiens	107-110
10746169-1	1999	The reversal effect of itraconazole on P-glycoprotein (P-gp)-mediated resistance of vinblastine, daunorubicin and doxorubicin was analyzed from a cellular pharmacokinetic point of view, namely by [3H]azidopine photoaffinity labeling, intracellular accumulation and transcellular transport experiments.	Itraconazole	23-35	phosphoglycolate phosphatase	Homo sapiens	55-59
10709776-6	2000	Ketoconazole and itraconazole are potent inhibitors of the major drug-metabolising CYP isoform in humans, CYP3A4.	Itraconazole	17-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
10668858-6	2000	Clinically important CYP3A4 inhibitors include itraconazole, ketoconazole, clarithromycin, erythromycin, nefazodone, ritonavir and grapefruit juice.	Itraconazole	47-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
10746169-4	1999	[3H]Azidopine photoaffinity labeling demonstrated that itraconazole, vinblastine, daunorubicin and doxorubicin showed higher binding ability for P-gp compared with digoxin, suggesting the following results were via P-gp.	Itraconazole	55-67	phosphoglycolate phosphatase	Homo sapiens	145-149
10746169-4	1999	[3H]Azidopine photoaffinity labeling demonstrated that itraconazole, vinblastine, daunorubicin and doxorubicin showed higher binding ability for P-gp compared with digoxin, suggesting the following results were via P-gp.	Itraconazole	55-67	phosphoglycolate phosphatase	Homo sapiens	215-219
10746169-7	1999	However, their basal-to-apical transport was hardly affected by itraconazole, and this was explained by the fact that itraconazole inhibited P-gp, and subsequently increased their intracellular concentration and then the non-P-gp mediated transport from the intracellular space to apical side.	Itraconazole	118-130	phosphoglycolate phosphatase	Homo sapiens	141-145
10746169-7	1999	However, their basal-to-apical transport was hardly affected by itraconazole, and this was explained by the fact that itraconazole inhibited P-gp, and subsequently increased their intracellular concentration and then the non-P-gp mediated transport from the intracellular space to apical side.	Itraconazole	118-130	phosphoglycolate phosphatase	Homo sapiens	225-229
10746169-8	1999	The apical-to-basal transport of [3H]vinblastine, [3H]daunorubicin and [14C]doxorubicin was increased by itraconazole, and this was reasonably explained by the inhibition of P-gp, and partly also by the increase of their intracellular concentration via the inhibition of P-gp.	Itraconazole	105-117	phosphoglycolate phosphatase	Homo sapiens	174-178
10746169-8	1999	The apical-to-basal transport of [3H]vinblastine, [3H]daunorubicin and [14C]doxorubicin was increased by itraconazole, and this was reasonably explained by the inhibition of P-gp, and partly also by the increase of their intracellular concentration via the inhibition of P-gp.	Itraconazole	105-117	phosphoglycolate phosphatase	Homo sapiens	271-275
10426160-1	1999	A possible interaction of itraconazole, a potent inhibitor of CYP3A4, with intravenously administered methylprednisolone, was examined.	Itraconazole	26-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
10730911-4	1999	For example, itraconazole, and to a lesser extent fluconazole (in high doses) are inhibitors of CYP3A4.	Itraconazole	13-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	96-102
10544287-10	1999	The lanosterol demethylase activity of the reconstituted system of CYP51m was inhibited by ketoconazole, itraconazole and fluconazole with apparent IC(50) values of 0.2, 0.7, and 160 microM, respectively.	Itraconazole	105-117	cytochrome P450, family 51	Rattus norvegicus	67-72
10463320-2	1999	OBJECTIVE: We investigated pharmacokinetic interaction between bromperidol and itraconazole, a potent inhibitor of CYP3A4, to clarify the involvement of CYP3A4 in the metabolism of bromperidol and its reduced metabolite.	Itraconazole	79-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-121
10600094-5	1999	The time course suggested a possible interaction between clarithromycin and itraconazole, presumably through itraconazole"s effects on cytochrome P450 3A4 activity.	Itraconazole	76-88	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	135-154
10600094-5	1999	The time course suggested a possible interaction between clarithromycin and itraconazole, presumably through itraconazole"s effects on cytochrome P450 3A4 activity.	Itraconazole	109-121	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	135-154
10471571-4	1999	While both BMS-207147 and itraconazole displayed a stepwise decrease in activity against isolates for which the fluconazole MICs were elevated, BMS-207147 had two- to fourfold greater activity than itraconazole both against Candida spp.	Itraconazole	26-38	histocompatibility minor 13	Homo sapiens	232-235
10426160-11	1999	Care should be taken when itraconazole or other potent inhibitors of CYP3A4 are used concomitantly with methylprednisolone.	Itraconazole	26-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
10546485-4	1999	In these patients the itraconazole trough concentrations exceeded 500 ng ml-1 (measured by high performance liquid chromatography) significantly less often (median 48%, interquartile range 0-100%) than in another group of 150 leukaemia patients without invasive fungal infections who received 287 courses of prophylaxis with itraconazole at our institution (median 100%, interquartile range 38-100%, P = 0.039).	Itraconazole	22-34	interleukin 17F	Homo sapiens	73-77
10211916-1	1999	The effects of itraconazole, a potent inhibitor of cytochrome P450 (CYP) 3A4, on the steady-state plasma concentrations of haloperidol and reduced haloperidol were examined in schizophrenic patients.	Itraconazole	15-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-76
10027433-1	1999	STUDY OBJECTIVES: (1) To determine the relationship between IgE levels and the prevalence of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) patients, (2) to establish the usefulness of assessing atopy as an identifying risk factor for ABPA, (3) to evaluate the clinical course of patients receiving and not receiving itraconazole as reflected in oral steroid dose requirements and number of acute episodes of ABPA, and (4) to determine the role of acute episodes of ABPA in pulmonary exacerbations of CF.	Itraconazole	341-353	immunoglobulin heavy constant epsilon	Homo sapiens	60-63
10546485-6	1999	Patients with fatal invasive fungal infections had lower median itraconazole concentrations immediately before occurrence of the infection than patients with non-fatal infections: 120 (0-478) ng ml-1 versus 690 (305-1908) ng ml-1 (P = 0.039).	Itraconazole	64-76	interleukin 17F	Homo sapiens	225-229
10546485-7	1999	In conclusion, this analysis of breakthrough invasive fungal infections during prophylaxis with itraconazole demonstrates that patients with itraconazole trough concentrations below 500 ng ml-1 were significantly more likely to develop fungal infections and that the last itraconazole trough concentration before occurrence of the infection was significantly lower in patients with fatal invasive fungal infections.	Itraconazole	141-153	interleukin 17F	Homo sapiens	189-193
10546485-7	1999	In conclusion, this analysis of breakthrough invasive fungal infections during prophylaxis with itraconazole demonstrates that patients with itraconazole trough concentrations below 500 ng ml-1 were significantly more likely to develop fungal infections and that the last itraconazole trough concentration before occurrence of the infection was significantly lower in patients with fatal invasive fungal infections.	Itraconazole	141-153	interleukin 17F	Homo sapiens	189-193
11252341-1	1999	The protein binding of itraconazole and fluconazole in the serum of patients with insulin-dependent (IDDM) and non-insulin-dependent (NIDDM) diabetes mellitus was investigated in vitro.	Itraconazole	23-35	insulin	Homo sapiens	82-89
10449937-3	1999	Itraconazole can inhibit the metabolism of drugs by CYP 3A4 and therefore might affect the efficacy of antidiabetic agents.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-59
10027660-1	1999	OBJECTIVE: To determine the effects of itraconazole, a potent inhibitor of CYP3A4, on the pharmacokinetics of cerivastatin, a competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.	Itraconazole	39-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
10027660-1	1999	OBJECTIVE: To determine the effects of itraconazole, a potent inhibitor of CYP3A4, on the pharmacokinetics of cerivastatin, a competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.	Itraconazole	39-51	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	138-195
10067059-7	1999	RFP induces cytochrome P450 3A in the liver to decrease the activities of many drugs, such as cyclosporin A, tacrolimus, protease inhibitor, itraconazole, and clarithromycin.	Itraconazole	141-153	tripartite motif containing 27	Homo sapiens	0-3
10546485-6	1999	Patients with fatal invasive fungal infections had lower median itraconazole concentrations immediately before occurrence of the infection than patients with non-fatal infections: 120 (0-478) ng ml-1 versus 690 (305-1908) ng ml-1 (P = 0.039).	Itraconazole	64-76	interleukin 17F	Homo sapiens	195-199
10680434-1	1999	We have previously shown that a trough concentration of at least 500 ng ml-1 itraconazole is necessary for an effective antifungal prophylaxis in neutropenic patients.	Itraconazole	77-89	interleukin 17F	Homo sapiens	72-76
9726699-1	1998	Itraconazole is a potent inhibitor of CYP3A4 isoenzyme and it can cause clinically significant interactions with some other drugs.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
10680434-4	1999	After the first week, patients taking 800 mg day-1 or 400 mg day-1 (s/c1200) itraconazole solution achieved significantly higher trough concentrations (high-performance liquid chromatography) than patients in other groups (P &lt; 0.05) and 87 and 100%, respectively, of these had concentrations &gt; 500 ng ml-1.	Itraconazole	77-89	interleukin 17F	Homo sapiens	307-311
11362022-9	1998	In patients with CD4 counts of &lt; or = 150/microL, itraconazole is effective primary prophylaxis.	Itraconazole	53-65	CD4 molecule	Homo sapiens	17-20
9784084-1	1998	To assess the effect of itraconazole, a potent inhibitor of cytochrome P450 (CYP) 3A4, on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam, the study was conducted in a double-blind randomized crossover manner with two phases of treatment with itraconazole-placebo or placebo-itraconazole.	Itraconazole	24-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-85
9784084-6	1998	It is suggested that itraconazole, a potent CYP3A4 inhibitor, increases plasma concentration of alprazolam via its inhibitory effects on alprazolam metabolism.	Itraconazole	21-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-50
9832299-1	1998	OBJECTIVE: We have studied the possible interaction of erythromycin and itraconazole, both inhibitors of cytochrome P450 3A4 isoenzyme (CYP3A4), with intravenous lignocaine in nine healthy volunteers using a randomized cross-over study design.	Itraconazole	72-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-134
9832299-1	1998	OBJECTIVE: We have studied the possible interaction of erythromycin and itraconazole, both inhibitors of cytochrome P450 3A4 isoenzyme (CYP3A4), with intravenous lignocaine in nine healthy volunteers using a randomized cross-over study design.	Itraconazole	72-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	136-142
9884817-14	1998	Itraconazole is a potent inhibitor of cytochrome P450 (CYP) 3A4 and, thus, can also considerably change the pharmacokinetics of other drugs.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-63
9855331-3	1998	All the substrates and inhibitors of CYP3A4 such as the azole antifungals (itraconazole, ketoconazole), cyclosporine, isoniazid, and nifedipine have very high propensity to interfere with vincristine metabolism.	Itraconazole	75-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
9797792-2	1998	In this study, a possible interaction of itraconazole, a potent inhibitor of CYP3A4, with orally administered methylprednisolone was examined.	Itraconazole	41-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-83
9797792-9	1998	CONCLUSIONS: Itraconazole considerably increases plasma concentrations and effects of oral methylprednisolone, probably by inhibiting its CYP3A4-mediated metabolism.	Itraconazole	13-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-144
9797792-10	1998	Care should be taken if itraconazole or other potent inhibitors of CYP3A4 are used concomitantly with oral methylprednisolone, particularly during long-term use.	Itraconazole	24-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73
9661014-8	1998	Moreover, the uptake of vincristine or vinblastine, both of which are substrates of the P glycoprotein (P-gp), into mouse brain capillary endothelial cells was also significantly increased by ITZ or verapamil.	Itraconazole	192-195	phosphoglycolate phosphatase	Mus musculus	88-102
9695720-1	1998	BACKGROUND: Itraconazole, a potent inhibitor of CYP3A4, increases the risk of skeletal muscle toxicity of some 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors by increasing their serum concentrations.	Itraconazole	12-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54
9695720-1	1998	BACKGROUND: Itraconazole, a potent inhibitor of CYP3A4, increases the risk of skeletal muscle toxicity of some 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors by increasing their serum concentrations.	Itraconazole	12-24	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	111-168
9695720-2	1998	The aim of this study was to characterize the effect of itraconazole on the pharmacokinetics of atorvastatin, a new HMG-CoA reductase inhibitor that is metabolized at least in part by CYP3A4.	Itraconazole	56-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	184-190
9695720-12	1998	The mechanism of increased serum concentrations of atorvastatin and HMG-CoA reductase inhibitors is inhibition of CYP3A4-mediated metabolism of atorvastatin and its metabolites by itraconazole.	Itraconazole	180-192	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-120
9695720-13	1998	Concomitant use of itraconazole and other potent inhibitors of CYP3A4 with atorvastatin should be avoided or the dose of atorvastatin should be reduced accordingly.	Itraconazole	19-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-69
9661014-8	1998	Moreover, the uptake of vincristine or vinblastine, both of which are substrates of the P glycoprotein (P-gp), into mouse brain capillary endothelial cells was also significantly increased by ITZ or verapamil.	Itraconazole	192-195	phosphoglycolate phosphatase	Mus musculus	104-108
9626923-1	1998	OBJECTIVE: We studied a possible pharmacokinetic interaction between clozapine and itraconazole, a potent CYP3A4 inhibitor.	Itraconazole	83-95	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
9594936-11	1998	Itraconazole has an affinity for mammalian cytochrome P-450 enzymes as well as for fungal P-450-dependent enzyme, and thus has the potential for clinically important interactions (e.g., astemizole, terfenadine, rifampin, oral contraceptives, H2 receptor antagonists, warfarin, cyclosporine).	Itraconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	43-59
9626922-2	1998	Itraconazole strongly interacts with many substrates of CYP3A4 such as midazolam and triazolam.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
9584328-5	1998	Ketoconazole inhibited oxybutynin N-deethylation by the recombinant CYP3A4 and CYP3A5 almost completely, whereas itraconazole inhibited the activity of CYP3A4 more potently than that of CYP3A5.	Itraconazole	113-125	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	152-158
9390107-2	1997	Itraconazole interacts with some but not all of the substrates of CYP3A4; it is therefore important to study the possible interaction of itraconazole with quinidine.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72
9551703-2	1998	Itraconazole is an inhibitor of CYP3A4, whereas fluconazole affects CYP2C9 more than CYP3A4.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
9542477-0	1998	Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.	Itraconazole	93-105	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82
9542477-1	1998	BACKGROUND: Itraconazole increases the risk of skeletal muscle toxicity of some 3-hydroxy-3-methylglutaryl coenzyme A" (HMG-CoA) reductase inhibitors by increasing their serum concentrations.	Itraconazole	12-24	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	80-138
9542477-14	1998	CONCLUSIONS: Itraconazole greatly increased serum concentrations of simvastatin, simvastatin acid, and HMG CoA reductase inhibitors, probably by inhibiting CYP3A-mediated metabolism, but it had only a minor effect on pravastatin.	Itraconazole	13-25	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	103-120
9421099-1	1997	Itraconazole strongly interacts with some drugs metabolized by cytochrome P450 3A4, for example, felodipine and lovastatin, by inhibiting their metabolism.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-82
9390107-12	1997	CONCLUSIONS: Itraconazole increases plasma concentrations of oral quinidine, probably by inhibiting the CYP3A4 isozyme during the first-pass and elimination phases of quinidine.	Itraconazole	13-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	104-110
9321523-11	1997	SV was &gt; 30-fold less potent than ketoconazole and itraconazole as an inhibitor of CYP3A.	Itraconazole	54-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-91
9326581-9	1997	Azole antibiotics (clotrimazole, ketoconazole, and itraconazole) widely used to combat fungal infections are known to do so by inhibiting the ERG11 gene product, the 14alpha-demethylase.	Itraconazole	51-63	sterol 14-demethylase	Saccharomyces cerevisiae S288C	142-147
9333111-2	1997	Erythromycin and itraconazole are potent inhibitors of CYP3A4, and they increase plasma concentrations and effects of certain drugs, for example, oral midazolam and triazolam.	Itraconazole	17-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-61
9386354-8	1997	160 ng/g-4, 010 ng/g of itraconazole was detected in aspergilloma in 4 measurable cases.	Itraconazole	24-36	chromosome 6 open reading frame 47	Homo sapiens	7-10
9333111-14	1997	CONCLUSIONS: Both erythromycin and itraconazole greatly increased plasma buspirone concentrations, obviously by inhibiting its CYP3A4-mediated first-pass metabolism.	Itraconazole	35-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-133
8936563-11	1996	The mechanism of the itraconazole-digoxin interaction is unclear but may be related to CYP3A4-mediated changes in the pharmacokinetics of digoxin.	Itraconazole	21-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	87-93
16854169-14	1997	Not only fluconazole, ketoconazole and itraconazole are substrates for CDR1, terbinafine and amorolfine have also been established as substrates, BEN(r) overexpression only accounts for fluconazole resistance.	Itraconazole	39-51	cerebellar degeneration related protein 1	Homo sapiens	71-75
9129558-2	1997	Itraconazole strongly interacts with some of the substrates of CYP3A4 (e.g., terfenadine, triazolam and lovastatin); hence it is important to uncover the possible interaction of itraconazole with felodipine.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-69
9129558-2	1997	Itraconazole strongly interacts with some of the substrates of CYP3A4 (e.g., terfenadine, triazolam and lovastatin); hence it is important to uncover the possible interaction of itraconazole with felodipine.	Itraconazole	178-190	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-69
9375500-5	1997	The concentration of itraconazole, ketoconazole or miconazole needed to inhibit iNOS activity by 50% in RAW 264.7 cells, MPM and DLD-1 cells was &gt; or = 10 mumol l-1.	Itraconazole	21-33	nitric oxide synthase 2, inducible	Mus musculus	80-84
9272412-3	1997	Because itraconazole, a widely used mycotic, is a potent inhibitor of CYP3A4, we wanted to study a possible interaction between oxybutynin and itraconazole.	Itraconazole	8-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
9272412-10	1997	CONCLUSIONS: Itraconazole moderately increases serum concentrations of oxybutynin, probably by inhibiting the CYP3A-mediated metabolism.	Itraconazole	13-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-115
8689812-13	1996	Inhibition of CYP3A4-mediated metabolism probably explains the increased toxicity of lovastatin caused not only by itraconazole but also by cyclosporine, erythromycin, and other inhibitors of CYP3A4.	Itraconazole	115-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
8689812-4	1996	Because itraconazole is a potent inhibitor of CYP3A4, we wanted to study a possible interaction between these drugs.	Itraconazole	8-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-52
8712747-10	1996	Itraconazole and its analogues are inhibitors of both cytochrome P450 and lipoxygenase and since itraconazole can modulate BU pharmacokinetics, oxidative catabolism is probably a determinant of BU metabolism.	Itraconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	54-86
7995001-2	1994	Ketoconazole and itraconazole may seriously interact with some of the substrates of CYP3A4 (e.g., terfenadine); hence their possible interaction with triazolam in humans is important to uncover.	Itraconazole	17-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90
8873882-3	1996	Burdens of Histoplasma capsulatum in the liver and spleen of survivors showed that D0870 given QD or QOD and itraconazole given BID caused dose-responsive reduction of infectious burden.	Itraconazole	109-121	BH3 interacting domain death agonist	Mus musculus	128-131
18611706-1	1996	Itraconazole is an orally active, broad-spectrum, triazole antifungal agent which has a higher affinity for fungal cytochrome P-450 than ketoconazole but a low affinity for mammalian cytochrome P-450.	Itraconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-131
18611706-1	1996	Itraconazole is an orally active, broad-spectrum, triazole antifungal agent which has a higher affinity for fungal cytochrome P-450 than ketoconazole but a low affinity for mammalian cytochrome P-450.	Itraconazole	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-199
8605275-6	1996	These results suggested the involvement of itraconazole in the mdr gene and/or mrp gene product-associated resistance.	Itraconazole	43-55	ATP binding cassette subfamily C member 1	Homo sapiens	79-82
8846621-6	1995	The azole antifungal agents ketoconazole and itraconazole are potent inhibitors of human CYP3A isoforms.	Itraconazole	45-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-94
10684424-3	1996	Itraconazole, an oral antifungal agent, is an inhibitor of cytochrome P450 (CYP3A4) metabolism and may elevate serum drug levels of compounds metabolized by this pathway.	Itraconazole	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82
7884727-1	1994	Eight cats with histoplasmosis were treated with itraconazole at 5 mg/kg per dose PO bid.	Itraconazole	49-61	BH3 interacting domain death agonist	Felis catus	85-88
1319312-7	1992	Over the past 8 years, itraconazole has been used in clinical trials for all 3 mycoses.	Itraconazole	23-35	paired box 5	Homo sapiens	73-78
8064660-2	1994	Two horses with Aspergillus spp nasal granulomas and 1 horse with Conidiobolus coronatus nasal infection were treated with itraconazole (3 mg/kg PO bid).	Itraconazole	123-135	BH3 interacting domain death agonist	Equus caballus	148-151
8064660-7	1994	Itraconazole (3 mg/kg PO bid) appears to be effective in the treatment of nasal Aspergillus spp infections in horses because the fungal infection was eliminated in both horses.	Itraconazole	0-12	BH3 interacting domain death agonist	Equus caballus	25-28
1330944-5	1992	Similar observations were made in experiments using IL-2-stimulated CTLL-2 cells: the growth inhibition in the presence of 10 microM ketoconazole or 1 microM itraconazole could be counteracted by increased serum supplementation.	Itraconazole	158-170	interleukin 2	Mus musculus	52-56
7518966-2	1994	Nonspecific inhibitors of cytochrome P-450, such as ketoconazole, itraconazole, fluconazole and SKF 525 A, and most of the cytochrome P-450 IIIA specific substrates used in this study significantly inhibited FK 506 metabolism.	Itraconazole	66-78	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	26-42
7518966-2	1994	Nonspecific inhibitors of cytochrome P-450, such as ketoconazole, itraconazole, fluconazole and SKF 525 A, and most of the cytochrome P-450 IIIA specific substrates used in this study significantly inhibited FK 506 metabolism.	Itraconazole	66-78	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	123-139
33771716-4	2021	In this study, we aimed to estimate the effect of itraconazole (a strong inhibitor of CYP3A4) on the pharmacokinetics of alflutinib.	Itraconazole	50-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-92
1951574-9	1991	The triazole antifungals, terconazole and itraconazole, combine a high affinity for Candida P-45014DM with an exceptionally low effect on mammalian cytochrome P-450.	Itraconazole	42-54	cytochrome P450 family 51 subfamily A member 1	Homo sapiens	92-101
1951574-9	1991	The triazole antifungals, terconazole and itraconazole, combine a high affinity for Candida P-45014DM with an exceptionally low effect on mammalian cytochrome P-450.	Itraconazole	42-54	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164
2128178-3	1990	The effects of the new antimycotic drugs, itraconazole and fluconazole, on the 5-lipoxygenase pathway in human polymorphonuclear leukocytes (PMNL), on the eicosanoid metabolism in platelets, platelet aggregation and on cyclooxygenase activity were investigated and compared with miconazole and ketoconazole.	Itraconazole	42-54	arachidonate 5-lipoxygenase	Homo sapiens	79-93
2091733-9	1990	Of all the azoles tested, itraconazole shows the highest affinity for the cytochrome P450 involved.	Itraconazole	26-38	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	85-89
2091733-11	1990	Itraconazole"s high affinity for the fungal P450 originates from its triazole group as well as from the nonligating lipophilic tail.	Itraconazole	0-12	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	44-48
2128178-4	1990	Itraconazole inhibited the formation of 5-lipoxygenase metabolites in human PMNL (IC50 = 2 x 10(-6) mol/l), while it had no effect on cyclooxygenase and platelet aggregation at concentrations up to 10(-4) mol/l and 10(-5) mol/l, respectively.	Itraconazole	0-12	arachidonate 5-lipoxygenase	Homo sapiens	40-54
33235852-0	2020	Topical Itraconazole Formulations: Unscrupulous Pharmaceutical Companies and Lax Indian Drug Regulators Endangering a Precious Drug.	Itraconazole	8-20	lymphocyte transmembrane adaptor 1	Homo sapiens	77-80
34417912-4	2022	Clinical studies investigated the effect of a strong CYP3A4 inhibitor (itraconazole) and inducer (rifampin) on single-dose entrectinib pharmacokinetics.	Itraconazole	71-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-59